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Abstract 
 
Pain is the major reason patients seek for medical care. Neuropathic pain is a form of 
chronic pain associated with neuropathy, which remains an area of considerable 
therapeutic need. The lack of effective therapeutic treatment for neuropathic pain is 
largely due to the fact that the underlying mechanism is incompletely understood.  
 
Recent studies revealed vgf is the commonly upregulated gene in different animal 
models of neuropathic pain. In addition, VGF-derived peptides, TLQP-21, LQEQ-19 
and TLQP-62 have recently been demonstrated to modulate pain pathways when 
applied in vivo. However, the precise underlying mechanisms of VGF-derived peptides 
in neuropathic pain and the molecular identity of the receptor for VGF-derived peptides 
have not yet been investigated. Here, I demonstrated that TLQP-21, but not LQEQ-19 
nor TLQP-62, acts on the primary macrophage in a calcium-dependent and 
dose-dependent manner. The peptide induces release of calcium from the intracellular 
stores, and repetitive treatment of TLQP-21 desensitises the calcium response in the 
macrophages. In addition, intraplantar injection of TLQP-21-treated macrophages to 
the rat hind paw is demonstrated to elicit mechanical hypersensitivity. I have also 
verified GC1qR, the globular heads of the C1q receptor, is the potential receptor for 
TLQP-21 on macrophages by neutralising antibody and siRNA knock-down techniques. 
Moreover, application of the GC1qR neutralising antibody to partial sciatic nerve 
ligation model rats is shown to potentially delay the onset of mechanical 
hypersensitivity in vivo. Furthermore, I demonstrated TLQP-21 treatment induces 
differential gene expression in the primary macrophages by microarray. The results 
presented in this thesis highlighted the importance of VGF-deriveid peptide, TLQP-21 
and its receptor, GC1qR, in the neuropathic pain development through, at least partly, 
activation of macrophages. The findings furthered our current understanding of the 
peripheral mechanism of neuropathic pain development, thus suggesting new potential 
target, and shed lights, for new neuropathic pain analgesic development. 
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5HT-3R 5-HT receptor subtype 3  
AGRP Agouti-related peptide 
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SSRI Selective serotonin reuptake inhibitor 
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TNF-α Tumor necrosis factor-α 
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1.1. PAIN 
 
1.1.1. The problem of pain 
 
Pain is a commonality among humans. According to the International Association for 
the Study of Pain (IASP), pain is a phenomenon described as “an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage” (Merskey 1994). The sensation of pain is an 
unique and subjective experience, which could be dependent on an individual’s past 
experience of pain, sex, personality, emotion and genetic predisposition. Due to all 
these contributory factors, the pain intensity perceived by different individuals, or 
even the same individual on different occasions, is more than often not in a fixed 
relationship to the same harmful or “noxious” stimulus. With so many variables and 
its underlying mechanism being incompletely understood, the pain assessment and 
management continues to challenge physicians and scientists.  
 
Transient and acute pain, which exists for a limited duration, has evolved as a 
protective mechanism that is necessary for survival. It allows one to detect noxious 
stimuli, body injuries or diseases, which leads to the avoidance of the hazardous 
situation and other needed actions to stop it. The other benefit of such pain is that it 
forces one to rest and protect the wounds while repairing occurs, thereby enhances the 
body’s healing processes. Memories of earlier pain experiences also prevent 
re-exposure to the hazardous situations. Despite its many valuable functions, the 
molecular mechanism of pain still remains incompletely understood. It is currently 
known that pain perception process involves the detection of noxious stimuli by 
specialised sensory neurons (i.e. nociceptors). Upon encountering noxious stimuli, 
nociceptors respond by membrane depolarisation leading to subsequent events of 
action potential generation and signal transmission. Nociceptive signals are transmitted 
from the periphery to the spinal cord and, through an ascending pathway, to the brain. 
The brain could exert inhibitory controls over transmission in the dorsal horn and hence 
modulate the spinal output signals through a descending control system. The 
mechanism triggers the response of a body to injuries is extremely sensitive and 
sophisticated. Upon tissue damage, acute pain is typically reported, followed by an 
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increase in pain sensitivity to noxious stimuli (a phenomenon known as hyperalgesia) 
and pain response to innocuous stimuli (a phenomenon known as allodynia). Such 
transient acute pain serves as a protective mechanism that allows one to detect noxious 
stimuli and body injuries, and hence subsequently avoiding the dangerous situations 
while repair occurs.  
 
However, when pain outlasts its usefulness and persists after the wound is healed (or 
exist without any identifiable causes), it becomes problematic. When pain becomes 
“chronic”, it is becoming a syndrome on its own rather than a by-product of injuries or 
diseases. Unlike acute pain that often goes away once the primary cause is resolved, 
chronic pain often persists for a long time or even life-long. Indeed, in a 4-year 
follow-up study of 2184 individuals, Elliott et al. revealed that the average annual 
incident rate of chronic pain in Grampian (UK) is about 8.3%, and only about 5% of the 
patients make a recovery (Elliott, Smith et al. 2002). Furthermore, chronic pain is 
problematic also in terms of the secondary psychological symptoms incurred. 
Secondary psychological symptoms such as anxiety and depression can profoundly 
affect patients’ physical activities and the quality of life. Indeed, a World Health 
Organisation collaborative survey of about 26,000 primary care patients across 15 
centres around the world (including Asia, Africa, Europe and Americas) reported that 
22% of the primary care patients (age between 18-65) suffer from persistent pain that 
lasts more than 6 months. It is also demonstrated that these pain sufferers are more 
prompt to psychological disorders such as depression and anxiety distress compared to 
the patients without pain. Moreover, some of these pain patients also reported physical 
disability that can affect their work, and often perceive themselves in moderate or even 
poor health (Gureje, Von Korff et al. 1998). 
 
Neuropathic pain is a subtype of chronic pain that often associate with neuropathy. It is 
defined as “pain arising as direct consequence of a lesion or disease affecting the 
somatosensory system” (Geber, Baumgartner et al. 2009). Neuropathic pain affects a 
large proportion of patients suffering from a wide range of peripheral or central nervous 
system diseases. These include the direct nerve trauma, diabetes, viral infection such as 
human immunodeficiency virus (HIV) or Varicella Zoster Virus (VZV), cancer, spinal 
cord injury and as a side effect of anti-viral or anti-cancer treatments. Unlike effective 
treatment available for acute pain, the available treatments for neuropathic pain are 
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inadequate, and more than often, patients’ conditions are not completely relieved after 
the treatments. Determining the treatment for individual patients and special 
populations (such as child) remains challenging. Knowledge of the molecular and 
pathophysiological mechanism underlying neuropathic pain may help the development 
of more specific, mechanisms-based analgesic for neuropathic pain, and hence shed the 
light for better neuropathic pain therapy and management. Thus, the aim and focus of 
this thesis is to further the understanding of the peripheral mechanism(s) contributing to 
the initiation and/or maintenance of neuropathic pain development. 
 
1.1.2. Involvement of the primary sensory afferents in sensory transmission  
 
Pain sensation is part of the somatosensory system. Indeed, the somatosensory system 
can be broadly divided into two major components: the mechanosensory system that 
detects mechanical stimulations (such as pressure, light touch, vibration, and physical 
distortion including bending and stretching) and the nociceptive system that is 
responsible for the detection of pain arising from tissue injuries or noxious thermal, 
mechanical, and chemical stimuli. Together, these two systems allow animals to sense 
the surrounding environment and events in their bodies, and most importantly, to 
evaluate these events for self-protection, survival and reproduction.  
 
Initiation of nociception, as well as mechanoreception, requires the activation of the 
primary sensory neurons that innervate the stimulated regions. Such primary sensory 
fibres differ in sizes, peptide contents, and electrophysiological properties.  All the 
sensory fibres that innervate regions of body arise from cell bodies in the dorsal root 
ganglia (DRG) and can be roughly divided into two groups, A fibres and C fibres, 
according to the myelination status and the corresponding axon diameters. The A fibres 
are subdivided into three subgroups, designated as Aα, Aβ, Aδ, in the order of 
decreasing in sizes (figure 1.1). These primary afferent fibres propagate action 
potentials at different conduction velocities, which are directly related to their axonal 
diameter and the extent of myelination (Djouhri, Bleazard et al. 1998).The myelinated, 
large-diameter Aα/β fibres transduce fast action potential conductivity, and are 
involved in mechanoreception or proprioreception (perception of the positions of limbs 
and other body parts in space). The sensory neurons involved in touch sensation are 
collectively known as low-threshold mechanoreceptor, because weak stimulus intensity 
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is sufficient to trigger action potentials in these fibres.  
 
Sensory neurons that can be activated by the pain-producing stimuli are known as the 
nociceptors. Most of the nociceptors are small or medium in sizes, including the 
unmyelinated C-fibres that confer slow conductivity and thinly myelinated Aδ fibres 
with moderate conductivity. It is worth noting that, some nociceptive neurons do 
exhibit fast conduction range of Aα/β fibres (Lawson 2002). In general, nociceptors are 
duller than the mechanoreceptors and are referred to be the high-threshold sensory 
afferents, as the stimulation must be intense enough to activate these neurons and 
resulting in the subsequent perception of pain. C fibres are suggested to be the most 
abundant of the nociceptive fibres (Lawson 2002). Most, but not all, C-fibres are 
responsive to noxious thermal, mechanical and chemical stimulations, and hence are 
known as ‘polymodal’. Some C-fibres respond only to the noxious thermal stimulation 
and some are only mechanically sensitive. Moreover, a small number of C-fibres are 
known as the ‘silent’ nociceptors as they only become responsive when sensitised by 
tissue injury (Schmidt, Schmelz et al. 1995). The C-fibres can be differentiated into two 
main groups by their neurochemistry, the peptidergic and the non-peptidergic 
population. The peptidergic C fibres express peptide neurotransmitter including 
substance P (SP) and calcitonin gene-related peptide (CGRP). Moreover, they are nerve 
growth factor (NGF) responsive as they express TrkA high-affinity NGF tyrosine 
kinase receptor. The peptidergic C fibres terminate superficially in the lamin I and outer 
lamina II in the spinal horn (Snider and McMahon 1998)The non-peptidergic C fibres, 
on the other hand, express α-D-galactosyl-binding lectin IB4, P2X3 (a subtype of ATP 
receptor) and receptors for glial cell line-derived neurotrophic factor (GDNF). In 
addition, they terminate in the inner lamina II of the spinal horn (Snider and McMahon 
1998).  
 
The primary afferent inputs have been demonstrated to be pivotal in neuropathic pain 
by pharmacological evidences. AM1241 is a selective agonist for CB2 cannabinoid 
receptor, which is not expressed in the neurons of the central nervous system. 
Administration of AM1241 systemically has been shown to relief mechanical and 
thermal hyperalgesia in the Spinal Nerve Ligation (SNL) animal model of neuropathic 
pain (Ibrahim, Deng et al. 2003), suggesting a peripheral mechanism and the 
involvement of peripheral primary sensory afferents in the neuropathic pain 
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development. Moreover, intrathecal administration of antisense oligodeoxynucleotides 
targeting voltage-gated sodium channel Nav 1.8, which is exclusively expressed in the 
small-diameter peripheral sensory afferents, results in reversal of mechanical 
hyperalgesia in the SNL animals (Porreca, Lai et al. 1999). Together, it is suggested that 
the peripheral sensory neuronal input plays an important role in, at least partly, the 
initiation and/or maintenance of neuropathic pain.  
 
Nevertheless, the subsequent molecular mechanism of neuropathic pain has not been 
fully puzzled. It is generally believed that there is an initiation process and a 
maintenance step of neuropathic pain development occurring peripherally and centrally. 
Indeed, neuropathic pain normally develops gradually, which implies the onset and the 
maintenance of neuropathic pain is a complicated process. The current understanding 
of the molecular mechanisms of neuropathic pain can be divided into the peripheral 
mechanism and the central mechanism. It is currently believed both mechanisms play a 
pivotal role in initiating and maintaining neuropathic pain, which will be introduced in 
the following sessions. 
 
 
Figure 1. 1 Schematic illustration of different type of primary afferent neurons.  
Aα/Aβ fibres are the heavily myelinated sensory fibres with large diameter axons. They confer 
conduction velocity up to 120 ms
-1
 (Aα fibre: 80-120 ms-1, Aβ fibre: 35-75 ms-1). Aδ fibre is 
thinly myelinated and possesses medium-size axon diameter, which propagate action potential 
at a velocity of 5-30 ms
-1
. In contrast to the A fibres, C fibres are not myelinated and have a 
small axon diameter, which conduct at a velocity ranging from 0.5 – 2 ms-1. 
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1.1.3. Peripheral mechanism of neuropathic pain 
 
The existing understanding of peripheral mechanism of neuropathic pain can be 
roughly divided into two broad mechanisms, the neuronal mechanism of peripheral 
sensitisation and the peripheral non-neuronal mechanism of neuropathic pain.  
 
Peripheral neuronal mechanism of neuropathic pain 
 
Abnormal transduction 
Upon nerve injuries, aberrant nociceptive signal transduction typically occurs. Such 
abnormal transduction can originate either from the injured neuron itself or the 
non-injured intact sensory neuron. Injured nociceptors produce spontaneous activity, 
which may play an important role in neuropathic pain (Matzner and Devor 1987). 
Indeed, the action potential propagation has been evident to be aberrant in the injured 
sensory afferents in the pathological condition, which change from regular firings to 
irregular bursts with increased spike duration, reduced threshold and slow rise- and 
fall-time kinetics (Liu, Michaelis et al. 2000). Moreover, clinical evidence also shown 
that blockade of the injured nerves by local anaesthetic attenuated spontaneous and 
evoked pain in patients with peripheral nerve injury (Arner, Lindblom et al. 1990). 
Study of the neuropathic pain animal model also suggested anaesthetic treatment of 
the L5 DRG relieved the mechanical hypersensitivity behaviour in SNL model 
(Sukhotinsky, Ben-Dor et al. 2004). Although the spontaneous and increased activities 
of injured nociceptors are believed to contribute to the enhanced nociception in the 
neuropathic condition, it has been demonstrated that activation of nociceptors is not 
the only way to trigger pain in the pathological condition. Low threshold sensory 
fibres that normally convey signals for light touch and other innocuous stimuli also 
start to elicit pain in the neuropathic condition. This is evident by enhanced 
spontaneous activity in the A fibre afferents recorded from the L5 dorsal root after 
spinal nerve injury (Liu, Wall et al. 2000). In addition, it is possible that A fibres could 
undergo phenotype switch, e.g. in terms of altered neurochemistry (Noguchi, Dubner 
et al. 1994), thus enhancing nociceptive transmission in the neuropathic condition. 
 
The non-injured/intact nociceptor adjacent to the injured nerve has also been proposed 
to account for certain aspects of the aberrant nociceptive signalling upon peripheral 
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nerve injury. Removal of the injured afferents in the SNL animal by L5 ganglionectomy 
was demonstrated to still develop neuropathic pain, suggesting a role of the intact 
afferents in the initiation and maintanence of neuropathic pain (Sheth, Dorsi et al. 
2002). In addition, it was demonstrated that after lesion to the L5 spinal nerve in the 
SNL model, spontaneous activity was observed in most of the C fibre afferents of the 
non-injured L4 spinal nerve within 1 day post-surgery, which is hypothesised to be 
resulted from the process of Wallerian degeneration (Wu, Ringkamp et al. 2001). It is 
thus speculated that the intact nociceptors that terminate around the same region as 
the injured nerve fibres may innervate the territory of the injured fibres and develop 
sensitisation and spontaneous activity, which contribute to neuropathic pain 
development. Indeed, sensitisation has been suggested in the intact nociceptors of the 
SNL model, in which an increase in responsiveness to heat and mechanical stimuli 
was observed in the intact nociceptor (Shim, Kim et al. 2005). Moreover, it has been 
shown, in the same animal model of neuropathic pain, that the intact nociceptor 
displays increase sensitivity to tumor necrosis factor-α (TNF-α) by single-fibre 
recording (Schafers, Lee et al. 2003). 
 
Altered expression of key molecules in the nociceptors 
Nerve injuries are often associated with neuroma formation at the injured nerve ending, 
which can elicit spontaneous activity and hypersensitivity to mechanical, thermal and 
chemical stimuli (Breward and Gentle 1985, Seltzer, Paran et al. 1991, Burchiel, 
Johans et al. 1993). It is revealed that large numbers of proteins are altered in 
expressions in the injured nerves, which are postulated to contribute to the 
hyperexcitability of the neuroma upon injury (Huang, Cendan et al. 2008). Thus, 
altered protein expressions in the injured neurons are speculated to profoundly change 
the threshold, excitability and transmission properties of the nociceptors, which may 
account for, at least partly, the hypersensitivity and the persistent nociception. 
 
Indeed, altered expression or trafficking of voltage-gated sodium channels on the 
injured nociceptors has been suggested to cause the membrane hyperexcitability and 
subsequent spontaneous generation of action potentials. This resultant neuronal 
hyperexcitability is associated with ectopic nociceptor activities in the neuropathic 
condition. Among all members of voltage-gated sodium channels, altered expressions 
of Nav1.3, Nav1.7, Nav1.8 and Nav1.9 have been associated with neuropathic pain, 
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which will be briefly covered here.  
 
Voltage-gated sodium channel Nav1.3 is traditionally thought to be one of the sodium 
channels involved in embryonic nervous system development (Felts, Yokoyama et al. 
1997). The expression of Nav1.3 in the adult DRG is typically only observed at very 
low level in about 3% of the DRG neuronal population, which is shown to markedly 
increase in expression in a larger population (up to 21%) after peripheral nerve injury 
(Kim, Oh et al. 2001). In addition, the Nav1.3 mRNA and protein expression in the 
DRG neurons has been shown to be significantly upregulated in a number of 
neuropathic pain animal models including axotomy (Waxman, Kocsis et al. 1994, 
Xiao, Huang et al. 2002), SNL (Kim, Oh et al. 2001), spared nerve injury (SNI) 
(Lindia, Kohler et al. 2005), chronic constriction injury (CCI) (Dib-Hajj, Fjell et al. 
1999) and diabetic neuropathy model of neuropathic pain (Hong, Morrow et al. 2004). 
Nav1.3 facilitates a tetrodotoxin (TTX)-sensitive current. The channel exhibits fast 
activation and inactivation kinetics with rapid repriming ability. The differential 
expression of Nav1.3 in the neuropathic condition has been associated with the new 
emerged rapid-repriming TTX-sensitive current in the injured nociceptors (Kim, Oh 
et al. 2001). The plasticity and the increased rapid-repriming TTX-sensitive current in 
the injured nerve are postulated to account for the hyperalgesia of neuropathic pain 
(Dib-Hajj, Fjell et al. 1999). However, the hypothesis of the upregulated Nav1.3 in the 
DRG after nerve injury plays an important role in development of neuropathic pain 
remains controversial. As it is demonstrated in the Nav1.3 knock out mice that robust 
ectopic activity from the injured nociceptors are still observed in the absence of 
Nav1.3, and the mechanical hypersensitivities are unaltered in both the Nav1.3, 
conditional and global knock out. Thus, Nassar et al. proposed that Nav1.3 is neither 
sufficient nor important for the development of nerve injury-induced neuropathic pain 
(Nassar, Baker et al. 2006). 
 
Nav1.7 is predominately expressed on the myelinated A-fibres. The expression of 
Nav1.7 in the DRGs of the injured nerves is noticeably decreased following segmental 
spinal nerve ligation (Kim, Oh et al. 2002). Paradoxically, the Nav1.7 expression and 
phosphorylation of the channel are shown to increase in the DRGs of the diabetic 
neuropathy models of neuropathic pain (Hong, Morrow et al. 2004). Such differential 
expression and channel phosphorylation are proposed to play roles in the neuropathic 
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pain associated with diabetic neuropathy. However, this concept is shown to 
contradict with the Nav1.7 conditional knock out studies, in which the mechanical 
hyperalgesia associated with neuropathic pain developed normally in mice lacking 
Nav1.7 or Nav1.7 and Nav1.8 (Nassar, Stirling et al. 2004, Nassar, Levato et al. 2005). 
 
One of the other member of the voltage-gated sodium channel, Nav1.8, has been 
proposed to be essential for the generation of spontaneous activity in the injured 
sensory neurons and is suggested to account for the development of aberrant 
mechano-hypersensitivity in the neuropathic condition (Roza, Laird et al. 2003). 
Unlike Nav1.7, Nav1.8 is mainly expressed on the unmyelinated nociceptive C-fibres. 
Surprisingly, when the expression pattern of this channel is examined in the 
neuropathic condition, a reduced expression of Nav1.8 is observed in the DRGs of 
injured nerves in animal models of neuropathic pain (Boucher, Okuse et al. 2000, 
Decosterd, Ji et al. 2002, Wang, Sun et al. 2002). Such reduction in Nav1.8 expression 
is also observed in the DRG of human patients (Coward, Plumpton et al. 2000). 
Although it is once suggested that an increase in Nav1.8 expression is observed in the 
DRGs of non-injured nerves in the SNL model (Boucher, Okuse et al. 2000), 
Decosterd et al. showed that the Nav1.8 expression in the non-injured nerves are not 
altered in the SNI, SNL, CCI and sciatic axotomy models of neuropathic pain 
(Decosterd, Ji et al. 2002). Therefore, the hypothesis of enhanced Nav1.8 expression 
in the non-injured neurons, upon peripheral nerve injury, contributes to neuropathic 
pain still remains contrary and requires further investigation. Nevertheless, it has been 
claimed that Nav1.8 undergoes redistribution in the axons of non-injured nerves 
without much affecting the expression in the DRG, and antisense 
oligodeoxynucleotides targeting Nav1.8 prevents the channel redistribution along the 
axon and attenuates neuropathic pain in vivo (Gold, Weinreich et al. 2003). 
 
Nav1.9 is another voltage-gated sodium channel that is predominately expressed in the 
unmyelinated nociceptive C-fibres. Nav1.9 expression has been shown to be 
significantly downregulated in DRGs in a number of models of neuropathic pain 
(Dib-Hajj, Tyrrell et al. 1998, Boucher, Okuse et al. 2000, Wang, Sun et al. 2002) and 
human patients in pain states (Coward, Plumpton et al. 2000). However, it is 
suggested by Nav1.9 knock out mice that the channel contributes little to the 
mechanical and thermal hypersensitivity in the neuropathic condition (Priest, Murphy 
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et al. 2005). Nevertheless, it was demonstrated in the same study that inflammatory 
mediators could potentially modulate the function of Nav1.9, and hence contribute to 
the inflammation-associated neuronal hyperexcitability. 
 
Although some evidences are still controversial, the current literatures suggest that 
ectopic neuronal activity of the injured nerves, and possibility the non-injured 
afferents, is enhanced after neuropathy possibility through remodeling of sodium 
channel conductance. The alteration in sodium channel conductance can be resultant 
from changes in sodium channel trafficking, redistribution of the sodium channel and 
the differential expressions of the sodium channels upon nerve injury. Thus resulting 
in an increase in membrane hyperexcitability and reduced in firing threshold in the 
injured afferents and the subsequent neuropathic hypernociception. However, it is 
worth noting that voltage-gated sodium channel is merely one of the families that 
exhibit altered expressions upon nerve injury. Indeed, Hung et al. has demonstrated 
that about 200 proteins display changes in expression level at the injured nerve upon 
peripheral nerve injury. It is identified that various cytoskeletal proteins, metabolic 
proteins, redox proteins and protein chaperones are dysregulated after injury (Huang, 
Cendan et al. 2008). Moreover, other ion channels have also been shown to be 
dysregulated in gene expression upon nerve injury. Voltage-gated potassium channels 
(including Kv1.4, Kv4.3 and Kv9.3), kainite receptor GLUR5, serotonin receptor 
5-HT3R and nicotinic acetylcholine receptor α3 are evident to downregulate in 
expression in the DRGs of SNL model (Wang, Sun et al. 2002). Whist voltage-gated 
calcium channel α2δ subunit, together with a number of ion transporters, 
neuropeptides and signalling molecules, are shown to be upregulated in the DRGs of 
SNL animals (Luo, Chaplan et al. 2001, Wang, Sun et al. 2002).  
 
The disregulation process of differential gene expressions upon nerve injury and the 
exact mechanisms of how they contribute to the onset and maintenance of neuropathic 
pain are likely to be more complicated than one could comprehend. Nevertheless, the 
changes in the ion channels expressions in the injured nerves appear to suggest a 
potential modulatory mechanism to the injured nerve conductance, and the resultant 
ectopic activity subsequently contributes, at least partly, to the phenotypes of 
neuropathic pain. 
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Peripheral non-neuronal mechanism of neuropathic pain 
 
It is now widely accepted that neuron is not the only cell type that is involved in the 
neuropathic pain development (Scholz and Woolf 2007). Schwann cells, satellite cells, 
glial cells and a number of immune cells including mast cells, neutrophils, 
macrophages and T cells have been implicated in the peripheral mechanism of 
neuropathic pain development. 
 
Activation and infiltration of non-neuronal cells at the site of injury and DRG 
Immediately after nerve injury, a cascade of signalling often occurs, which includes 
activation of resident mast cells, infiltration of neutrophils and macrophages to the site 
of injury, T cell activation and increased expression/release of proinflammatory 
cytokines (Olsson 1967, Perry, Brown et al. 1987, Kim and Moalem-Taylor 2011).  
 
Indeed, peripheral resident mast cells are, among all, the first to be activated. The 
activated mast cells undergo degranulation at the site of injury, releasing histamine, 
proteases and cytokines (Zuo, Perkins et al. 2003). Degranulation of mast cells has 
been suggested to play an important role in initiating neuropathic pain development in 
the partial sciatic nerve ligation (PSNL) model of neuropathic pain. It is demonstrated 
inhibiting mast cell degranulation significantly attenuated neuropathic pain 
development in PSNL animals and the number of subsequent infiltrated neutrophils 
and macrophages are reduced (Zuo, Perkins et al. 2003). Moreover, denervated 
Schwann cells at the site of injury release chemoattractants such as leukemia inhibitory 
factor (LIF) and monocyte chemoattractant protein-1 (MCP-1) to recruit resident 
macrophages to the lesion site (Sugiura, Lahav et al. 2000, Tofaris, Patterson et al. 
2002). Consequently, both activated macrophages and denervated Schwann cells 
release matrix metalloproteases that acts on the basal lamina of endoneurial blood 
vessels, leading to blood-nerve barrier interruption. 
 
Blood circulating neutrophils subsequently adhere to the vascular endothelium, 
followed by rolling and transendothelial migration to the site of injury (Witko-Sarsat, 
Rieu et al. 2000). A significant number of neutrophils are observed in the site of injury 
after peripheral nerve damage, which is often not found in the intact nerves (Perkins 
and Tracey 2000). It has been evident that neutrophils further infiltrate to the DRG 
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seven days after nerve injury. The number of neutrophils in the DRG ipsilateral to the 
side of injury is shown to increase by three folds. In addition, the isolated neutrophils 
from the peripheral nerve injured animals 7 days post surgery exhibit enhanced 
activity of superoxide production by 170% (Morin, Owolabi et al. 2007). Moreover, 
ablation of circulating neutrophils prior to nerve injury is demonstrated to alleviate 
the peripheral hypersensitivity in vivo. However, when neutrophils are depleted at day 
8 post-injury, the peripheral hypersensitivity is developed normally (Perkins and 
Tracey 2000). This suggests a role for neutrophil in the early stage, possibly the 
initiation, of neuropathic pain development.  
 
Increased activation of resident macrophages and enhanced peripheral macrophages 
infiltration to the injured nerve and the ipsilateral DRG have also been observed 
following peripheral nerve injury (Perry, Brown et al. 1987, Hu and McLachlan 2002, 
Hu, Bembrick et al. 2007, Isami, Haraguchi et al. 2013). Intriguingly, it is suggested 
that different subtypes of macrophages are differentially recruited to the injured nerve 
and the DRG. The M1 classically activated macrophages are predominantly recruited 
to the injured nerve after nerve injury. On the other hand, the M2 alternatively activated 
macrophages infiltrate the DRG ipsilateral to the injury on day 2 post-injury (Komori, 
Morikawa et al. 2011). In addition, it is recently evident that macrophage infiltration 
further proceeds to the central nervous system. Infiltration of peripheral macrophages 
into the spinal cord is observed 14 days after peripheral injury (Isami, Haraguchi et al. 
2013). Furthermore, systemic depletion of macrophages prior to nerve injury has been 
demonstrated to alleviate peripheral nerve injury-induced thermal hypersensitivity, 
suggesting a role of macrophage in the development of neuropathic hypersensitivity 
following peripheral nerve injury (Liu, van Rooijen et al. 2000). 
 
Following peripheral nerve injury, infiltration of T cells to the injured nerve and the 
ipsilateral DRG has also been reported (Hu and McLachlan 2002, Moalem, Xu et al. 
2004, Hu, Bembrick et al. 2007). Infiltration of T cells to the injured nerve is first 
observed on day 3 post-peripheral nerve injury and peaks at day 21 (Moalem, Xu et al. 
2004). The number of T cells is also observed to drastically increase in the ipsilateral 
DRG 3 days after sciatic nerve lesions, which is sustained up to 11 weeks post-injury 
(Hu and McLachlan 2002). It is hence suggested that T cells may contribute to the 
development of neuropathic pain. Indeed, it is demonstrated that rats lacking mature T 
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cells develop significantly less mechanical and thermal hypersensitivity after CCI 
surgery (Moalem, Xu et al. 2004). Although a role is suggested for T cell in the 
development of neuropathic pain, it is recently demonstrated that a subpopulation of T 
cells, regulatory T cells (Tregs), alleviate mechanical hypersensitivity after sciatic 
nerve injury. Depletion of this subpopulation of T cells is demonstrated to exacerbate 
hypersensitivity to mechanical stimulus following partial sciatic nerve ligation (Austin, 
Kim et al. 2012). Thus, it is possible that different subpopulations of T cells could 
contribute to the development of neuropathic pain differently.  
 
Ectopic discharge of inflammatory mediators 
As discussed, peripheral nerve injury is often accompanied by a dense cellular 
infiltration to the site of injury and DRGs ipsilateral to the injury. The infiltrated cells 
secret many cytokines, chemokines and inflammatory mediators, which are postulated 
to contribute to the initiation of neuropathic pain. These inflammatory mediators 
include bradykinin (Janig, Levine et al. 1996), prostaglandin E2 (PGE2)(Ma and 
Eisenach 2003), nerve growth factor (NGF)(Boucher and McMahon 2001), serotonin, 
adenosine triphosphate (ATP)(Toulme, Tsuda et al. 2010), histamine, and endothelin-1 
(Campbell and Meyer 2006). Proinflammatory cytokines such as IL-1β (Okamoto, 
Martin et al. 2001), IL-6(Wei, Na et al. 2013), IL-18 (Miyoshi, Obata et al. 2008), 
interferon-γ (Racz, Nadal et al. 2008), tumor necrosis factor- α (TNF-α)(Wagner and 
Myers 1996, George, Schmidt et al. 1999), and leukemia inhibitory factor (LIF)(Tofaris, 
Patterson et al. 2002) have also been evident to play roles in the development of 
neuropathic pain, possibly by exacerbating the axonal damage (Keswani, Polley et al. 
2003) and modulating nociceptor hyperexcitability (Wolf, Gabay et al. 2006) and 
stimuli hypersensitivity (Schafers, Lee et al. 2003) in the neuropathic condition.  
 
The ectopic discharge of inflammatory mediators from the infiltrated cells play a role in 
the peripheral sensitisation of the nociceptors, and consequently account for, at least 
partly, the maintenance of neuropathic pain. Indeed, many of these inflammatory 
mediators rapidly excite primary sensory neurons in the peripheral nervous system and 
increase their excitability and ectopic firing. Such hyperexcitability of the peripheral 
nociceptors is fundamental to the neuropathic pain development. 
For instance, Serotonin acts on the 5-HT3 receptor that is expressed on sensory neurons. 
Activation of this ligand-gated ion channel causes sodium ions influx and neuronal 
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excitation upon binding. In addition, TNF-α is shown to induce ectopic activity in 
nociceptive primary afferent neurons (Sorkin, Xiao et al. 1997) and is evident to induce 
hyperalgesia upon endoneurial administration (Wagner and Myers 1996). Furthermore, 
ATP released at the extracellular space is evident to enhance neuronal activity through 
activation of its receptors. One of which, P2X3, is shown to be selectively expressed at 
high level in the nociceptive sensory neurons (Chen, Akopian et al. 1995), and is 
implicated in neuropathic and chronic inflammatory pain conditions.  
 
1.1.4. Mechanism of neuropathic pain: Central mechanism 
 
In addition to the changes described at the periphery for neuropathic pain development, 
a diverse range of events also occur at the central nervous system upon nerve injury, 
which are believed to play important roles in the maintenance of neuropathic pain. 
 
The nociceptive input is typically relayed from the periphery to the central locus via the 
nociceptive primary afferents that terminate in different laminaes of the spinal dorsal 
horn. Here, various convergences and modulations can occur through input from, for 
example, the secondary nociceptive spinal neurons, wide dynamic range (WDR) 
excitatory neurons and inhibitory interneurons. The modulated nociceptive signal is 
subsequently transmitted to the brain via an ascending pathway. Secondary modulation 
of the nociceptive signals can also occur during descending signal transduction from 
the brain back to the spinal cord, and via neuronal plasticity within the spinal cord and 
higher structures. Modulations at these sites generally enhance neuronal excitability 
and disinhibition, and hence contributing to neuropathic pain development.  
 
Spinal and supraspinal mechanisms 
 
Neurotransmitters that are released from the central terminals of peripheral afferent 
fibres after nerve injury, such as SP and CGRP, are believed to induce amplification and 
prolongation of the postsynaptic response of spinal dorsal horn neurons to the 
nociceptive inputs (Budai and Larson 1996).This phenomenon is known as wind up, 
which is a form of long term plasticity of dorsal horn neurons. The enhanced activity is 
resulted from introduction of prolonged slow depolarization of the neurons by the 
neurotransmitters, and the subsequent activation of NMDA receptors. NMDA receptor 
 38 
activation is evident to play a pivotal role in enhancing nociceptive signalling and 
resulting in hyperalgesia in the neuropathic conditions (Price, Mao et al. 1994, Sindrup 
and Jensen 1999). The output from the dorsal horn is transimitted by spinal projection 
neurons along the ascending pathway. Vast majority of these projection neurons are 
found at superficial dorsal horn in laminae I. About 80% of these neurons express the 
neurokinin 1 (NK1) receptor for SP. It is widely believed that NK1-positive cells 
transmit signals on to the brain regions such as thalamus, the periaqueductal grey 
(PAG), and parabrachial area (PB) (Todd 2002). In addition, these cells also project into 
brainstem areas such as rostral ventromedial medulla (RVM). Interestingly, RVM has 
been shown to be one of the regions where descending projection back to the dorsal 
horn occurs. The NK-1 expressing cells hence modulate spinal processing via this 
spino-bulbo-spinal loop, which first projects up from the spinal cord to the brain as 
described, via brainstem structure to modify the signals, and then descend back down to 
the spinal cord. Ablation of projections of NK1-expressing cells by substance P and 
saporin conjugate (SP-SAP) has shown to reduce excitability of deep dorsal horn 
WDRs, reverse neuropathy pain and plasticity in dorsal horn neurons (Suzuki, 
Morcuende et al. 2002). It has also been evident these changes are mediated, at least in 
part, by serotonin (5HT) acting on facilitatory 5HT3 receptors. 
 
Central immune mechanism and disinhibition of GABAergic neurons 
 
There is growing evidence suggesting the central immune mechanisms also play a role 
in central sensitization. Microglia is a population of resident macrophages in the CNS, 
consisting about 5-12% of all cells in the CNS. Resting microglia have small soma with 
fine processes, which allow them to sense changes in the microenvironment. Once 
activated by stimuli such as trauma, ischemia or inflammation, they adapt an amoeboid 
shape and function as phagocytes in CNS (Vilhardt 2005). Activation of microglia 
promotes release of cytokines and chemokines such as IL-1β, TNF-α and free radicals 
and increase in major histocompatibility complex (MHC) expression (McMahon, 
Cafferty et al. 2005). The MHC on the microglia in turn presents antigen to the T 
lymphocytes and causes their subsequent release of proinflammatory cytokines upon 
activation. Moreover, astrocytes in the CNS are also shown to be activated in response 
to nerve injury. There is growing evidence suggesting that astrocytes, along with 
microglia, contribute to neuropathic pain development (Colburn and DeLeo 1999, 
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Watkins, Milligan et al. 2001, McMahon, Cafferty et al. 2005). They are activated by 
peripheral nerve injury, and inhibition of their activations has been shown to attenuate 
the development of hyperalgesia and allodynia in many animal models of neuropathic 
pain (Raghavendra, Tanga et al. 2003, Ledeboer, Sloane et al. 2005).  
 
Several inflammatory mediators play important roles in activating astrocyte and 
microglia in CNS, which include ATP, bradykinin, substance P and prostaglandins. ATP 
acts through one of its receptors, P2X4, which is selectively expressed on the active 
microglia in response to the nerve injury and is suggested to be required for neuropathic 
pain development (Tsuda, Shigemoto-Mogami et al. 2003). Indeed, it is proposed that 
ATP induces a microglia-dependent disinhibition mechanism on GABAergic neurons, 
which results in aberrant excitatory signalling of the inhibitory neurons. The resultant 
aberrant signalling in turn contributes to the hypernociception in the neuropathic state 
(Tsuda, Shigemoto-Mogami et al. 2003, Coull, Beggs et al. 2005, De Koninck 2007). 
An increase in synthesis and activation of P2X4 receptor is observed in hyperactive 
microglia after nerve injury through an ATP-dependent pathway, which stimulates the 
release of Brain-derived neutrophic factor (BDNF) from the microglia. The secreted 
BDNF, in turn, acts on tyrosine kinase B (TrkB) receptors on the GABAergic neurons 
and results in downregulation of K
+
-Cl
-
 co-transporter isoform 2 (KCC2) (Rivera, Li et 
al. 2002, Rivera, Voipio et al. 2004) and upregulation of Na
+
-K
+
-2Cl
-
 co-transporter 
(NKCC1). The homeostasis of Cl
-
 in these neurons is altered as the Cl
-
 accumulates, 
which disrupts in the transmembrane chloride gradient and results in anion flux in the 
inverted direction when activated (Coull, Beggs et al. 2005). Thus, activation of these 
neurons becomes excitatory and the GABAergic neurons are ‘disinhibited’, which is 
proposed to be one of the central mechanisms that underlies neuropathic pain 
development (Coull, Boudreau et al. 2003) (figure 1.2).  Interfering this disinhibition 
mechanism has been shown to alleviate neuropathic pain, in which inhibition of P2X4 
receptor is demonstrated to inhibit allodynia associated with neuropathy (Nagata, Imai 
et al. 2009). 
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Figure 1. 2 Schematic diagrams illustrating the central mechanism of disinhibition in the 
pathophysiological condition compared to the normal inhibition at the physiological 
condition. 
 
1.1.5. Therapeutic treatment of neuropathic pain and obstacles  
 
Neuropathic pain therapy, unlike therapy available for acute and inflammatory pain, 
remains an area of considerable therapeutic need. Neuropathic pain often develops 
gradually, and it is believed rarely can one single mechanism be responsible for 
initiating and maintaining the symptoms. The process of generating and maintaining 
the symptoms is complicated and not fully understood. Despite large pharmaceutical 
interests in developments of analgesic for neuropathic pain, therapeutic treatment for 
neuropathic pain remains difficult. Currently, there is no single treatment that can be 
employed to treat all conditions of neuropathic pain, and more often than not, certain 
treatment could work on a subgroup of patients but not others with the same 
neuropathic symptom. It is also observed that drugs from the same categories can have 
completely opposite effect in pain relief.  
 
The current treatments to neuropathic pain can be broadly divided into five drug classes, 
antidepressants, anticonvulsants, opioids, NMDA antagonists, and miscellaneous 
(Finnerup, Otto et al. 2005). Tricyclic antidepressants such as amitriptyline (other 
related drugs include imipramine, despiramine, venlafaxine and paroxetine) has been 
shown to relief central post-stroke pain (Leijon and Boivie 1989) post-herpetic 
neuralgia (Watson, Evans et al. 1982, Kishore-Kumar, Max et al. 1990), painful 
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diabetic and non-diabetic polyneuropathy (Young and Clarke 1985, Sindrup, Ejlertsen 
et al. 1989, Sindrup, Gram et al. 1990, Sindrup, Bach et al. 2003) and post-mastectomy 
pain syndrome (Kalso, Tasmuth et al. 1996). However, the same class of drug has been 
shown to be ineffective in relieving spinal cord injury (Cardenas, Warms et al. 2002), 
phantom limb pain (Robinson, Czerniecki et al. 2004) and HIV-associated neuropathic 
pain (Kieburtz, Simpson et al. 1998) The fact that effect of amitriptyline on pain relief 
in certain types of neuropathic pain but not others and the efficacy of pain reliefs 
differed for different types of pain underlies the complicated mechanism involved in 
neuropathic pain. 
 
Unlike antidepressants that have been shown to be ineffective in relieving pain 
associated with Phantom limb pain and HIV-associated neuropathic pain, another class 
of drug, anticonvulsants (such as gapapentin and lamotrigine), has been demonstrated 
to exhibit positive effect in some small trials (Simpson, Olney et al. 2000, Bone, 
Critchley et al. 2002). Anticonvulsant drugs also reduce pain associated with painful 
diabetic neuropathy (Eisenberg, Lurie et al. 2001) post-stroke pain (Vestergaard, 
Andersen et al. 2001), post-herpetic neuralgia (Rowbotham, Harden et al. 1998, Rice, 
Maton et al. 2001, Sabatowski, Galvez et al. 2004), spinal cord injury (Levendoglu, 
Ogun et al. 2004). It is worth noticing that anticonvulsant drug such as Topiramate 
could induce adverse side effects, and hence its frequent high withdrawal rate in most 
of the clinical trials.  
 
The third class of drugs used to treat neuropathic pain is the Opioids. This class of drug 
is often combined with others to achieve better analgesic effect in clinic. For example, 
morphine has been shown to increase pain relief at lower doses when combined with 
gabapentin for treatments to painful diabetic neuropathy and postherpectic neuralgia 
when compared to single agent treatment (Gilron, Bailey et al. 2005). Morphine has 
also been shown to exhibit profound effect on pain relief for patients with phantom 
limb pain (Huse, Larbig et al. 2001). In addition, other opioids drug such as oxycodone 
also exhibits effects on reducing pain associated with post-herpetic neuropathy (Watson 
and Babul 1998) and diabetic-associated neuropathy (Watson, Moulin et al. 2003), and 
the effect is as good as to that of morphine.  
One of the other drug classes that has been extensively studied and used in clinical trial 
is the NMDA antagonists. This class of drug (such as dextromethorphan, riluzole and 
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memantine) have been applied in a number of small neuropathic pain trials. However, 
the outcome of the studies showed there is no or little pain relieving effect. 
Nevertheless, two trials of high doses of dextromethorphan have been shown to be 
effective to treat pain associated with diabetic polyneuropathy (Nelson, Park et al. 1997, 
Sang, Booher et al. 2002). 
 
Other treatments for neuropathic pain that does not fall into any of the classes described 
have been classified into the Miscellaneous class (for example, lidocane patch, 
capsaicin and cannabis). Cannabinoids from this group has been shown to alleviate 
pain in multiple sclerosis (Svendsen, Jensen et al. 2004) and central neuropathic pain 
from brachial plexus avulsion (Berman, Symonds et al. 2004), which has not been 
demonstrated by other drug classes listed.  
 
Despite the growing evidence for effective treatments of neuropathic pain, current 
therapy for neuropathic pain is still inadequate. The current best available therapies 
only offer about 50% pain relief in one in 2-3 patients treated. In addition, the available 
drugs currently in use for treatments of neuropathic pain often exhibit dose-limiting 
adverse side effects and limited efficacy. Regardless of the great interest and efforts in 
neuropathic pain drug development, most compounds predicted to be effective from the 
animal models show no or limited effect alleviating pain in the clinical trials. This 
failure in translation into the clinical trials may be due to the fact that animal models of 
neuropathic pain are often restricted to physical damage to the nerve. It is hence hard to 
reflect the broad range of clinical neuropathic pain diseases, in particular those 
originated from causes other than nerve trauma.  
 
In the hope to overcoming this issue, there is a growing interest in the pain research 
field recently to identify the common genes, which are implicated in different types of 
neuropathic pain derived from different origins. Microarray studies of differential gene 
expression in the DRGs of different animal models and subsequent comparison have 
been heavily employed to achieve this. This approach allowed us to elucidate genes that 
are commonly upregulated, in the neuropathic condition, among different animal 
models. This dissects out the genes that are truly related to neuropathic pain 
development as opposed to those associated with other aspects of pathophysiological 
response to a nerve lesion (e.g. regeneration and repair). As a result of this, vgf is found 
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to be one of the common genes that is upregulated in different animal models of 
neuropathic pain, and is hypothesised to play a pivotal role in the initiation and/or 
maintenance of neuropathic pain (Costigan, Befort et al. 2002, Xiao, Huang et al. 2002, 
Maratou, Wallace et al. 2009).  
 
1.2. vgf: plate V nerve Growth Factor inducible gene 
 
1.2.1. Identification of vgf and its selective inducibility 
 
Vgf is the non-acronymic abbreviation for “plate V nerve Growth Factor inducible 
gene”. It was originally identified as a nerve growth factor (NGF)-indicible gene in 
PC-12 rat phaeochromocytoma cells by Levi et al. in 1985 (Levi, Eldridge et al. 
1985). In response to NGF stimulation, PC-12 cells are able to differentiate into 
mature sympathetic neurons. During differentiation, vgf has been characterised as one 
of the many genes that is profoundly upregulated in expression, and the increase in 
mRNA level is observed at the ‘delayed-early’ stage (Levi, Eldridge et al. 1985, Cho, 
Skarnes et al. 1989, Salton 1991). The cell line has, therefore, been employed as a 
model of neuronal differentiation and extensively used for the investigations of 
neurotrophin-induced mechanisms and regulation mechanism of vgf expression 
(Greene and Tischler 1976, D'Arcangelo, Habas et al. 1996, Levi, Ferri et al. 2004). 
 
Further to its response to NGF, vgf has been demonstrated to exhibit selective 
inducibility to a diverse range of stimuli in vitro and in vivo, which include 
neurotrophins, antidepressants and several other physical activities. Indeed, vgf 
expression is also robustly induced by BDNF, GDNF and neurotrophin 3 (NT-3) 
(Eagleson, Fairfull et al. 2001, Alder, Thakker-Varia et al. 2003, Cerchia, Duconge et 
al. 2005). Intriguingly, such robust induction of vgf mRNA is restricted to a subset of 
growth factors only, as it is demonstrated that epithelial growth factor (EGF) and 
fibroblast growth factor (FGF) could only induce trivial vgf expression in PC12 cells 
(Hawley, Scheibe et al. 1992, Possenti, Di Rocco et al. 1992). 
 
Apart from neurotrophin inductions, vgf expression has also been shown to be 
modulated by selective serotonin reuptake inhibitor (SSRI) antidepressants. SSRI 
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antidepressants, such as fluoxetine and paroxetine, profoundly increase vgf mRNA 
expression in astrocytes (Allaman, Fiumelli et al. 2011). The induction vgf upregulation 
by SSRI antidepressants is suggested to be independent from the serotonin-mechanism 
(Allaman, Fiumelli et al. 2011). The finding here presents two surprises. The first 
surprise is the specific inducibility of SSRI antidepressants on vgf expression, as it is 
demonstrated that another class of antidepressants, tricyclic antidepressants (such as 
desipramine) is unable to alter vgf expression. The second surprise is that VGF is 
expressed in the cortical astrocytes, whereas previous work demonstrated that it is not 
expressed in the spinal astrocytes (Moss, Ingram et al. 2008). Although there is a 
possibility that the neurochemistry of cortical astrocytes and spinal astrocytes could be 
different, it is intriguing that SSRI antidepressants may play a role in initiating and 
upregulating vgf expression in astrocytes upon stimulation.  
 
In addition vgf is also shown to be induced by physical conditions such as fasting 
(Hahm, Mizuno et al. 1999, Hahm, Fekete et al. 2002), circadian rhythmicity (Wisor 
and Takahashi 1997), seasonal changes (Ebling and Barrett 2008), oestrous cycle (Ferri, 
Gaudio et al. 1995), consumption of salt (Mahata, Mahata et al. 1993), learning 
(Bozdagi, Rich et al. 2008) and sleep deprivation (Cirelli and Tononi 2000) 
 
1.2.2. Structure and tissue expression of vgf gene 
 
Following to the identification of vgf, cloning of the vgf cDNA from the PC12 cells 
revealed a 2.7kb fragment (Levi, Eldridge et al. 1985). The human vgf gene was 
subsequently isolated from a genomic library, and chromosomal mapping revealed that 
vgf gene is situated in human chromosome 7q22 (Canu, Possenti et al. 1997). The 
gene is demonstrated to be a single-copy gene spanning approximately 6 kb of the 
genomic sequence. The organisation of the vgf gene is fairly simple, which is 
consisted of three exons flanking two introns in between. The entire VGF protein 
sequence is encoded by exon 3, while the 5’ untranslated sequence contains two 
introns(figure 1.3) (Salton, Fischberg et al. 1991). 
 
 
Figure 1. 3 Schematic diagram illustrating the organisation of vgf gene.  
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Vgf is a single copy gene with fairly simple organisation. The entire protein coding sequence is 
harboured by exon 3. 
 
Vgf exhibits high sequence conservation between human and rodent. The evolutionary 
conserved sequence can be found not only in the coding region, but also within the 
untranslated region and the promoter region. Indeed, the promoter sequences between 
human and rat display over 80% homology (Canu, Possenti et al. 1997). The 
structural organisation of the mice gene is similar to that of human vgf gene, and is 
revealed to locate in the chromosome 5 (Hahm, Mizuno et al. 1999). The rodent vgf 
gene has been shown to produce two mature mRNA forms by alternative splicing 
mechanism. The two spliced variants differ in the untranslated sequence, in which 
exon 2 is omitted in the shorter form of mature vgf mRNA, while the coding 
sequences remain unaffected (Hawley, Scheibe et al. 1992). Nonetheless, the 
functional consequences for such splicing event still remain unclear.    
 
The expression of vgf is highly regulated developmentally. In situ hybridisation 
experiment on prenatal and postnatal rat demonstrated that vgf mRNA expression is 
first observed in the primordial of the cranial, dorsal root and sympathetic ganglia as 
early as E11.5. The distinct expression in regions of the brain starts as early as E13.5 
during embryogenesis, and by E19.5, the thalamic nuclei, telencephalon, pituitary, 
spinal cord, sensory and autonomic ganglia, and most of the diencephalon and 
brainstem are stained labelled positive vgf expression (Snyder, Pintar et al. 1998). 
Interestingly, expression of vgf is temporally correlated with the neuronal 
differentiation, as seen in, among many others, the developing hippocampal neurons 
(Snyder, Pintar et al. 1998). The vgf mRNA expression is found to be expressed at high 
levels in most part of the brain, spinal cord, adrenal, stomach and pancreas by birth 
(Ferri, Levi et al. 1992, Snyder, Pintar et al. 1998, Snyder, Peng et al. 2003). In the 
adult rat brain, vgf mRNA is abundantly expressed in the olfactory system, 
hippocampus, septal, thalamus, amygdaloid, brainstem and cerebellum (van den Pol, 
Decavel et al. 1989, van den Pol, Bina et al. 1994, Snyder and Salton 1998).  
 
Summing the existing vgf expression localisation data, vgf mRNA is believed to be 
distributed throughout the nervous system including the central nervous system (most 
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part of the brain, spinal cord and brainstem) and the peripheral nervous system (dorsal 
root and sympathetic ganglia). It is worth noting though, the expression is only 
extensively found in the neurons of the nervous system, the white matter is typically 
unlabelled. Moreover, vgf mRNA expression is shown to express at high level in the 
neuroendocrine cells, including that of adrenal medulla, pituitary, pancreas and gut. 
More recently, and unexpectedly, vgf mRNA is found to be expressed in the precursor 
cells of oligodendrocytes. The expression is shown to diminished after differentiateon 
(Dugas, Tai et al. 2006). Moreover, it is also suggested that vgf expression is 
upregulated in the astrocytes following to SSRI antidepressant treatment (Allaman, 
Fiumelli et al. 2011). Thus, the traditional classification of vgf being a 
neuro-endocrine specific gene is recently challenged, and the expression of the gene 
in other cell types may implicate their roles in other cellular functions. 
 
1.2.3. Regulatory mechanism of vgf expression 
 
The regulatory mechanism of vgf expression during the development and/or 
maintenance of traumatic- or disease-induced neuropathic pain is largely unknown. 
Nevertheless, using PC12 cells as a neuronal model, a number of studies revealed the 
potential regulatory elements within the promoter region of vgf.  
 
Vgf gene expression was first found to be largely impaired by mutation in the cyclic 
AMP responsive element (CRE) in PC12 cells in 1992 (Hawley, Scheibe et al. 1992). 
Since CRE binding proteins are mostly ubiquitous and respond to a variety of 
different stimuli, it was hence postulated other regulatory elements must be involved 
in conferring transcriptional regulation of vgf gene. A few studies have attempted to 
elucidate the regulatory mechanisms of vgf expression in response to neurotrophin in 
the PC12 cells. However, some of the findings from different groups are contradictory 
and the mechanism of vgf expression regulation in the PC12 cells still remains 
controversial.  
 
D’Arcangelo et al. was the first group to show that at least three distinct promoter 
elements play a role in regulating vgf expression in the PC12 cells (D'Arcangelo, 
Habas et al. 1996). They confirmed CRE is one of the important elements regulating 
the expression of vgf in response to NGF stimulation in the PC12 cells. They also 
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further demonstrated CRE binds ATF-1, ATF-2 and CREB in the PC12 nuclear extract. 
In addition, a CCAAT box was found within the vgf promoter region and is required 
for NGF inducibility of vgf in the PC12 cells. CCAAT box often binds to transcription 
factors that belong to the C/EBP family member. In this study, they showed CCAAT 
box was able to bind proteins in nuclear extracts of PC12 cells. However, the complex 
formed did not contain a C/EBP family member, and hence it was proposed that a 
novel CCAAT-binding protein is required for the transcriptional activation of vgf 
expression upon NGF stimulation in the PC12 cells. Furthermore, it was also 
proposed a G(S)G element is required for the NGF-induced response in PC12 cells. 
Mutation of G(S)G element showed no significant change in vgf basal expression 
level but the NGF-induced response was reduced. In addition, it was suggested that 
NGF-induced transcription factor, NGF1-A, may bind to G(S)G element and amplify 
the transcriptional response. Lastly, they demonstrated an E box consensus core 
sequence found at position -56 did not alter vgf expression level in response to NGF 
induction after being mutated, and concluded this element is not an essential 
regulatory components for the induction of vgf expression in the PC12 cells (Figure 
1.4.A for summary).  
 
Contradictory to this story, Di Rocco et al published a study one year later showing 
two E-box elements (at position -56 and -170) confer weakly positive role in inducing 
vgf expression in response to NGF in the PC12 cells. More interestingly, they also 
showed the same E-boxes exhibit strongly inhibitory roles in the non-neuronal cell 
line - 3T3 cells. Mutation of either E-boxes relieved the low expression of vgf in the 
3T3 cells (Di Rocco, Pennuto et al. 1997). However, the role of G(S)G elements in 
regulating vgf expression was not described in this study. Nevertheless, in agreeing 
with the previous study by D’Arcangelo et al, they also demonstrated the importance 
of CRE and CCAAT box in regulating vgf gene expression in PC12 cells. In 2001, the 
same group further published the roles of HEB and MASHI binding to the E box at 
position -170, suggesting its contribution towards neuron-specific expression of vgf 
(figure 1.4 C). In non-neuronal cells, HEB (a ubiquitously expressed transcription 
factor that belongs to the basic helix-loop-helix bHLH family) binds to both the E-box 
and CRE elements simultaneously, forming an inactive complex inhibiting 
transcription. On the other hand, another bHLH family transcription factor, MASH1 
(found specifically in neurons), bind to -170 E box and CCAAT box forming an 
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activation complex that drives vgf transcription in the PC12 cells.  
 
Although some parts of the studies of vgf regulatory mechanism remain controversial, 
it is clear that the vgf promoter is enrich in regulatory elements and that, at least in 
part, confer cell- and tissue-dependent expression of vgf. Much of what we know 
about the vgf expression regulating mechanism is restricted to the PC12 cell line 
invetigations. Future study will need to be carried out to elucidate the regulatory 
mechanism of vgf expression in primary sensory neurons, in the context of 
neuropathic pain to further our understandings on this subject.  
 
 
A)                                       B) 
  
 
C) 
 
 
Figure 1. 4 Regulatory mechanisms of vgf expression in response to NGF stimulation in 
the PC12 cell line. 
A) Diagram adopted from D'Arcangelo, Habas et al. 1996. NGF induced vgf expression in 
PC12 cells through a Ras-dependent pathway, which also induces exprssion immediate early 
gene NGF1-A that subsequently binds to G(S)G element in vgf promoter further induce vgf 
expression. CRE and CCAAT elements are shown to be play parts in the gene expression in 
response to NGF induction B) Diagram adopted from Di Rocco, Pennuto et al. 1997. First 
evident demonstrationg roles of two E boxes in regulating vgf expression in the PC12 cells C) 
Diagram adopted from Mandolesi et al., 2002. The first evident demonstrating the oppose 
effect of E boxes in the non-neuronal cell line, 3T3 cells. It is also suggested that CREB is 
phosphorylated on serine 133 in activated PC12 cells. In addition, bHLH family transcription 
factors (HEB and MASHI) confer neuron-specific expression of vgf gene.  
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1.2.4. VGF propeptide precursor and functional peptides 
 
As mentioned previously, vgf is profoundly upregulated in the delayed early phase of 
NGF-induced response. The upregulated vgf gene encodes a polypeptide precursor 
comprising of 615 amino acids in human and 617 amino acids in rodents. The 
polypeptide sequence is demonstrated to display no homology with any known 
sequence (Salton, Fischberg et al. 1991). The N terminus of the synthesised 
propolypeptide is hydrophobic harbouring a 22 amino acid long secretory leader 
sequence, which is essential for endoplasmic reticulum translocation. Cleavage of the 
secretory leader sequence results in VGF polypeptide precursor with a calculated 
moleculer weight of 68kDa and an isoelectric point (pI) of 7.1. Proline and Glutamic 
acid are prominent in the polypeptide, taking up 11% and 14% sequence identity, 
respectively, and are shown to cluster at the C terminus (Ferri and Possenti 1996). 
 
The vgf polypeptide precursor is proteolytically processed into smaller peptide 
fragments. Indeed, analysis of neuroendocrine tissue using antiserum against the 
N-terminus of VGF by western blots typically reveals two polypeptide bands at 90 
and 80 kDa, which corresponds to the polypeptide precursor. It is unexpectedly 
migrated at a higher molecular weight most likely due to the high content of proline in 
the sequence. However, smaller size bands down to 10kDa are prominent when using 
antiserum targeting the C-terminus, suggesting proteolytic processing of VGF 
polypeptide (Trani, Ciotti et al. 1995). The processed VGF peptides are stored in the 
secretory granules of neurons where it is released upon depolarisation (Possenti, 
Eldridge et al. 1989). To date, there are about 13 VGF-derived peptides that have been 
identified, which are named by the first four amino acids followed by the overall 
length of the peptide (figure1.5). 
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Figure 1. 5 Schematic diagram illustrating the processing of VGF peptide precursor into 
functional peptides. 
VGF is synthesised as a 615 (human) and 617 (rodent) amino acids polypeptide precursor, 
which is proteolytically cleaved into smaller functional peptides that ultimately carry out 
functional activities (Picture modified from Jethwa and Ebling 2008). 
 
1.2.5. Function of VGF 
 
VGF knockout mice phenotype 
 
Genetically engineered knockout mice inactivating vgf gene allow the assessment of 
vgf gene function by monitoring the consequences of the loss of gene activity, in terms 
of changes in the mouse phenotype. In 1999, Hahm et al. reported the first target 
deletion of the entire vgf coding sequence in mice by homologous recombination in 
the embryonic stem cells (Hahm, Mizuno et al. 1999). The study revealed a number of 
profound changes in the phenotype and suggested functional roles of VGF in a 
number of biological processes.  
 
Firstly, the homozygous VGF mutant mice were observed to be smaller in the body 
size. Although the size of VGF-deficient pups were indistinguishable from its normal 
littermates at birth, the body weight of VGF mutants were 10-20% less by postnatal 
day 3 (P3), which dropped further to 40-60% less compared to the wild-type 
littermates by the third week. The body weight plateaus at 30-50% less than those of 
the wild-type mice after weaning. Interestingly, VGF deficiency was suggested to 
 51 
prevent weight gain in the animal model of obesity and genetically obese mice, 
suggesting a functional role of vgf in obesity (Hahm, Fekete et al. 2002). Nonetheless, 
the survival rates of the VGF mutants were observed to be lower than that of the 
heterozygous and wild-type counterparts, especially during the time prior to weaning 
(Hahm, Mizuno et al. 1999).  
 
VGF-mutant mice are also hypermetabolic. The basal metabolic rates of the mutants 
were significantly higher, as demonstrated with higher oxygen consumption and carbon 
dioxide output in these mice. Moreover, it was shown that the mutants exhibit an 
increase in the daily food intake per gram of the body. In addition, VGF mutant mice 
are also hyperactive as the activity (distance travelled per time) of these mice were 
shown to be about 5 times more than that of the wild type (Hahm, Mizuno et al. 1999).  
 
Moreover, VGF-deficient mice have reduced fertility, suggesting a role of VGF in 
reproduction. Repetitive mating of the wild-type and heterozygous mice for four 
months demonstrated >90% of fertility. On the other hand, when the homozygous VGF 
mutants were mated, it was shown 85% of the male mutant mice and 90% of the female 
mutant mice were infertile. It was also observed that VGF mutant mice exhibit delayed 
in puberty and sexual maturation. In the mutant females, 50% display prolonged 
oestrous cycle and the other 50% failed to cycle. The ovaries, oviducts and uteri of 
these females were shown to be much smaller, comprising only 18-30% the weight of 
the normal mice. The VGF-deficient males exhibit abnormal sexual behaviours and 
have smaller testis and seminal vesicles (30% and 65% less in weight, respectively, 
when compared to the wild-type).  
 
In terms of biochemistry, VGF mutants display reduced serum insulin and glucose 
levels (20% and 40% less than that in normal mice, repectively). The peripheral fat 
stores were also profoundly reduced in the mutants. The serum corticosterone level, on 
the other hand, was increased by 40% in the mutants when compared to that in the wild 
type. Moreover, VGF-deficient mice have reduced hormone contents (reduced in serum 
T4 thyroid hormone and pituitary thyroid-stmulating hormone). The neuropeptide 
expression levels were also altered in the mutant mice. Indeed, the mRNA expression 
level of neuropeptide Y and agouti-related peptide (AGRP) were shown to be increased 
by 6 and 8 folds in the hypothalamus, respectively. Whereas, the hypothalamic 
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pro-opiomelanocortin (POMC) expression was shown to be 75% lower than that of the 
wild type littermates. Furthermore, the leptin expression in the epididymal fat and the 
circulating leptin hormone were shown to be markedly reduced in the mutants.  
 
Energy homeostasis and food intake  
 
The VGF knock out mice exhibit high oxygen consumption and metabolic rate, 
suggested a role of VGF in inhibiting energy expenditure. Surprisingly, however, it was 
demonstrated by Bartolomucci et al. chronic intracerebroventricular injection (i.c.v.) of 
TLQP-21, in fact, increased the energy metabolism and rectal temperature in mice 
(Bartolomucci, La Corte et al. 2006). In addition, TLQP-21 i.c.v. injection prevented 
the high-fat diet-induced obesity in normal mice (Bartolomucci, La Corte et al. 2006) 
and fast weight gain mice (Bartolomucci, Bresciani et al. 2009). Further, the primary 
action of TLQP-21 was, controversially, suggested to decrease the food intake in 
Siberian hamster rather than increase energy expenditure (Jethwa, Warner et al. 2007). 
However, i.c.v. injection of another VGF-derived peptide, NERP-2, was shown to 
increase feeding and metabolism in rats (Toshinai, Yamaguchi et al. 2010). Although 
the data still remains controversial and the precise role yet to be characterised, 
VGF-derived peptides were demonstrated to play a role in the energy expenditure and 
food intake.  
 
Depression 
 
VGF has been implicated in depression. It has been demonstrated that the VGF protein 
level is markedly decreased in the hippocampi of animals subject to the depression 
paradigms (Thakker-Varia, Krol et al. 2007). Thakker-Varia et al. employed the forced 
swim test (FST) and learned helplessness test (LH), the two commonly used animal 
models of depression, and showed the VGF protein levels were decreased by more than 
20% in the hippocampi, a brain region implicated in depression, of the animals exposed 
to FST and LH. In addition, it was also demonstrated that the effect of depression was 
reversible in the FST by intrahippocampal infusion of a VGF-derived peptide, 
TLQP-62, suggesting VGF elicits antidepressant-like effects when introduced to the 
depressed animals (Thakker-Varia, Krol et al. 2007). The antidepressant effect of VGF 
has been confirmed by the hippocampus transcription profiling in animals of the 
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exercise model (Hunsberger, Newton et al. 2007). It is suggested that exercise promotes 
antidepressant actions. Interestingly, vgf mRNA expression was found to be profoundly 
increased in the hippocampus of animals that exercised for 7 days. The VGF protein 
expression was also confirmed be markedly induced in the mice hippocampus after 
exercise by immunohistochemistry. Behavioural assessments in FST and 
tail-suspension test (TST) also revealed VGF-derived peptide (AQEE) infusion to the 
hippocampus promoted antidepressant actions, which lead to reduction in the 
immobility time in both of the test. Furthermore, the VGF heterozygous null mice were 
shown to exhibit depression-like behaviour in the FST and TST, and the depression-like 
behaviour was shown to be unaltered after exercise in the VGF deficient mice, whereas 
exercised wild-type mice had an antidepressant-like response. The unaltered 
depression-like behaviour in the VGF deficient mice was proposed to be correlated to 
the lower VGF expression in the hippocampi of the VGF deficient mice (Hunsberger, 
Newton et al. 2007). Interestingly, the vgf mRNA levels in leukocytes of the drug-free 
depressed patients were found to be significantly lower than the normal population, 
and the expression could be restored in antidepressant responsive patients (Cattaneo, 
Sesta et al. 2010). 
 
Reproduction  
 
Despite the delayed puberty, delayed sexual maturation and infertility observed in the 
VGF knock out mice, the function role of VGF-derived peptide in reproduction was 
demonstrated by a number of other in vivo works. It was demonstrated hypothalamic 
Paraventricular Nucleus injection of C-terminal VGF-derived peptides induced rat 
penile erection. Four out of the five C-terminal VGF-derived peptides (HHPD-41, 
AQEE-30, LQEQ-19 and AQEE-10, but not TLQP-21) showed a positive effect in 
penile erection in a dose-dependent manner. It is proposed this process may be 
nitric-oxide mediated and the paraventricular oxytocinergic neurons are involved 
(Succu, Cocco et al. 2004, Succu, Mascia et al. 2005). Although TLQP-21 was shown 
to be ineffective in eliciting penile erection in rats, it was demonstrated it, in fact, 
modulates reproductive axis in male rats in various levels. Indeed, central 
administration of TLQP-21 was shown to modulate the gonadotropin response in vivo. 
In addition, TLQP-21 stimulated luteinizing hormone (LH) secretion from the 
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pituitaries and testosterone from the testicular tissue of pubertal male rats and adult 
male rats, respectively (Pinilla, Pineda et al. 2011). The multiple actions of the 
c-terminal VGF-derived peptides together revealed the role of VGF in reproduction.  
 
Neuronal apotosis/neurogenesis  
 
VGF-derived peptide, TLQP-21 has been demonstrated to exhibit anti-apoptotic effect 
in rat cerebellar granule cells (CGCs) culture. Indeed, the apoptotic effect induced by 
serum and potassium deprivation in the CGCs culture was prevented by TLQP-21 
treatment in a dose- and time-dependent manner. Such neuroprotective effect was 
evident to be protein kinase C(PKC)- and c-Jun N-terminal Kinase (JNK)- dependent 
(Severini, Ciotti et al. 2008). Moreover, the anti-apoptotic effect of VGF is also 
demonstrated in the in vitro model of Amyotrophic lateral sclerosis (ALS). Exogenous 
full-length vgf expression in the primary mixed spinal cord neuron cultures of the ALS 
animal model significantly attenuated excitotoxic injury-induced cell death (Zhao, 
Lange et al. 2008). Furthermore, Shimazawa et al. demonstrated SUN N8075 (a small 
molecule) treatment drastically upregulated the vgf mRNA expression in SH-SY5Y 
neuroblastoma cells, and pre-treatment of SUN N8075 prevented Tunicamycin and 
Thapsigargin-induced cell apoptosis in a dose-dependent manner. In addition, siRNA 
knockdown of vgf in the SH-SY5Y cells abolished the anti-apoptotic effect induced by 
SUN N8075. Such molecule has also been shown to attenuate the decrease of VGF 
protein expression in the ALS animal model and delay the disease progression. The 
results together suggested that SUN N8075-induced vgf expression prevents the cells 
from endoplasmic reticulum-induced cell death both in vitro and in vivo (Shimazawa, 
Tanaka et al. 2010), and hence implicating a role for vgf in neuroprotection, in terms of 
anti-apoptosis.  
 
Pain signalling and modulation  
 
Maratou et al. has recently reported an extensive study to search for the common gene 
that is upregulated in three different animal models of neuropathic pain, the peripheral 
nerve trauma - Sciatic Nerve Transection (SNT) model, the chemotherapy drug/viral 
protein-induced neuropathy - Gp120 + ddC model, and Varicella Zoster Virus infection 
– VZV infection model) (Maratou, Wallace et al. 2009). Gene expression profiling of 
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the L4 and L5 DRGs from these models were performed, and the comparison between 
the data revealed that only three genes were commonly upregulated among the three 
animal models. Two of which are the expressed sequence tags, and the third gene is vgf. 
Quantitative PCR study of DRGs from these three models also confirmed that vgf was 
commonly upregulated. In addition, they also showed Neuropeptide Y (NpY) and 
Pap/Reg2 were also commonly increased in expression in all three animal models by 
quantitative PCR. Furthermore, vgf is also found to be upregulated in other peripheral 
nerve injury animal models of neuropathic pain (SNT, SNL, SNI, and CCI models) by 
other groups (Costigan, Befort et al. 2002, Xiao, Huang et al. 2002, Valder, Liu et al. 
2003, Moss, Ingram et al. 2008). The studies described collectively suggest that vgf, as 
a commonly upregulated gene in all animal models of neuropathic pain tested, may 
play a pivotal role in initiation and/or maintenance of neuropathic pain, rather than 
involving in other pathophysiological events upon nerve injury. 
 
As described earlier, vgf is profoundly expressed in both sympathyetic ganglia and 
dorsal root ganglia, and the expression is induced by neuronal lesion and neurotrophin 
stimulation (Levi, Ferri et al. 2004). One of the other evidence suggesting a possible 
role of VGF-derived peptides modulating pain signal transduction came from the 
study showing vgf expression was increased in the sensory neurons in response to 
NGF stimulation to the primary afferent (Ferri, Levi et al. 1992). In addition, it is also 
demonstrated that the increase VGF expression after traumatic nerve injury is also 
detected at the protein level. Indeed, VGF protein expression is increased and detected 
in 80% of the neurons of the L5 DRG that is ipsilateral to the injury site in SNL 
model. Comparatively, VGF protein expression is only observed in 37% of the 
sensory neurons in L5 DRG of the sham-operated animal and 20% of that in the naïve 
animals. (Riedl, Braun et al. 2009). This increase in VGF expression at protein level is 
shown to sustain for at least 7 days after SNL surgery. Interestingly, VGF-positive 
neurons in the ipsilateral L5 DRG immediately after nerve injury are the small and 
medium diameter neurons. Seven days after SNL surgery, the VGF protein expression 
in these groups of neurons is reduced back to the level that is similar to day 1 
expression. Interestingly, at this time point, the number of large diameter, 
VGF-positive, neurons is increased. In addition, it is also demonstrated that VGF 
protein expression in the DRG neurons is colocalised with TrkA and P2X3 receptors, 
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which have been implicated in the pain pathways. Indeed, about 52% of the 
VGF-positive neurons are shown to also express TrkA, and 52.3% of the 
VGF-expressing neurons are co-expessing P2X3 (Riedl, Braun et al. 2009). Further to 
its increase in expression in the ipsilateral DRG, VGF expression is also shown to be 
upregulated in the spinal cord after nerve injury. Moreover, an increase in 
co-localisation of VGF with CGRP in the superficial dorsal horn ipsilateral to the 
nerve injury site is also reported (Riedl, Braun et al. 2009). 
 
Besides the evidence of increases in VGF expression, at both mRNA and protein 
levels, after peripheral nerve injury, VGF-derived peptides have demonstrated 
functional properties in vivo and are functionally implicated in the pain pathways. 
One of the VGF peptide derivative, TLQP-21, is shown to induce a significant 
increase in the pain-related licking response in the second phase of formalin test 
following to the subcutaneous injection (Rizzi, Bartolomucci et al. 2008). Moreover, 
the same peptide alone at a dose of 4mM increases the nociceptive-like licking 
response. Other VGF peptide derivatives, such as AQEE-30 and LQEQ-19, have been 
shown to evoke thermal hypersensitivity in mice when injected intrathecally (Riedl, 
Braun et al. 2009). AQEE-30 injection induces thermal hypersensitivity to warm 
water tail immersion assay within 10 minutes, which peaks at 30 minutes and persists 
up to 90 minutes at high dose. LQEQ-19 contains the last 19 amino acids of 
AQEE-30. Intrathecal injection of the LQEQ-19 peptide also demonstrates a 
comparable thermal hypersensitivity with similar magnitude but a shorter duration. 
Interestingly, AQEE-11 (the first 11 amino acid of AQEE-30), on the other hand, 
shows no statistical significant effect on the thermal hypersensitivity. The LQEQ-19- 
and AQEE-30-evoked thermal hypersensitivity has recently been demonstrated to be 
reversible by p38 inhibitor SB202190, indicating the involvement of p38 MAPK in 
the signal transduction downstream to vgf. Indeed, p38 phosphorylation has been 
shown to increase, for more than 3 folds, in the spinal microglia after intrathecal 
injection of LQEQ-19 (Riedl, Braun et al. 2009). In consistence with this finding, a 
preliminary data also shows that the mechanical hypersensitivity is induced within 10 
minutes upon intraplantar injection of LQEQ-19 (Unpublished data, Professor 
Andrew Rice, Chelsea and Westminster Hospital). Furthermore, an in vivo 
electrophysiological study also demonstrates the action potential amplitude of the 
nociceptive C-fibre components after LQEQ-19 application to the lumbar 5 and 6 
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DRGs is increased. However, such increase in the action potential amplitude is not 
observed in the Aβ- and Aδ- fibres (unpublished data, Dr Istvan Nagy, Chelsea and 
Westminster Hospital). 
 
Human diseases states 
 
Alternation of vgf mRNA and protein expressions has been associated with a number 
of human diseases, particularly the psychiatric disorders. It was demonstrated the 
level of vgf mRNA was reduced in postmortem brain of patients with bipolar disorder, 
particularly in region of hippocampus and prefrontal cortex (Thakker-Varia, Jean et al. 
2010). In addition, as mentioned, the vgf mRNA was also reduced in leucocytes of 
patients with depression disorder (Cattaneo, Sesta et al. 2010). In terms of VGF 
protein expression, VGF peptide is detectable in the cerebrospinal fluid of normal 
human (Yuan and Desiderio 2005), and a higher level of VGF peptide was reported in 
the cerebrospinal fluid samples of schizophrenia patients by mass spectrometry 
analysis, as well as in a few depressed and obsessive-compulsive disorder patients 
(Huang, Leweke et al. 2006). In addition, VGF peptide was also demonstrated to be 
reduced in the cerebrospinal fluid of patients with neurodegenerative diseases such as 
ALS (Ranganathan, Williams et al. 2005, Pasinetti, Ungar et al. 2006), Alzheimer’s 
(Carrette, Demalte et al. 2003, Jahn, Wittke et al. 2011), Encephalopathy (Asano, 
Koizumi et al. 2011) and dementia (Ruetschi, Zetterberg et al. 2005). Due to the change 
in the relative abundance in the cerebrospinal fluid in disease pathological states, VGF 
has been proposed to be the biomarker for the mentioned neurological and psychiatric 
disorders (Bartolomucci, Pasinetti et al. 2010). However, the relative expression of 
VGF peptides in the cerebrospinal fluid of neuropathic pain patients has not yet been 
investigated and still awaits to be elucidated.  
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1.3. Aims 
 
Although a number of VGF-derived peptides have been identified and some of their 
functions revealed in the pain pathway, the exact underlying mechanism(s) and the 
signalling pathway(s), in the context of pain, still remain largely unknown. The aim 
and emphasis of this thesis is to further the understanding of the peripheral 
mechanism(s) of action of VGF-derived peptides in the pain pathway, with particular 
focus on cells implicated in the neuropathic pain development.  
 
The objectives of this project are to: 
 
1. Establish an in vitro functional calcium assay for the investigation of effects of 
the VGF-derived peptides (LQEQ-19, TLQP-21 and TLQP-62) on cells that has 
been implicated in the peripheral mechanism of neuropathic pain (DRG neuron 
and macrophage). 
 
2. Investigate the in vivo effect of intraplantar injection of the VGF-derived 
peptide (TLQP-21)-stimulated cells on nociception. 
 
3. Verify the potential VGF receptor (GC1qR) as the receptor for VGF-derived 
peptide (TLQP-21) on primary macrophages by neutralising antibody and 
siRNA knock-down methodologies.  
 
4. Investigate the effect of blocking the potential VGF receptor (GC1qR) in vivo 
on the mechanical sensitivity of neuropathic pain animal model (partial sciatic 
nerve ligation model). 
 
5. Elucidate the downstream signalling events in the target cells after 
VGF-derived peptide application using quantitative real time PCR (qRT-PCR), 
PCR array and microarray. 
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CHAPTER 2: 
THE MECHANISM OF ACTION OF THE VGF-DERIVED 
PEPTIDES 
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Synopsis  
 
In the general introduction I have outlined that vgf is the commonly up-regulated gene 
in different animal models of neuropathic pain and several VGF-derived peptides have 
been implicated in the pain pathway. In this chapter, the mechanism of actions of 
VGF-derived peptides, LQEQ-19, TLQP-21 and TLQP-62 (with a more in-depth study 
on TLQP-21) has been explored. A function assay, calcium imaging, has been 
developed for investigating the effects of the peptides on different cell types including 
the primary DRG neurons and untreated/polarised bone-marrow-derived primary 
macrophages. In addition, the effect of repeated treatment of peptides on its target cells 
has been investigated. Moreover, the origin of the calcium source and the effects of the 
VGF-derived peptide-conditioned media from the primary macrophages on the DRG 
neurons have been assessed. Lastly, an outline is presented for my data that explores the 
involvement of the VGF-derived peptide-stimulated macrophages in the in vivo study 
and finding is discussed in the context of pain. 
 
2.1. Introduction 
 
2.1.1. Investigating calcium signalling 
 
Calcium is a simple ion that can be found ubiquitously. It is one of the most versatile 
and pluripotent ions that regulates a variety of physiological and pathological 
signalling events. Dynamic changes in the concentration of calcium need to be tightly 
regulated spatially, temporally and kinetically, in order to maintain its homeostasis and 
thus control various events of biological activities. In order to understand the role of 
calcium and elucidate its underlying regulatory mechanisms in any biological event, 
measurement and monitoring of intracellular calcium become essential. Due to this 
reason, there are a wide range of synthetic and biosynthetic calcium sensors developed, 
which allow quantification and visualisation of intracellular calcium in a 
spatio-temporal controlled manner. In this session, the commonly employed strategies 
for studying calcium signalling in vitro using optical techniques will be described, and 
that for studying calcium signalling in vivo will be briefly mentioned. 
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Strategies for studying calcium signalling in vitro 
  
The spatio-temporal modulation of calcium concentrations initiates biological 
processes range from egg fertilisation, cell proliferation to cell death. Elucidating how 
calcium functions in cell physiology and investigation of its underlying mechanisms 
necessitates visualisation and/or measurements of the intracellular calcium. Here, the 
methods that are commonly coupled with optical techniques for studying calcium 
signalling in vitro are discussed. 
 
Fluorescent chemical probe-based method 
In the recent year, fluorescence-based visualisation becomes an influential method to 
detect and study calcium signalling in vitro. The method allows live cells to be 
examined and provides detailed information on spatio-temporal resolution and 
quantification of calcium concentration once the loading condition is optimised. All 
fluorescence-based methods rely on both calcium indicators and sophisticated 
detection technology to read out the emitted fluorescence signals, which will both be 
briefly discussed here. 
 
The fluorescent-based calcium indicators available for studying calcium signalling can 
be broadly divided into two groups, ratiometric and non-ratiometric indicators. The 
ratiometric calcium indicators rely on ratio measurements of two fluorescence 
intensities. In general, ratiometric dye can work either by “excitation ratioing” or 
“emission ratioing”. For excitation ratio, the dye is excited by alternating two different 
wavelengths and the fluorescence emission of a single wavelength is captured. The 
ratio of emission at the excitation wavelengths correlates to the amount of intracellular 
calcium. For example, fura-2 ratiometric calcium dye is often used in excitation 
ratioing. The dye is excited at 340nm and 380nm wavelength and the emission is 
always measured at ~510nm. To correlate to the exact amount of calcium after 
calibration, the emission excited at 340nm is divided by the emission at 380nm. Should 
there be an increase in the intracellular calcium in the cell, an increase in 340/380 ratio 
will be observed. Fura-2 dye was employed in vitro to investigate the effect of 
VGF-derived peptide, TLQP-21, on cerebellar granule cells (CGCs) in calcium 
imaging. It was demonstrated that TLQP-21 elicited an increase in intracellular calcium 
level in the CGCs and exhibited neuroprotective effects (Severini, Ciotti et al. 2008). 
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Emission ratioing, on the other hand, works by exciting the dye at a single wavelength 
while capturing emission at two different wavelengths. Indo-1 is an example of 
emission ratioing ratiometric calcium dye. The dye is often excited at ~350nm 
wavelength, and the emission is measured at ~400nm and ~475nm simultaneously. The 
ratio between two emissions captured corresponds to the intracellular calcium 
concentration. The ratiometric quantification of calcium concentration is beneficial that 
it corrects the in vitro fluorescent artefacts due to photobleaching, changes in focus, 
uneven loading of the dye, or uneven thickness of the cells. Nevertheless, it exhibits 
drawbacks of more complicated data acquisition, measurement and processing. 
Moreover, not all microscopes are equipped with changeable excitation/emission 
wavelength and most of the ratiometric dyes, such as fura-2 and indo-2, require UV 
excitation that is often challenging to obtain. 
 
The second class of fluorescent-based calcium dyes is the non-ratiometric calcium 
indicators. The free non-ratiometric calcium indicators often exhibit weak fluorescence, 
and a change in intensity, rather than a spectral shift, is observed upon binding with 
calcium. Therefore, the fluorescent intensity detected corresponds to the calcium level 
in the cells. Non-ratiometric calcium indicators generally have a longer excitation and 
emission wavelengths, and most of these indicators use fluorescein or rhodamine 
derivatives as the fluorophore (with the exception of Fura Red, which is one of the few 
long wavelength ratiometric calcium dye)(Minta, Kao et al. 1989). The main 
differences between different non-ratiometric calcium indicators are the differences in 
excitation and emission maxima, the brightness of the dye in calcium free conditions, 
the extent of fluorescence intensity change upon binding to calcium, their affinity to 
calcium and if they exhibit a tendency to accumulate in mitochondria. Non-ratiometric 
calcium indicators based on fluorescein derivatives include Fluo-3, Fluo-4, Calcium 
Green-1, Calcium Green-2, Oregon Green 488 BAPTA, and those based on Rhodamine 
derivatives include Rhod-2, X-Rhod-2, Calcium Orange, Calcium Crimson. Of all the 
long wavelength non-ratiometric indicators, Fluo-4 emerges to be the most assuring 
dye to be used in studying calcium signalling event. Fluo-4 has been shown to exhibit 
brighter fluorescence than other fluorescein-based derivatives because of the chloride 
to fluorine substitution on the fluorescein ring. This halogen substitution makes the dye 
40% brighter than its structurally related dye, Fluo-3 (Gee, Brown et al. 2000). 
Moreover, Fluo-4, with a maximum excitation wavelength at 491nm, is suggested to be 
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better suited for the use with confocal microscopy that it is excited much more 
efficiently than Fluo-3 by a 488nm Argon laser. Furthermore, Fluo-4 also exhibits a 
better photostability than other indicators such as Oregon Green 488 BAPTA, which 
bleaches rapidly and possesses a lower dynamic range. Lastly, Fluo-4 also has an easier 
loading procedure when compared to other dyes including rhodamine-based indicators. 
The major advantages of non-ratiometric indicators over ratiometric indicators are that 
the increase in fluorescence signal can be directly correlated to the increase in calcium 
level, and changeable excitation/emission wavelengths are not required. However, it 
also exhibits a number of drawbacks, such as being prone to artefacts. 
 
Both membrane permeable and membrane impermeable derivatives of ratiometric and 
non-ratiometric fluorescent chemical calcium dyes are commercially available. The 
most common detection methods for these dyes are the wide-field fluorescence 
imaging and the laser scanning confocal microscopy. The conventional wide-field 
fluorescence imaging often requires a xenon or mercury bulb to deliver excitation light. 
The excitation wavelength required for exciting the probe is controlled by optical filters. 
The fluorescence signals emitted from the cells are detected with a CCD digital camera 
or intensified video camera. Laser scanning confocal microscopy allows visualisation 
of the changes in the intracellular calcium level. The signal-to-noise ratio can be 
improved in confocal microscope by capturing the fluorescence emission that 
originates from the plane of focus only. Most of the confocal microscopy system is 
equipped with an argon-krypton light source, which produce excitation wavelength at 
488nm, 568nm and 647nm. Calcium signals emitted from the cells can be recorded in 
one of the three possible imaging modes: xt-scanning mode, xyt-scanning mode or 
xyzt-scanning mode. The images are subsequently acquired by a high sensitivity, high 
speed digital CCD. 
 
Calcium sensitive protein –based method: Aequorin-/fluorescent protein-based 
measurement  
Apart from the fluorescent chemical probes, fluorescent and luminescent proteins have 
also been utilised to monitor calcium signal in the biological events. Here, the 
applications offered by aequorin (a calcium sensitive protein) in the study of 
intracellular calcium signalling will be discussed, and a brief introduction to the new 
bioluminescent probes that couple aequorin to GFP emission will be mentioned.  
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The bioluminescence of the jellyfish Aequorea Victoria is a result of two proteins, GFP 
and aequorin. The aequorin was isolated from the jellyfish in 1962 (Shimomura, 
Johnson et al. 1962) and has been widely employed in studying intracellular calcium 
since the late 1960s (Ridgway and Ashley 1967, Allen and Blinks 1978). Aequorin is a 
22kDa protein that contains four helix-loop-helix EF-hand domains, and three of those 
are able to bind to calcium. Binding of calcium to the EF-hand domains induces a 
conformational change that results in the oxidation of Coelenterazine and the 
subsequent release of CO2 and blue light. Since the protein itself is not cell permeable, 
aequorin was initially used in studying changes in calcium in larger cells by 
microinjection procedures. Thanks to the advancement in molecular biology, 
recombinantly expressed aequorin can now be generated and transfected to different 
cell types. The transfected clone synthesises apo-aequorin that can be reconstituted to 
an active probe by adding Coelenterazine to the culture medium (which diffuse freely 
across membrane and bind to the polypeptide once inside the cells). The detection of 
the signal is classically performed in the dark by a low-noise photomultiplier. After 
adding stimulus to the cells, photons are emitted from the aequorin upon calcium 
binding, and an amplifier generates pulses that can be detected by a photon counting 
board connected to a computer.  
 
One of the major advantages using recombinantly expressed aequorin over fluorescent 
chemical probe in the calcium detection is that it is possible to localise the photoprotein 
to different cellular compartments by introducing appropriate leader sequence to the 
aequorin coding sequence. This has been widely utilised to monitor calcium levels in 
the nucleus (Brini, Murgia et al. 1993), mitochondria (Rizzuto, Simpson et al. 1992), 
plasma membrane (Marsault, Murgia et al. 1997), Golgi apparatus (Pinton, Pozzan et al. 
1998), endoplasmic reticulum and sarcoplasmic reticulum (Robert, De Giorgi et al. 
1998). Another advantage of the use of photoprotein is that aequorin enables detection 
of calcium in the higher micromolar range that may occur, for example, in neurons 
upon excitation. The detection of such high concentration using fluorescent chemical 
probes is generally not permitted because most of the probes are saturated at high 
micromolar concentration. Moreover, aequorin is not toxic to cells, can be expressed in 
a variety cell types and efficiently folds into functional protein upon synthesis. The 
expressed fully functional protein is not secreted, exported, nor sequestered within cells 
thus allowing monitoring of the changes in the calcium levels over a relatively longer 
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period of time. However, aequorin-based calcium visualisation has a big limitation to 
image single cell, because each aequorin molecule emits one proton only and hence the 
measurable signal is often very low in a cell. Even with the most sophisticated 
high-resolution camera, higher emission of the light is required to detect the change in 
the calcium level in the single cell imaging. Due to this limitation, the aequorin-based 
detection has mostly been replaced by using the new modified bioluminescent calcium 
probe in single cell imaging. To overcome the low signal limitation, aequorin is 
combined with the GFP. A fusion protein is generated with the calcium sensitive 
aequorin acting as a calcium sensor, which generates an intra-molecular 
bioluminescence resonance energy transfer (BRET) to the GFP acceptor upon calcium 
binding. The improved higher signal-to-noise ratio of the new bioluminescent calcium 
probe enables investigation of calcium in a single cell in real time with modified 
detection using a fluorescence microscope coupled with a sensitive camera (Baubet, Le 
Mouellic et al. 2000).   
 
A similar-in-concept approach has been used to generate fluorescent protein-based 
calcium indicators such as Cameleons. Cameleons are the GFP-based calcium 
indicators generally containing two fluorescent proteins that emit fluorescence at 
different wavelengths. The first constructed Cameleons consists two fluorescent 
proteins (BFP and GFP) that are bridged by a calcium sensitive protein (Xenopus laevis 
calmodulin) and calcium sensitive protein binding protein (M13, a calmodulin-binding 
protein). Binding of calcium to the calcium sensitive protein induces a conformational 
change, which consequently brings the two fluorescent proteins closer and results in 
fluorescence resonance energy transfer (FRET). Thus, the increase in FRET between 
the two fluorescent proteins is directly correlated to the calcium concentration in the 
cells (Miyawaki, Llopis et al. 1997). Various forms of Cameleons have been developed 
to improve the brightness, photostability and signal-to-noise ratio by replacing the 
BFP/GFP to enhanced CFP/YFP. In contrast to Cameleons, other fluorescent 
protein-based calcium sensors such as Camgaroo, G-CaMP and Pericam have been 
developed based on the direct changes in fluorescent intensities upon calcium binding, 
instead of FRET. The binding of calcium results in electrostatic changes in the 
microenvironment of the fluorescent proteins, leading to a calcium sensitive change in 
structure of the fluorophore and subsequent increase in fluorescent emission. The 
increase in the fluorescence intensity of these sensors is hence directly correlated to the 
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increase in the calcium level (Zhang, Campbell et al. 2002). The fluorescent 
protein-based calcium sensors exhibit a number of advantages over aequorin-based 
calcium sensor. Firstly, the enhanced fluorescence of fluorescent protein-based sensors 
allows the use of simpler detection system and results in comparatively high temporal 
resolution. The second major advantage would be that the calcium-induced increase in 
fluorescent is reversible. Calcium binding to aequorin-based sensor irreversibly 
consumes the indicator, which can introduce an artefact that mimics lowering calcium 
concentration. This limitation is not presented when using fluorescent protein-based 
calcium sensor. Lastly, the use of fluorescent protein-based sensors does not require 
specific cofactors as aequorin-based sensors, which gives a simpler experimental 
procedure. However, on the downside, the fluorescence of the fluorescent proteins is 
sensitive to the pH, particularly with YFP (Kneen, Farinas et al. 1998), and hence the 
pH differences in the intracellular compartments of the cells could alter the 
fluorescence intensity detected. 
 
Strategies for studying calcium signalling in vivo  
 
As mentioned previously, the development of different calcium indicators opened the 
door for investigating intracellular calcium signal at high temporal and spatial 
resolution. Imaging calcium signals in isolated primary cells, cell lines and tissue slides 
in vitro has become routine in most of the laboratories today. However, it is essential to 
visualise calcium dynamics in the whole animal to better understand the signal flows 
between cells in a complex system. Advances in microscope and optical technologies 
allow this goal to be achieved to enhance our understandings of the complexity of cellar 
functions and relationship between different cell populations in a complicated 
biological event in vivo.  
 
The calcium indicators used in in vivo calcium imaging are similar to those in vitro. 
However, the loading of the calcium indicators to cells for in vivo calcium imaging is 
trickier. The simplest way is by microinjecting the calcium indicator to a single cell 
(Helmchen, Svoboda et al. 1999). However, this limits the in vivo imaging to the loaded 
cell only. Thus, more complex cell-cell interactions and signalling within cell 
populations cannot be monitored. To overcome this limitation, bulk loading of a 
population of cells within tissue can be achieved by local electroporation (Nagayama, 
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Zeng et al. 2007), retrograde passive diffusion (Takahashi, Narushima et al. 2002) or by 
pressure ejection of the dye (e.g. multi-cell bolus loading technique)(Stosiek, 
Garaschuk et al. 2003). These loading options provide rapid staining of cells within a 
local area thus allowing real-time calcium imaging of cell population activity. 
Nonetheless, these methods do not provide cell-type specific staining as it often results 
in a homogenous staining of all cells within the stained area. Cell type specificity 
expression of calcium indicator can be achieved by using the transgenic animals 
carrying genetically encoded fluorescent protein-based indicators (Hirrlinger, Scheller 
et al. 2005), which enable investigation of calcium signalling in specific cell type in 
vivo. 
 
2.1.2. Behavioural assessment of nociception    
 
The in vivo experimental studies of the mechanisms underlying nociception 
necessitate the behavioural testing. It is inevitable to employ the appropriate stimuli to 
provoke the sensation. Moreover, it is of great importance that these stimuli and the 
methods utilised to monitor the changes in the animal behaviours are sensitive, 
quantifiable, reproducible and noninvasive.  
 
Because pain cannot be directly measured from the animals, a number of different 
sensitive and quantifiable surrogates have been suggested. The most commonly 
exploited nociception assessments in vivo can be divided into two broad categories, 
the Mechanical and Thermal assessment. In this session, both types of nociception 
assessments will be briefly described with particular highlight on the von Frey 
Mechanical assessment, which is the assessment used in my study. 
 
Assessment of Mechanical nociception in rodent  
 
Allodynia and hyperalgesia are two of the many problematic clinical symptoms of 
chronic pain patients. The International Association for the Study of Pain (IASP) 
defines allodynia as pain evoked by a stimulus that does not normally produce pain, 
and hyperalgesia as an elevated response to a stimulus that is normally 
painful(Merskey and Bogduk 1994). The in vivo assessment using mechanical stimuli 
accesses the mechanical allodynia-like behaviours in animals. It is important to note 
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that, as pain cannot be monitored directly in animals, it is only estimated by 
measuring their response to mechanical stimuli. However, such responses do not 
necessarily means there is a painful sensation. Therefore, the responses observed 
cannot be described as “mechanical allodynia” in animal, but rather an “allodynia-like 
hypersensitivity to mechanical stimuli”.  
Von Frey filaments 
The Von Frey filaments are Nylon monofilaments that give a calibrated amount of 
force when applied against tissue until they bend. The mechanical stimulus given by 
von Frey filaments is commonly employed for assessing the mechanical response 
threshold of an animal. The testing is simple, filaments of known graded mechanical 
force are applied to the hind paw of the animal for about one second, and a positive 
response is obtained if the animal lifts its paw during the application. In general, Von 
Frey testing is often conducted by applying a set of hair filaments, ranging from 0.6 to 
44mN as described by Fuchs et al(Fuchs, Roza et al. 1999). Each filament is applied 5 
times, with at least a 10 seconds interval between stimulation, and the positive 
responses are recorded. The frequency of paw withdrawal to stimulation given is then 
converted to percentage of positive responses for each filament, and the result is 
presented as percent response versus von Frey force given. 
 
More recently, the electronic von Frey system has been introduced to simplify the 
procedure and minimise the variability between researchers when using conventional 
von Frey filaments. Nonetheless, the operating principle remains similar for electronic 
von Frey. The tip of the probe is applied to the plantar surface of the hindpaw of an 
animal, and the animal will indicate the evoked noxious sensation by withdrawing its 
paw. The pressure, quantified in grams, applied to the paw is recorded in real time 
and the noxious threshold is recorded as an abrupt decrease in the applied force. It has 
been recently demonstrated that the electronic von Frey is more reliable and rapid 
than the conventional von Frey filament test in examining mechanical pain thresholds 
(Tena, Escobar et al. 2012). The reproducibility of repeated examinations, both by the 
same and by different observers, is good when using electronic von Frey system, and 
the time taken to conduct an experiment is almost half as that when using the 
conventional von Frey.  
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Randall Selitto apparatus 
The Randall Sellitto testing allows detection of the changes in nociception by 
measuring the thresholds of animals’ withdrawal reflexes to the nociceptive 
mechanical stimulation. Unlike Von Frey filament that normally can only apply to the 
intraplantar skin of the hindpaw, Randall Sellito apparatus can be applied to the 
forepaw, hindpaw and the tail of an animal. Typically, the animal is restrained and the 
paw/tail is placed under a pusher with a rounded tip. The force is applied until the 
animal attempt to withdraw the paw/tail. The applied force is measured and recorded. 
The paw/tail withdrawal threshold before and after treatments/surgery can then be 
compared. This testing has been widely used to evaluate the inflammatory pain 
response (Bujalska and Gumulka 2001, Lee, Li et al. 2001, Anseloni, Ennis et al. 
2003) and neuropathic pain response (Santos-Nogueira, Redondo Castro et al. 2012). 
 
Assessment of thermal nociception in rodents 
 
The acute application of thermal stimuli to an animal is another most commonly used 
assays in vivo to evaluate the nociceptive processing for testing physiological 
manipulation/ effects of drugs. The thermal nociception assays rely on a principle to 
assess animal’s ability to response to noxious thermal stimuli. The nociception 
responses are measured by behaviours such as withdrawal, licking and vocalisation. 
 
Hargreaves’ apparatus  
The Hargreave’s test measures animals’ response to an infrared heat stimulus. An 
infrared source is focused at the plantar surface of the animal’s hind paw, while a 
timer records the exposure time of the radiant source. When the animal feels pain, it 
will withdraw the paw. The withdrawal of the paw will cause a sudden reduction in 
the reflected radiation, which stops the timer and cut off the infrared source. The time 
latency to the paw withdrawal and the infrared intensity are hence automatically 
recorded by a fibre optic sensor. The infrared source is calibrated and allows the same 
power thermal stimulus to be delivered in the same given length of time. The 
Hargreaves’s apparatus allows the thermal stimulus to be given to the animal 
automatically and also enable the experiment to be conducted without relying on 
investigator’s observation of the animals’ behaviours. 
The radiant heat from the Hargreaves’s apparatus activates the high threshold sensory 
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fibres that innervate the skin. The infrared source increases the temperature of the skin 
on the hind paw, and the axons that innervate this area of the skin transduce the 
temperatures into electric signals, which convey the ‘painful signal’ to the brain. The 
mechanism of transduction is believed to involve the temperature-induced opening of 
thermosensitive channel (TrpV1 channel) (Caterina, Leffler et al. 2000) and ATP 
receptor (P2Y2 and P2X3 receptors) (Malin, Davis et al. 2008). The keratinocytes in 
the epidermis releases ATP in response to the heat generated from the infrared source. 
The ATP then subsequently acts as secondary messenger at the cutaneous afferent 
terminals, which activates ATP receptors and conveys signalling in the sensory 
neurons. The increase in skin temperature also activates TrpV1 channels on the 
afferent terminal, and hence modulates the signal transduction. 
 
Hot plate 
The hot plate apparatus assesses the acute response of the animal to a strong thermal 
stimulus by allowing the animal to stand on a heated metal plate. The hot plate is 
preheated to a selected target temperature (typically between 50 and 55°C), and the 
animal is placed onto the hot plate while a timer is started immediately. The timer is 
immediately stopped when the animal displays the criterion behaviours including 
jumping, restless behaviours, licking, shaking and withdrawal of the hind paws, 
repeated elevation of hind paw(s), volcalisation and increasing walking activity. The 
animal is immediately removed from the hot plates when the timer is stopped to prevent 
tissue damage. The latency to observe criterion behaviour is compared before (baseline) 
and after physical manipulation/drug treatments. Nevertheless, it has been shown by 
Wilson and Mogil repeated testing on hot plate within 30 minutes shows decreased in 
latencies, even in sham animals that are not given any treatment. This phenomenon is 
described as behavioural tolerance (Wilson and Mogil 2001). 
 
Tail-flick test appratus 
The tail-flick test requires restraining the animal to the apparatus. The animal is 
placed in a small cylinder with the tail in a tail groove exposing to a beam of light that 
produces high intensity of heat. A built-in sensor in the tail groove can detect the tail 
flick of the animal, and a timer will measure the latency and/or temperature threshold 
when the animal flicked their tail out of the beam. The test is often carried out with a 
10 second cut-off time of exposure to the beam to prevent tissue damage. 
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2.2. Aim 
 
Despite the growing evidences in the literature today suggest that VGF-derived 
peptides play roles in the pain pathway, the target cells of the VGF-derived peptides at 
the periphery still remain unknown. The molecular mechanisms of how VGF-derived 
peptides signal are also incompletely understood. The aim of this chapter is to: 
 
1. Develop a calcium-based functional assay to investigate the effects of 
VGF-derived peptides on the intracellular calcium levels on different cell types 
that have been implicated in the pain pathway (DRG neuron and the primary 
macrophage). 
 
2. Better understand the mechanism of action of the VGF-derived peptide on its 
target cell by determining the source of calcium and repetitive applications of 
the peptide in the calcium imaging.  
 
3. Investigate the effect of VGF-derived peptide-stimulated cell in vivo by 
peripheral intranplantar injection and behavioural assessment. 
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2.3. Material and method 
 
2.3.1. Animal 
 
All the experiments conducted here conformed to the guidelines of the Committee for 
Research and Ethical Issues of the IASP. The experimental protocols were approved by 
the United Kingdom Home Office (under project license PPL70/7162). All 
experiments were carried out using adult Wistar rats (between 150 – 250 g). The rats 
were housed with standard laboratory conditions, and the food and water were 
available ad libitum. Artificial lighting was given on a fixed 12 hours light-dark cycle. 
 
2.3.2. Primary culture of adult DRG neurons 
 
Female Wistar rats (6 weeks old, ~150 g) were sacrificed by CO2 asphyxiation. Spinal 
dorsal root ganglia (~40 per dissection) were removed from the rats and desheathed 
from the roots using Vannas micro-dissection scissor (Fine Science Tools) under a 
stereomicroscope. The dissected ganglia were digested in 0.125 % collagenase XI 
(Sigma Aldrich) and 0.1 mg/ml deoxyribonuclease II (Sigma Aldrich) for 90 minutes at 
37 
o
C. After enzymatic digestion, DRGs were mechanically dissociated by gentle 
trituration for 10-15 times with a cut 1 ml tip, until a cloudy cell suspension was 
obtained. Dissociated DRG neurons were subsequently filtered through a 70 μm cell 
strainer (BD Biosciences). The filtered DRG cell suspension was gently applied to a 10 
% BSA cushion (PAA) and centrifuged at 1100 rpm for 7 minutes. The cell debris and 
non-neuronal cells were removed from the interphase of the cushion after 
centrifugation, and the DRG neurons were recovered from the pellet. The pellet was 
resuspended in 1ml pre-warmed Dulbecco’s Modified Eagle Medium (DMEM, 
Invitrogen) supplemented with 10 % Fetal Bovine Serum (FBS, Gibco Invitrogen). 10 
µl of cell suspension was removed and applied to a haemocytometer to perform cell 
counting. The remaining cell suspension was centrifuged at 1100 rpm for 3 minutes, 
and the pellet was resuspended to a final volume adjusted.  
 
The harvested DRG neurons were seeded on a 35 mm borosilicate glass bottom plate 
(10mm glass, MatTek) that had been pre-coated with 100 μg/ml poly-L-lysine (Sigma 
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Aldrich) and 10 µg/ml laminin (invitrogen) at a cell density of 8000 cells/plate. 2ml 
DMEM medium supplemented with 10% Fetal bovine serum, Penicillin-Streptomycin 
solution (P/S, 1:100, Sigma Aldrich) and NGF (50ng/ml, Peprotech) was added to each 
plate. Cells were kept in a humidified incubator at 37 
o
C in a 5 % CO2-enriched 
atmosphere. After 5 hours incubation, 10 µM Aphidicolin (Sigma) was added to each 
plate. The culture was used for calcium imaging 2 days after initial plating. 
 
2.3.3. Bone-marrow derived macrophage culture 
 
Bone marrow-derived macrophage cultures were generated using the protocol derived 
from Zhang et al. (Zhang, Goncalves et al. 2008). Female Wistar rats (6 weeks old, 
~150 g) were euthanized, and the femur and tibias were removed bilaterally using 
aseptic techniques. Marrow cores were flushed from the bones into a sterile 50 ml 
Falcon tube using a 50 ml syringe fitted with 25G needle and filled with ice-cold sterile 
Dulbecco’s phosphate buffered saline (PBS, PAA). The bone marrow was triturated 10 
times using 10 ml stripettes. The dissociated cells were filtered through a 70 µm cell 
strainer (BD Biosciences), followed by centrifugation at 1500 rpm for 5 minutes at 4 
o
C. PBS was carefully removed and discarded, and the pelleted cells were recovered in 
100 ml pre-warmed macrophage culture medium (C-IMDM). The C-IMDM comprises 
the Iscove’s Modified Dulbecco’s Medium (IMDM, Invitrogen), 10 % fetal bovine 
serum (FBS, GIBCO Invitrogen), Penicillin-Streptomycin solution (P/S, 1:100, Sigma 
Aldrich) and 5 ng/ml macrophage colony stimulating factor (M-CSF, Peprotech). The 
additional supplementation of M-CSF is needed in order to promote the differentiation 
of bone marrow cells into macrophages.  
 
The cells were plated onto 10 cm tissue culture dish (BD Bioscience) with 10 ml of cell 
suspension per plate. The plated cells were allowed to differentiate for 3 days in a 
humidified incubator at 37 
o
C with 5 % CO2- enriched atmosphere. The plates were 
washed once on the 3
rd
 day in vitro (DIV), and re-supplemented with 10 ml fresh 
pre-warmed C-IMDM. The cells were then allowed to further differentiate for 3 more 
days in the incubator. After 6 DIV, the cells were ready to be re-plated onto the 35mm 
borosilicate glass bottom plate (10 mm glass, MatTek) for subsequent calcium imaging. 
After two washes with 5 ml PBS to remove residual media and undifferentiated cells, 
each plate of cells was incubated with 4ml pre-warmed non-enzymatic cell dissociation 
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solution (Sigma Aldrich) at 37 
o
C for 5 minutes. The cells were harvested by gentle 
pipetting and collected into a 50ml Falcon tube, followed by centrifugation at 1500rpm 
for 5 minutes at 4
o
C. The cell pellet was washed twice in 5ml pre-warmed C-IMDM to 
remove residual dissociation solution and carefully resuspended in 2 ml of pre-warmed 
C-IMDM. The cells were counted and plated at 40,000 cells per plate on the 35 mm 
glass bottom dishes. Cells were allowed to settle for 24 hours in 37 
o
C in a 95 % air / 5 
% CO2 humidified incubator. The media was replaced with 2 ml IMDM with P/S 
only for 24 hours prior to the calcium imaging experiments. To promote macrophage 
polarisation into M1, M2a or M2c macrophages, DIV7 cells (24 hours after replating) 
were treated with LPS (1 µg/ml, Sigma Aldridge), IL-4 (20 ng/ml, Peprotech) or IL-10 
(20 ng/ml, Peprotech), respectively, for 24 hours in IMDM + P/S only media. 
 
Macrophage conditioned media (MCM) for in vitro experiment was prepared from 
supernatant of stimulated macrophages. DIV8 cells (2
nd
 day post replating, on the day 
of experimentation) were treated with 100 nM TLQP-21, 100 nM ScrTLQP-21 or 
vehicle (same volume of sterile water) in 1 ml of extracellular solution (see calcium 
imaging session for detail) for 4 hours. Two additional plates were treated with 100 nM 
TLQP-21 for 1 hour and 2 hours respectively. The supernatants were collected from the 
plate, centrifuged for 5 minutes at 4 
o
C at 1200rpm to remove cell debris. The spun 
supernatants were transferred to a sterile tube, clearly labelled and kept on ice until 
needed for experiments. The MCMs were removed from ice and leave at the room 
temperature for 15 minutes before experimentation to prevent activating temperature 
sensitive channels on DRG neurons.  
 
Stimulated macrophages for in vivo experiment were prepared by stimulating DIV6 
macrophages (in 10 cm plates) with 10 ml of IMDM+P/S media supplemented with 
either 500 nM TLQP-21 or 500 nM ScrTLQP-21, for 24 hours. The stimulated cells 
were washed three times in sterile PBS before harvest. The cells were dislodged from 
the plate using non-enzymatic cell dissociation solution as described before. The final 
volume is adjusted so that the harvested cells were resuspended in PBS at densitiy of 
35,000 cells/10µl. 10µl of the stimulated cells (i.e. 35000 cells) were injected to the rat 
intraplantarlly using a 30G needle attached to a Hamilton syringe. 
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2.3.4. Calcium imaging 
 
Fluo-4 AM staining protocol 
 
The calcium fluorescent dye Fluo-4 AM (Molecular probes, Invitrogen) was 
reconstituted in dimethyl sulfoxide (DMSO) to a final concentration of 4 mM (1000X 
solution). The reconstituted solution was aliquoted at 1 µl per tube and stored at -20 
o
C. Primary DRG neuronal culture and primary bone marrow derived macrophage 
culture were prepared prior to calcium imaging experiment as described in session 
2.3.2 and 2.3.3. 1 hour prior to the calcium imaging experiment, the media was 
removed from the cultures and the cells were washed three times in 1ml balanced 
extracellular solution (140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1.8 mM CaCl2, 10 mM 
D-Glucose and 10 mM HEPES buffer, pH 7.4). 1ml of balanced extracellular solution 
was added to an aliquot of Fluo-4 to dilute it to the working concentration (4 µM). 500 
µl of working concentration Fluo-4 was applied to the cells, and allowed to stain for 30 
minutes at room temperature protected from light exposure. The cells were 
subsequently washed three times with 1ml balanced extracellular solution, followed by 
30 minutes incubation in fresh extracellular solution to allow de-esterification of the 
dye. The cells were washed for another three times with 1ml extracellular solution, and 
left in 1ml fresh extracellular solution ready for imaging. All solutions used in staining 
protocol were sterile filtered in the tissue culture hood using a 0.2 µm filter, and all the 
compounds and reagents used were tissue culture grade. 
 
The composition of calcium-free extracellular media used was the same as the balanced 
extracellular solution except the CaCl2 was omitted and 2 mM EGTA was 
supplemented. The cells used to investigate the effect of TLQP-21 in calcium-depleted 
extracellular solution were still stained in the balanced extracellular solution (with 
calcium) before experiment to maintain healthiness of the cells. However, the cells 
were washed three times with 1ml calcium free extracellular solution after 
de-esterification, and left for 5 minutes in 1ml of fresh calcium free extracellular 
solution prior to imaging (to allow EGTA to chelate residual calcium). All treatments 
(i.e. TLQP-21 and ATP) applied in calcium free experiment were diluted in calcium 
free extracellular solutions.  
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Imaging acquisition and analysis 
 
The cells were imaged on a Leica SP5 inverted confocal microscope and the 
acquisition was performed using Leica LAS AF Lite software. The cell images were 
acquired in both fluorescent and bright field. This allowed the detection in change in 
fluorescence intensity and possible morphology change throughout the experiment. 
Figure 2.1 A, 2.1 B and 2.1 C are the representative pictures of macrophage stained 
with Fluo-4 in fluorescence channel (in pseudocolor), bright field and both channels 
overlaid, respectively. The Fluo-4 staining protocol used here showed staining of 
100% of the cells within the field of view.  
 
To start, the acquisition was set to record the emitted fluorescent every 6 seconds (per 
frame) using 20x objective, and the maximum pinhole aperture at 600 µm, 
determining minimal confocality, was used. Two lines average was performed 
throughout acquisition. The cells were imaged at room temperature in the balanced 
(or calcium free) extracellular solution. The plate was placed in the recording chamber, 
and a random field of view was selected by looking down the eyepiece. The Fluo-4 
dye was excited with Argon laser (15% laser maximum power) at 488 nm wavelength, 
and the emission fluorescence was captured between 500-570 nm wavelength. The 
gain and offset of the acquisition was adjusted so that minimum saturated and black 
pixels were observed.  
 
The cells were first recorded without any treatment for at least 20 frames. This was 
essential because such baseline recordings could provide information of cells that 
were already spontaneously increasing intracellular calcium prior to any treatment. 
These spontaneous active cells were not therefore included in the data analysis at the 
end of the experiment. After baseline recording, a VGF derived peptide was applied to 
the cells, followed by ATP/KCl (1 mM ATP for primary macrophage and 60 mM KCl 
for primary DRG neurons) treatment as a viability assay to ensure the cells tested 
were alive. Only the cells that responded to ATP/KCl were selected for subsequent 
analysis.  
 
The change in fluorescence recorded corresponds to the change in intracellular 
calcium level after treatment. Thus, the fluorescence recorded was quantified using 
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the LAS AF Lite software after imaging. To do so, all the cells from the field of view 
were circled and defined as the region of interest (ROI) (as illustrated in figure 2.1D). 
The changes in the fluorescent intensities in the ROIs were quantified by the software 
and exported as an excel file as represented in figure 2.1E. These raw data were 
further analysed by expressing the fluorescence intensity in respective to their 
baseline. Any cell that showed an increase in fluorescence more than 20 % of the 
baseline was classified as “responsive” and those below 20 % of the baseline was 
known as “non-responsive” to the stimulation. The cut off was set to be 20 % of the 
baseline because a small increase in the background fluorescence could be observed 
when any solution was applied to the plate during recording, including vehicle control. 
Therefore, a 20 % baseline cut off was set to reduce false positive selection of 
non-responsive cells as responsive. Figure 2.1F is an illustrative example of the 
averaged fluorescence profile of ‘non-responsive’ cells. In this demonstrative picture, 
the fluorescent intensity was not changed after peptide application. However, the ATP 
viability control showed a significant increase in the intracellular calcium level, 
indicating that the cells were viable. On the other hand, figure 2.1G demonstrates the 
typical averaged fluorescence profile from the “responsive” cells in an experiment. 
Application of peptide in this experiment induced a robust and immediate increase in 
the intracellular calcium level that is greater than 20 % of the baseline, which 
gradually returned to the baseline. ATP stimulation at the end of this experiment also 
showed that the cells analysed were viable and able to respond to the positive control. 
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Figure 2.1 Representative field of view, cell selection and fluorescence profiles 
(The staining and acquisition protocol for calcium imaging is demonstrated here using 
primary macrophage as an example.) The stained cells were visualised under confocal 
microscope and real-time live cell imaging was performed while the peptides and positive 
controls (ATP) were added. All cells from the field of view were selected and the fluorescence 
profiles of the cells were exported and analysed. The cells were classified to be “responsive” 
when the fluorescent intensity is increased by more than 20 % of the baseline after peptide 
application. Any cell with an increase in fluorescence less than 20 % of the baseline is 
classified as “non-responsive”. A. Representative field of view in fluorescence (shown in red 
pseudo-colour). B. Representative field of view in bright field. C. Overlay image of bright 
field and fluorescence. D. Image of region of interest (ROIs) cell selections in the field of 
view. E. Raw data of fluorescence recorded from different ROIs. F. A representative averaged 
fluorescence profile of all selected cells, showing the cells were not responsive. ATP (cell 
viability control) at the end of the experiment showed the cells were able to elicit an increase 
in calcium response. G. A representative averaged fluorescence, showing an increase in 
fluorescence intensity 20 % above the baseline after peptide application, indicating the cells 
were responsive to the peptide.  
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2.3.5. Quantitative real time polymerase chain reaction 
 
Total RNA from cultured cell was extracted using RNAeasy extraction kit (Qiagen), 
and cDNA was synthesized from total RNA using the Superscript III first-strand 
synthesis RT kit (Invitrogen). Real-time PCR was performed using the StepOnePlus 
Real-Time PCR System (Applied Biosystems) in combination with the Fast SYBR 
Green technology to accurately measure the expression levels of the target genes. The 
reaction was performed in a total reaction volume of 20 μl, consisting of 10 μl Fast 
SYBR Green master mix (Applied Biosystems) of 0.5 μM of primer mix of 
target-interested, and 20ng cDNA. The primers sequences for internal control/reference 
gene (Cyclophilin A), and gene of interests are shown in the table below. All 
experiments were repeated three times with independent batch of treated samples. The 
reaction was run with initial heating step at 95 
o
C for 20 second, followed by 40 cycles 
of denature step at 95 
o
C for 3 seconds, annealing step at 60 
o
C for 15 seconds, and 
extension step at 72 
o
C for 15 seconds. Product composition was verified at the end of 
each reaction with Melting Curve measurement. Melting Curve stage was performed at 
initial heating step to 95 
o
C for 15 seconds, followed by 0.6 
o
C increment increase steps 
from 60 
o
C to 95 
o
C. The melt curve allows verification of the purity of the PCR 
products; pure product is characterised by one sharp peak in melt curve graph. 
 
Targets Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
Cyclophilin A GCAAGACCAGCAAGAAGATC TCAGTGAGAGCAGAGATTACAG 
iNOS CACCTTGGAGTTCACCCAGT ACCACTCGTACTTGGGATGC 
Arg-1 TATCGGAGCGCCTTTCTCTA ACAGACCGTGGGTTCTTCAC 
IL-10 GTTGCCAAGCCTTGTCAGAAA TTTCTGGGCCATGGTTCTCT 
Table2. 1 Primer sequences for Cyclophilin A, iNOS, Arg-1 and IL-10  
 
2.3.6. Behaviour assessment: Electronic von Frey 
 
A custom-built isolation chamber with individual Plexiglas boxes (23 x 18 x 14cm) 
was used in behavioural study. In order to reduce the confounding affects of stressed 
animals, the animals received two sessions of 1 hour habituation in the Plexiglas 
boxes on two consecutive days. During the habituation (and behaviour testing later 
on), all animals were housed individually in the Plexiglas boxes and received 
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consistent handling from the experimenter. Two baseline measurements, on two 
separate consecutive days (at least 24 hours apart), prior to any treatment were 
recorded after two days of habituation. On the days of baseline measurement, the 
animals were moved into the testing room in their home cage group at least 20 
minutes prior to testing to allow acclimatisation. The animals were transferred to the 
Plexiglas boxes and allowed to acclimatise for another 15 minutes. The baseline paw 
withdrawal threshold was measured using a calibrated electronic von Frey device with 
0.5mm diameter tip (Electronic von Frey device, Somedic, type 735). The force 
transducer was applied to the surface of the hind paw at a rate of 8-15 g/sec until a 
limb withdrawal response was observed. Five applications were made to each of the 
hind paw and the mean baseline paw withdrawal thresholds were calculated. 
 
10 µl TLQP-21 stimulated macrophage/ScrTLQP-21 stimulated macrophage was 
injected intraplantarly to the left hindpaw of the animals the day after second baseline 
recording. In the in vivo experiments, the experimenter was blinded to the treatment 
group of all the animals tested. The male Wistar rats (~200g) were first anaesthetised 
under 2% isofluorane in 1% O2 and 1% N2O. The plantar surface of the left hindpaw 
was sterilised using isopropanol swab. A 30G needle attached to a Hamilton syringe 
was used to deliver 10 µl of stimulated macrophage intradermally at the sterilised area. 
The needle was allowed to rest in place for 1 minute after injection to prevent solution 
back-flow. The animals were allowed to recover for 24 hours in their home cage 
groups. The mean paw withdrawal thresholds were determined again on post 
operative day 1 (POD1), day 2 (POD2) and day 5 (POD5) as described. After POD5 
measurement, the experiment was terminated by euthanising the animal with CO2 
asphyxitaion. (The described in vivo study looking at the effect of 
TLQP-21-stimulated macrophages was done in collaboration with Dr Alessandro 
Pristera. The behaviour assessment was kindly performed by Dr Alessandro Pristera). 
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2.4. Results 
 
Vgf expression has been shown to be upregulated in different neuropathic pain animal 
models. However the cells that VGF-derived peptides target in the pain pathway still 
remain as an intriguing question to be answered. In this study, I sought to investigate 
what cell types do VGF-derived peptides work on, and what are the subsequent 
consequences upon their binding to the target cell(s), and the mechanism of action of 
the peptides on its target cells. In order to access what cell types do VGF-derived 
peptides work on, a functional assay, calcium imaging, was established (see section 
2.3.4 for detail protocol). Calcium is well known to be an important signalling ion 
involved in the majority of the intracellular and extracellular processes. Calcium 
imaging was exploited in this study as the functional assay to investigate the effect(s) 
of the peptides on intracellular calcium of different cell types.  
 
2.4.1. Effects of the VGF-derived peptides on the intracellular calcium level of 
different cell types: Primary DRG neurons. 
 
After nerve injury, the VGF-derived peptides are released from the storing vesicles of 
the sensory neurons upon depolarization. One of the most obvious cell targets that the 
VGF derived peptides could act on is the DRG neuron itself. It could be hypothesised 
that, upon nerve injury, DRG neurons release the VGF-derived peptides, which target 
the postsynaptic sensory neurons to exert their function, or they could target the 
neurons that they were released from allowing, for example, more peptides to be 
produced/released. Based on this hypothesis, we first assessed if different 
VGF-derived peptides induce a change in the intracellular calcium level in the rat 
primary DRG sensory neurons. Published data suggested, both in vitro and in vivo 
VGF derived peptides work at concentrations lower than 1 µM concentration (Moss, 
Ingram et al. 2008, Rizzi, Bartolomucci et al. 2008, Severini, Ciotti et al. 2008, Riedl, 
Braun et al. 2009), therefore, 1 µM maximum concentration of each peptide was used 
in this investigation. Figure 2.2 shows that the primary DRG neurons were not 
responsive to 1 µM LQEQ-19 (figure 2.2A), 1 µM TLQP-21 (figure 2.2B) and 
negative control peptide ScrTLQP-21 (figure 2.2C), in our calcium-based functional 
assay. Nevertheless, the 60 mM KCl applied after each peptide application induced a 
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robust and prolonged increase in the intracellular calcium level in the DRG neurons, 
indicating the cells were viable to respond to the stimulations.  
 
2.4.2. Effects of the VGF-derived peptides on the intracellular calcium level of 
different cell types: Primary bone marrow-derived macrophages. 
 
I next evaluated if VGF-derived peptides exert the functional effects by changing the 
intracellular calcium level of the primary macrophages. Macrophages are known to 
infiltrate DRG after nerve injury and depletion of macrophages has been show to 
relieve neuropathic-pain-like behaviours in animals (Liu, van Rooijen et al. 2000, 
Mert, Gunay et al. 2009). Based on this evidence, I hypothesized that VGF-derived 
peptides might be released from the DRG neurons after the nerve injury and 
subsequently, instead of acting on the neurons itself, acts on the adjacent cells such as 
the infiltrated macrophages to exert the function(s). To test this hypothesis, primary 
macrophages were differentiated from bone marrow stem cells using macrophage 
colony stimulating factor (M-CSF), and cultured for 7 days, followed by live cells 
imaging. Figure 2.3 shows the Fluo-4 fluorescence in pseudo-color on the left. The 
clipped pictures are associated with different time points during the recording, 
pre-application of VGF-derived peptide, application of VGF-derived peptide, post 
application of VGF-derived peptide and application of ATP, respectively. The graphs 
on the right in Figure 2.3 show the averaged fluorescence profiles of each experiment 
and the time point associated with the clipped pictures were numbered. Figure 2.3 A 
demonstrates that the primary macrophage were not responsive when an equal volume 
of vehicle control was applied to the plate. In addition, Figure 2.3 B and 2.3 D further 
demonstrate both LQEQ-19 and TLQP-62 VGF-derived peptides did not induce an 
increase in the intracellular calcium when applied to the primary macrophage in vitro. 
Nonetheless, when 1mM ATP was applied at the end of the experiments, the cells 
were able to induce a robust and transient increase in the intracellular calcium, which 
returned to the baseline within 2 minutes. This demonstrates that the cells were viable 
and were able to respond to ATP stimulation. Interestingly, when TLQP-21 peptide 
was applied to the primary macrophage, unlike TLQP-62 and LQEQ-19 that did not 
induce a response, it induced an immediate increase in the intracellular calcium that 
gradually returned to the baseline (Figure 2.3 C).  
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Figure 2.2 Effect of VGF derived peptides, LQEQ-19, TLQP-21 and ScrTLQP-21, on 
primary DRG neurons. 
Average fluorescence profile of DRG neurons. The time points, at which each treatment was 
applied to the cells, are indicated by arrows. A. 1 µM of LQEQ-19 was applied to cultured 
DRG neurons, followed by 60 mM KCl positive control. The fluorescence profile shows the 
cells were not responsive to LQEQ-19 peptide and KCl was able to elicit an increase in 
intracellular calcium after application. B. 1 µM of TLQP-21 did not induce an increase in 
calcium response in cultured DRG neurons. C. Negative scrambled control peptide did not 
elicit a calcium response in cultured DRG neurons.  
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Figure 2.3 Effects of different VGF-derived peptides on primary macrophage. 
Pesudo-color images of intracellular calcium levels at different time points are displayed on the 
left and the averaged fluorescence profile is shown on the right for macrophages stimulated 
with A. Vehicle B. LQEQ-19 C. TLQP-21 D. TLQP-62 
 
2.4.3. The TLQP-21 peptide specifically induced an increase in the intracellular 
calcium level in the primary macrophage, in a dose-dependent manner. 
 
To assess the specificity of the TLQP-21-induced calcium response in the primary 
macrophage, I tested its control peptide at the same molar concentration. The 
scrambled TLQP-21 peptide (ScrTLQP-21) is a synthesized peptide with the same 
amino acid residues but scrambled in the sequence. This control peptide, therefore, 
exhibits the same charge and retains in the same length as the wild type sequence. 
Figure 2.4 shows that TLQP-21 was able to induce an increase in the intracellular 
calcium level when applied to the primary macrophages at 100nM concentration. 
However, when the scrambled control peptide ScrTLQP-21 at the same concentration 
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was applied, the increase in the intracellular calcium was not observed. This 
demonstrates the specificity of action of TLQP-21 peptide on the primary 
macrophage.  
 
These data provide the first evidence, to our knowledge, of a VGF-derived peptide 
specifically acts on the primary macrophage, at least in vitro, in a calcium-dependent 
manner. To elucidate this further, we tested different concentrations of TLQP-21 and 
ScrTLQP-21 peptides. This provides information on the minimum and saturating 
concentrations of TLQP-21 that could elicit responses in the primary macrophages.  
 
 
Figure 2.4 Effect of TLQP-21 and its scrambled control peptide, Scr-TLQP-21, on 
primary macrophage. 
A. Florescence profile showing100 nM TLQP-21 specifically induced an increase in 
intracellular calcium in primary macrophage. B. The scrambled control peptide with same 
amino acid components and charge failed to elicit a calcium response at 100nM concentration 
in primary macrophage. The ATP viability control at the end of the experiments indicates the 
cells were viable and able to elicit an increase in intracellular calcium. C. Bar chart comparing 
percentage of cell responding to 100 nM TLQP-21 and 100nM ScrTLQP-21 to vehicle control. 
All data points were a combination of 4 experiments. The percentage of cell responding to 
TLQP-21 was significantly different to that responded to vehicle and ScrTLQP-21 (**P<0.01, 
One way ANOVA, Tucky post hoc test). The percentage of cell responding to ScrTLQP-21 is 
not statistically significant from that to vehicle control, indicating specific action of TLQP-21 
on primary macrophage in vitro.  
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Figure 2.5 A shows the dose response curve for the wild type TLQP-21 peptide on the 
primary macrophages. For each of the concentrations tested, minimum of 4 
independent repeats were performed. The primary macrophages were tested for 
different concentrations at 10 nM, 100 nM, 1 M, 10 M and 50 M. The fluorescence 
profile was analysed as described before, and a further analysis was carried out to 
calculate the percentage of cells responding (with 20% baseline cut off) to the peptide 
at a given concentration. All data sets of each concentration were combined and the 
graph was plotted with the percentage of cells responding against the log concentration 
of the peptide. It must be noted that there were always a small number of cells respond 
to any stimulation given (including vehicle negative control). This is to be expected, as 
macrophages are immune surveillance cells that respond to the subtle changes in the 
environment. To set the “background noise”, the primary macrophage was tested with 
vehicle negative control (same volume of water in the extracellular solution). A 
combination of 4 experiments shows that an average of 5.4  1.7% of the primary 
macrophages responded to the vehicle control, which is plotted as the red line in figure 
2.5 (as the background activity).  
 
As shown in figure 2.5 A, 1 nM of TLQP-21 (at log scale) induced an increase in the 
intracellular calcium in 9.7  2.6% of the cells, however, this is not statistically 
significant from the vehicle control. The lowest concentration that showed a significant 
increase in the percentage of cells responding to the wild-type TLQP-21, compared to 
the vehicle control, was at 10nM (p<0.01, One way ANOVA, Tukey post hoc test). 10 
nM of TLQP-21 peptide stimulated 56.1  6.2 % of the primary macrophages in a 
calcium dependent manner. The percentage of cells responding to TLQP-21 further 
increased to 73.5  6.5 % and plateaued at 100 nM concentration.The percentages of 
cells responding to 1 M, 10 M and 50 M TLQP-21 were 73.9  8.3 %, 74  8.0 % 
and 74.1  4.4 %, respectively, which did not significantly differed to the percentage of 
cells responding to 100nM TLQP-21, indicating no further increase in the percentages 
of responding cells to TLQP-21. 
 
Figure 2.5 B shows the dose response curve for scrambled control peptide, 
ScrTLQP-21. 100 nM, 1 M, 10 M and 50 M of ScrTLQP-21 peptides were used to 
test for the primary macrophages responsiveness. The percentages of cells responding 
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to ScrTLQP-21 were not significantly different from vehicle control at 100 nM, 1 M 
and 10 M concentrations. Even though at 10 M concentration, the percentage of cell 
responding increased to 39.5  17.1 %, the data was not significantly differed when 
compared to the vehicle control (p>0.07, One way ANOVA, Tukey post hoc test). The 
percentage of cell responding to 50 M of the ScrTLQP-21 was significantly different 
from the vehicle control (P<0.05, One way ANOVA, Tukey post hoc test), with 57.1  
6.1 % of the total analysed cells exhibited an increase in intracellular calcium. 
 
 
 
 
Figure 2.5 Dose response of TLQP-21 and ScrTLQP-21 on primary macrophage. 
A. Dose response curve of TLQP-21 on primary macrophage. 1 nM, 10 nM, 100 nM, 1 M, 
10 M and 50 M concentrations of TLQP-21 peptide were tested on primary macrophages. 
The responsiveness of cells was expressed in percentage of cell responding to different 
concentration stimulation. Each data set is a combination of at least 4 experiments. The data 
point is expressed in average percentage of cell responding  S.E.M. (**P<0.01, One way 
ANOVA, Tukey post hoc test). The percentage of cells responding to vehicle negative control 
is plot in red line as background noise that observed. B. Dose response curve of ScrTLQP-21. 
100 nM, 1 M, 10 M and 50 M concentrations of ScrTLQP-21 were tested. (*P<0.05, One 
way ANOVA, Tukey post hoc test). 
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2.4.4. TLQP-21 desensitises primary macrophage to further TLQP-21 
stimulation 
 
In order to further investigate the effects of TLQP-21 on the primary macrophage, a 
second application of TLQP-21 was applied to the cells. Macrophage are known to 
exhibit characteristic properties of desensitisation in the calcium imaging when, for 
example, ATP is applied repeatedly (Oshimi, Miyazaki et al. 1999). In this experiment, 
I sought to investigate if repeated application of TLQP-21 causes desensitisation 
(abolish or diminished in response), sensitisation (increased in response) or the same 
response as the first application. 
 
In this experiment, 100 nM of TLQP-21 was applied to the primary macrophage after 
the baseline recording, as this is the lowest dose that elicits the maximum number of 
cells responding to the wild type peptide. The cells were recorded for further 6 
minutes to allow the intracellular calcium level to return to the baseline. A second 
dose of 100 nM TLQP-21 was then applied to the cells after the fluorescence returned 
to the baseline. It was observed that the first TLQP-21 elicited a robust and immediate 
increase in the intracellular calcium as described before. However, when the second 
dose was applied, the cells were not responsive to the second stimulation of TLQP-21 
(Figure 2.6 A). 1 mM ATP was applied to the cells 6 minutes after the second dose of 
TLQP-21, and an increase in the intracellular calcium level was observed. This 
indicates that the cells were viable and able to elicit a calcium response. In order to 
rule out the possibility that the failure to induce an increase in the intracellular 
calcium by the second TLQP-21 dose was due to the insufficient time allowed for the 
cells to replenish the intracellular calcium, I allowed a longer time interval in between 
the first and the second applications. Figure 2.6 B shows the fluorescence profile of 
the experiment with two applications of 100nM TLQP-21, and a 30 minutes time 
interval was allowed in between the applications. The first dose of TLQP-21 was 
applied to the cells after baseline recording, the cells were further recorded for 8 
minutes and allowed to rest for 20 more minutes without recording. The recording 
was turned off during longer “resting time” to prevent laser damage to the cells that 
arises from long time period recording. The recording was switched back on 
afterwards and the second dose of the peptide was applied 2 minutes after the second 
recording started. The total time allowed between two applications was added up to be 
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30 minutes. The primary macrophage was still observed to be non-responsive to the 
second dose of TLQP-21 after a 30 minutes recovering time was allowed prior to the 
second dose application. The longest total time allowed between the two applications 
was one hour, as the live cells imaging was performed in extracellular solutions 
without serum. It was to ensure that the cells were in healthy condition prior to the 
second dose treatment, thus one hour time interval was the longest tested between two 
TLQP-21 applications. Figure 2.6 C shows that one hour after first TLQP-21 
application, the second dose of TLQP-21 still fail to elicit an calcium response in the 
primary macrophage, indicating a possible desensitisation mechanism in the 
macrophages for this peptide after repetitive treatments. The percentage of cells 
responding to the second dose of TLQP-21 after the first stimulation was 5.1  1.8 %, 
4.8  0.75 % and 11.6  9.6 % for experiments with 8 minutes, 30 minutes and 60 
minutes time intervals, respectively (figure 2.6 D). The percentages of cells responding 
to the second stimulation are not significantly different from each other in all the 
experiments, indicating desensitisation can be still observed up even one hour time 
interval was allowed between the two applications. 
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Figure 2.6 Desensitisation effect of TLQP-21 on primary macrophage. 
TLQP-21 desensitises the primary macrophages to the second TLQP-21 application. The 
desensitisation effect is observed with time intervals of, A. 6 minutes B. 30 minutes C.1 hour, 
between the two applications. D. Quantification of percentage of cells responding to the second 
stimulation after elicited a response to the first TLQP-21 stimulation. 
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2.4.5. Pre-application of ScrTLQP-21 at high concentration also desensitised the 
primary macrophage to further TLQP-21 stimulation, but not with 
pre-application of TLQP-62. 
 
Having demonstrated TLQP-21 desensitises the primary macrophage to a second 
TLQP-21 application. Here I sought to further exploit the sensitivity of the primary 
macrophage to the VGF-derived peptides. TLQP-62 is a longer VGF-derived peptide 
that harbours TLQP-21 peptide sequence at its N-terminus. I tested if pre-treatment 
with high concentration of TLQP-62 can cause desensitisation to a subsequent 
TLQP-21 stimulation in the macrophage. Figure 2.7 A shows when 10 μM of 
TLQP-62 was applied to the primary macrophage, the following100 nM TLQP-21 
treatment was able to elicit an immediate increase in the intracellular calcium similar 
to what was observed before. This possibly implies that pre-treatment of TLQP-62 
does not interfere with the TLQP-21 signalling pathway.  
 
It was demonstrated previously in this chapter that high concentration of ScrTLQP-21 
could cause a calcium response in the primary macrophage. I, therefore, tested if the 
TLQP-21 desensitisation can still be observed if high concentration of ScrTLQP-21 
was applied as the first stimulation. As shown in figure 2.7B, after 50 μM of 
ScrTLQP-21 stimulation, which induced a calcium response, the subsequent 100 nM 
TLQP-21 application failed to evoke calcium increase in macrophage. This suggests 
ScrTLQP-21 at extreme high concentration could possibly mimic the 
TLQP-21-induced response in the primary macrophage.  
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Figure 2.7 Effect of other VGF derived peptides on subsequent TLQP-21 induced 
calcium response in the primary macrophage.   
A. TLQP-62 pre-application does not interfere with the subsequent TLQP-21 response in 
primary macrophage. B. Pre-treatment with high concentration (50 μM) of ScrTLQP-21 
desensitises the primary macrophage to the following TLQP-21 stimulation. ATP response at 
the end of the experiment indicates the cells were viable, and the time allowed for calcium 
replenishment was sufficient.  
 
2.4.6. The TLQP-21-induced increase in the intracellular calcium was still 
observed when the calcium was excluded from the extracellular solution. 
 
I have demonstrated that TLQP-21 peptide specifically acts on the primary 
macrophage in a dose- and calcium-dependent manner, and it desensitises the target 
cells to further TLQP-21 stimulation. I was interested to further dissect whether the 
increase in the calcium level was a result of influx of calcium from the extracellular 
solution, or a release of calcium from the intracellular store. In this experiment, I 
investigated the percentage of cell responsiveness upon TLQP-21 application in the 
medium devoid of calcium and supplemented with 2 mM EGTA. The percentage of 
cells responding to TLQP-21 in the ‘calcium free’ extracellular solution was then 
compared to that tested in the medium with calcium. As expected when calcium was 
present, an immediate increase in the intracellular calcium level was observed, which 
gradually returned to the baseline as shown in figure 2.8A. Interestingly, when 
calcium was omitted from the medium, an increase in the intracellular calcium level 
in the primary macrophage, after 100 nM TLQP-21 stimulation, was still observed 
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(Figure 2.8B). It is worth noting that the ATP response in the ‘calcium free’ condition 
was relatively smaller when compared to that in the presence of calcium. This is 
expected as ATP works through both P2X and P2Y receptors and allowed both 
extracellular and intracellular calcium to go into the cytosolic space. Therefore, when 
the extracellular calcium was omitted, the change in the calcium level after ATP 
stimulation was expected to be lower, because the only calcium source was from the 
intracellular store. Figure 2.8 C compared the percentage of cells responding to 
TLQP-21 with presence or absence of calcium in the extracellular solution. Even 
though, the average percentage of cell responding to TLQP-21 in the ‘calcium free’ 
condition is slightly less than that in the condition with calcium (48.3  8.3 % in 
calcium free condition compared to 60.9  10.1 % in the presence of calcium), the two 
groups are not significantly different from each other (student t test). This indicates 
that TLQP-21 peptide, at least at 100 nM concentration tested, was able to elicit a 
similar response in the primary macrophage in media with or without calcium. The 
results here showed that the extracellular calcium is not essential for 
TLQP-21-induced calcium response in the primary macrophage. This suggests the 
calcium source of the observed TLQP-21-induced response was, at least partly if not 
all, coming from the intracellular calcium store.  
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Figure 2.8 Effect of extracellular calcium on TLQP-21 induced calcium response in 
primary macrophages. 
A. 100 nM TLQP-21 induces a calcium response in primary macrophage when calcium is 
present in extracellular solution. B. 100 nM TLQP-21 also elicits a calcium response in 
primary macrophages bath in extracellular solution devoid with calcium. C. Quantification of 
percentage of cells responding to 100 nM TLQP-21 in the extracellular solution devoid of 
calcium and with 1.8mM calcium. 
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2.4.7. The TLQP-21 induced intracellular calcium increase is observed in both 
M1 and M2 macrophages. 
 
In vitro, different distinctive stimuli endow macrophages with characteristic 
molecular phenotypes and effector functions (Mantovani, Sica et al. 2004, Mosser and 
Edwards 2008). Activating the cultured macrophages with lipopolysaccharide (LPS) 
promotes the “classical activated” M1 state. In these cells, oxidative metabolites (such 
as nitric oxide and superoxide) and pro-inflammatory cytokines are characteristically 
produced at very high levels. Therefore, M1 activated macrophage population 
typically displays high inducible nitric oxide synthase/ Arginase (iNOS/Arg1) ratio in 
the gene expression (Mills, Kincaid et al. 2000). Conversely, stimulations of the 
cultured macrophages with cytokines Interleukin-4 (IL-4) and Interleukin-10 (IL-10) 
encourage “alternatively activated” M2a and “anti-inflammatory” M2c phenotypes, 
respectively. Unlike M1 macrophage, M2 macrophages (both M2a and M2c subtypes) 
downregulate oxidative metabolites and facilitate expression of Arginase, and hence a 
low iNOS/Arg1 ratio (lower than 1) is phenotypically observed. Furthermore, M2c 
macrophage is known to be anti-inflammatory facilitating high expression of 
anti-inflammatory cytokine IL-10. 
 
It is evident that polarized macrophage populations are associated with systemic 
diseases (Gordon 2007) and polarisation of macrophages can contribute to the 
disease progression (Sica, Larghi et al. 2008, Villalta, Nguyen et al. 2009, Suganami 
and Ogawa 2010). It is appreciated that distinct macrophage subsets exhibit divergent 
effects and can react towards the same stimulus differently. It is currently unknown if 
distinctive macrophage subsets respond to TLQP-21 differently. Therefore, I sought to 
investigate here if certain macrophage subset responds predominately to the TLQP-21 
peptide.  
 
The experiment was set up by first differentiating the cultured macrophage in vitro 
into M1, M2a or M2c subsets by 24 hour stimulation with 1 g/ml LPS, 20 ng/ml 
IL-4 and 20 ng/ml IL-10, respectively. Figure 2.9A shows bright field images of 
untreated, LPS, IL-4 and IL-10 treated macrophage, respectively, after 24 hours of 
treatment. Remarkably, after 24 hours of treatments, the macrophages displayed 
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altered morphologies. The LPS-treated M1 macrophages were more flatten and 
rounded, and appeared as ”fried egg” morphology with an enhanced number of 
lamellipodia compared to the untreated control. On the other hand, IL-4 and IL-10 
treated M2 macrophages were more elongated in shape when compared to the control 
cells. Interestingly, untreated control macrophages appear to possess morphologies of 
both extremes, with some elongated cells and some rounded cells. 
 
To further confirm that the cells were differentiated into distinctive subsets, qRT-PCR 
was exploited to check the expression of M1 and M2 phenotypic markers. First, the 
iNOS and Arg1 expression of each subset was checked, and the gene expression was 
normalised against the untreated control. The iNOS/Arg1 ratio was then compared 
between the different subsets. Figure 2.9 B shows iNOS/Arg1 ratio in arbitrary units. 
As expected, the M1 macrophage subset expressed a high level of iNOS, and hence 
the iNOS/Arg1 ratio is much bigger than 1 arbitrary unit (37.7 ± 13.0). In contrast, 
both of the M2 macrophage subsets possess iNOS/Arg1 ratio lower than 1 (0.001 ± 
0.0002, 0.38 ± 0.1 for M2a and M2c, respectively) indicating a much higher 
expression of Arg1. To further dissect between M2a and M2c subset, the IL-10 
expression levels between these two groups were compared. Figure 2.9 C shows a 
significant IL-10 up-regulation by 43.7 folds in the M2c subset of macrophages when 
compared to that of M2a (p<0.05, student t test), indicating significantly higher level 
of anti-inflammatory cytokine production.  
 
Having confirmed that the macrophages had been differentiated into the distinctive 
subsets, I subsequently tested the different states of macrophages in the calcium 
imaging for their responsiveness to the TLQP-21 peptide. Figure 2.9 D shows the 
percentages of cells responding to 100 nM TLQP-21 after each treatment. The 
average percentages of cells responding to TLQP-21 are 67.6 ± 7.5%, 69.6 ± 7.28%, 
64.7 ± 7.3% and 65.1 ± 10.6% for control, LPS-treated, IL-4 treated and IL-10 treated 
macrophages, respectively. The result here demonstrated that all subsets of 
macrophages responded to the TLQP-21 peptide, and the percentages of cells 
responding to the peptide were not significantly different from each other.   
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Figure 2.9 Effects of macrophage polarisations on TLQP-21 induced calcium response.  
A. Bright field images of macrophages undergo I) no treatment II) 1 μg/ml LPS 24 hours 
treatment III) 20 ng/ml IL-4 24 hours treatment and IV) 20 ng/ml IL-10 24 hours treatment. B. 
qRT-PCR data of iNOS/Arg1 ratio expression in macrophages treated with LPS, IL-4 and 
IL10. (**p<0.01 One way ANOVA, Tucky post hoc test) C. Fold changes in IL-10 expression 
of macrophages treated with IL-4 and IL10 (*p<0.05, student t test). D. Calcium imaging 
result of the percentages of cells responding to 100 nM TLQP-21 in control, LPS-primed, 
IL-4-primed and IL-10-primed macrophages. 
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2.4.8. Investigating the effects of the conditioned media of the 
TLQP-21-stimulated macrophages on the primary DRG neurons. 
 
From the above data, it is clear that VGF-derived peptide TLQP-21 specifically 
targets primary macrophages and elicits the release of intracellular calcium. I 
hypothesised that some molecular effectors are likely to be released from the 
macrophage to the extracellular space after TLQP-21 stimulation. The released 
effectors, in turn, can act on the DRG neurons. If such hypothesis is true in the 
neuropathic pain condition, the released effectors from the macrophage could 
exacerbate the secondary damage to the neurons after injury and may contribute to the 
initiation and/or maintenance of neuropathic pain.  
 
To test whether the TLQP-21-stimulated macrophages confer effects on activating the 
sensory neurons, the primary DRG neurons were cultured for 2 days (DIV2), loaded 
with Fluo-4 and the macrophage conditioned medium (MCM) or control was applied 
to the neurons during imaging recording. The MCM was prepared from the 
supernatant of TLQP-21-stimulated macrophages, so if any effector was released that 
could activate the primary DRG neurons, fluorescence increases would be detected in 
the neurons. The primary macrophages were conditioned with 100 nM TLQP-21 for 
1hour, 2hours or 4 hours. The MCM was collected and spun to remove any cell debris. 
Two controls were used in this experiment; 100 nM ScrTLQP-21 and the same 
volume of vehicle conditioning for 4 hours.  
 
Results in figure 2.10 shows that the vehicle control has little effect on the primary 
DRG neurons, 17.9 % of the total analysed neurons responded to the vehicle control. 
Four hours ScrTLQP-21 MCM induced an increase in the intracellular calcium level 
in 15.0 % of the total analysed neurons. Conversely, the condition media of four hours 
TLQP-21 treatment elicits a calcium response in 29.8 % of the total neurons.  
The four-hour time point appears to stimulate the highest number of cells to respond, 
as one-hour and two-hour TLQP-21 MCM treatments only induce calcium response 
in 8.33% and 18.75%, respectively, of the total analysed cells. The number of neurons 
responding to four-hour TLQP-21 MCM is approximately 2 folds of that treated with 
ScrTLQP-21 MCM. This indicates that the effectors in the conditioned media of 
TLQP-21-stimulated macrophages can potentially excite the primary DRG neurons, at 
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least at the four-hour time point tested. Nevertheless, the experiment still awaits to be 
repeated to draw a more reliable conclusion.  
 
Figure 2.10 Effect of TLQP-21 conditioned media from macrophage on DRG neurons. 
The primary macrophages were stimulated with vehicle control, 100 nM ScrTLQP-21 or 100 
nM TLQP-21, and the conditioned media were collected and applied to the DRG neurons 
during calcium imaging. The percentages of cell responding to different conditioned media (1 
hour, 2 hours, 4 hours 100 nM TLQP-21 treated MCMs, 4 hours 100 nM ScrTLQP-21 treated 
MCM and 4 hours vehicle treated MCM) were compared. 
 
 
2.4.9. Intraplantar injection of TLQP-21-stimulated macrophages induced the 
pain-like behaviour in vivo.  
 
To further investigate the hypothesis that TLQP-21 acts on the macrophages and 
stimulates the release of the macrophage effectors, which subsequently convey the 
signals in the pain pathway, I next tested this hypothesis in an in vivo study.  
 
The overview of the experimental set up is shown in figure 2.11. Briefly, 200 g male 
Wister rats were habituated in the individual Plexiglas testing chambers for 1 hour for 
two consecutive days prior to the behavioural testing. This was necessary for the 
animals to get used to handling. The baseline paw withdrawal threshold (PWT) to the 
mechanical stimulation of each individual animal was measured by automate von 
Frey filament for the next two days before any treatment was given. The two baseline 
PWT measurements were taken at least 24 hours apart, in order to prevent viability 
caused by too frequent exposures to the testing technique. Primary macrophage was 
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cultured a week before the experiment and treated with either 500 nM TLQP-21 or 
ScrTLQP-21 for 24 hours before being used for the intraplantar injection. The 
conditioned macrophages were washed and harvested after treatment, and 35,000 
harvested cells in 10 l of PBS were injected to the rats’ hind paw using a 30G needle 
attached to a Hamilton syringe. The rats’ PWTs to the mechanical stimulation, of both 
treated paw (ipsilateral) and untreated paw (contralateral), were measured on the post 
operative day 1 (POD1), day 2 (POD2) and day 5 (POD5). The ipsilateral PWTs were 
then compared between the two groups injected with either TLQP-21-treated 
macrophages or ScrTLQP-21-treated macrophages.  
 
Figure 2.12 shows the animals tested in this study displayed consistent baseline to the 
mechanical stimulation. The raw data of the baseline measurements of each individual 
animal used were summarised in the tables of figure 2.12 A and 2.12 B (prior to 
injections with TLQP-21-treated macrophages and ScrTLQP-21-treated macrophages, 
respectively, n = 9 for both groups). Figure 2.12 C shows the averaged baseline 
measurements of the nine animals that were used the next day for injection with 
TLQP-21-treated macrophage. The averaged baseline measurements of the nine 
animals on day 1 and day 2 were not significantly different from each other, 
indicating a consistent response to the mechanical stimulation given. The baselines 
were also steady for the group of animals that were used the next day for injection 
with ScrTLQP-21-treated macrophages (figure 2.12 D). 
 
If TLQP-21, as hypothesised, specifically targets the primary macrophages and 
activates them for the subsequent cellular events in the pain signalling, it would be 
expected to observe a reduction in the PWTs (Hypersensitive to the mechanical 
stimulation) in the animals injected with TLQP-21-treated macrophages. Indeed, 
when compared to the control group injected with ScrTLQP-21-treated macrophages, 
the PWTs after TLQP-21-treated macrophages injection were significantly reduced on 
POD 1, POD 2 and POD5 (Figure 2.13 A, p<0.01, two way ANOVA, Tukey post hoc 
test). This implies that the TLQP-21-treated macrophages elicit some downstream 
events that subsequently produce a pain-like behaviour in the animals. Moreover, 
when compared to its own baseline, the PWTs of the animals injected with TLQP-21 
-treated macrophages were significantly reduced on the POD1 and POD2 (P<0.05, 
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two way ANOVA, Tukey post hoc test), but not on the POD5 (Data of each individual 
animal is tabulated in figure 2.13B). This shows the effect induced by the 
TLQP-21-treated macrophage injection is likely to be temporary. Nevertheless, the 
PWTs of the animals injected with ScrTLQP-21 treated macrophage, on any given 
testing day, were not significantly differed from its own baseline (Tabulated in figure 
2.13 C). This indicates that the effect induced by the injected macrophages is 
TLQP-21 treatment-specific, as the reduced in PWTs were not observed in the control 
group. 
 
Injection of TLQP-21-treated macrophages to the hind paw resulted in a marked 
reduction in the ipsilateral PWT to punctuate mechanical stimulus up to 5 days 
post-surgery when compared to the ScrTLQP-21-treated macrophages injection group. 
To test if the injected macrophages exert an effect on the contralateral paw of each 
group, the contralateral paw withdrawal threshold to the von Frey filament was also 
measured. Figure 2.14 A shows there was no difference between baseline and 
post-injection withdrawal threshold in the contralateral limb of the animals injected 
with TLQP-21-treated macrophages. No alternations between baseline and 
post-injection contralateral PWTs were observed in the animals injected with 
ScrTLQP-21-treated macrophages. The tabulated data of all animals tested were 
shown in figure 2.14 B and figure 2.14 C for the groups injected with 
TLQP-21-treated macrophages and ScrTLQP-21-treated macrophages, respectively. 
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Figure 2.11 Overview of experimental set up for in vivo TLQP-21 treated macrophage 
intraplantar injection behavioural study. 
The primary macrophage was treated with 500 nM TLQP-21/ScrTLQP-21 for 24 hours prior 
to be used for in vivo experiment. On the day of injection, the dishes were washed three times 
to remove residual peptides and the cells were collected in PBS. 35,000 
TLQP-21/Scr-TLQP-21 stimulated cells were injected to the plantar skin of the rat. The 
behaviours to mechanical stimulation were assessed by electronic von Frey on post operative 
day 1, day 2 and day 5.  
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Figure 2.12 Baseline hind paw withdrawal thresholds to punctuate mechanical stimuli in 
the naïve rats before injections. 
A. Tabulated data of two consecutive days baseline PWTs in all the animals that were later 
assigned to inject with TLQP-21-treated macrophages. B. Tabulated data of two consecutive 
days baseline PWTs in all the animals that were later assigned to inject with 
ScrTLQP-21-treated macrophages C. Averaged baseline 1 and baseline 2 of all nine animals 
assigned to be injected with TLQP-21-treated macrophages. D. Averaged baseline 1 and 
baseline 2 of all nine animals assigned to be injected with ScrTLQP-21-treated macrophages. 
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Figure 2.13 Effects of TLQP-21/ScrTLQP-21-treated macrophages intraplantar 
injections on the ipsilateral paw withdrawal thresholds to punctate mechanical 
stimulation. 
A. Intraplantar injection of TLQP-21 treated-macrophage significantly reduced the ipsilateral 
hind paw withdrawal threshold to the punctate mechanical stimulation when compared to the 
group injected with ScrTLQP-21-treated macrophages. (**P<0.01, Two way ANOVA vs 
scramble, Tuckey post hoc test). B. Tabulated data of ipsilateral PWTs on averaged baseline, 
POD1, POD2 and POD3 of all the animals injected with TLQP-21-treated macrophages. C. 
Tabulated data of ipsilateral PWTs on averaged baseline, POD1, POD2 and POD3 of all the 
animals injected with ScrTLQP-21-treated macrophages.  
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Figure 2.14 Effects of TLQP-21/ScrTLQP-21 -treated macrophages intraplantar 
injection on the contralateral paw withdrawal thresholds to mechanical stimulation. 
A. Intraplantar injection of TLQP-21-treated macrophages/ScrTLQP-21-treated macrophages 
does not affect contralateral hind paw withdrawal threshold to the punctate mechanical 
stimulation when compared to its own baseline. No difference in the contralateral PWT is 
observed when compared between the two groups. B. Tabulated data of contralateral PWTs on 
averaged baseline, POD1, POD2 and POD3 of all the animals injected with TLQP-21-treated 
macrophages. C. Tabulated data of contralateral PWTs on averaged baseline, POD1, POD2 and 
POD3 of all the animals injected with ScrTLQP-21-treated macrophages.  
  
 106 
2.5. Discussion 
 
2.5.1. Effects of VGF-derived peptides on the intracellular calcium level in the 
primary DRG neurons. 
 
VGF has been demonstrated, both in vitro and in vivo, to be upregulated in the DRG 
sensory neurons after peripheral neuronal injuries (Moss, Ingram et al. 2008, Rizzi, 
Bartolomucci et al. 2008, Riedl, Braun et al. 2009). However, the effects of VGF 
peptides on the DRG neurons have not been investigated in the literature. The present 
study looked at the effects of different peptides on the cultured primary DRG neurons 
by calcium imaging. I demonstrated that both LQEQ-19 and TLQP-21 (and its control 
peptide ScrTLQP-21) did not induce a calcium response in the DRG neurons in the 
setting used in this study. It is worth noting that the concentration tested, 1μM, might 
not be the “physiological functioning concentration” on the DRG neurons, even 
though evidence suggested 1 μM of LQEQ-19 can activate BV-2 microglial cells and 
increase p38 phosphorylation in these cells (Riedl, Braun et al. 2009). Moreover, 1 
μM of TLQP-21 has been shown to prevent cerebellar granule cells (CGCs) apoptosis 
induced by serum and potassium deprivation and is able to induce a significant 
increase in the intracellular calcium level in a subpopulation of CGCs (Severini, Ciotti 
et al. 2008). Although these evidences suggested 1 μM of VGF-derived peptides could 
activate other cell types including neurons in the central nervous system, it is still 
possible that DRG neurons are activated by lower/higher concentration at the 
periphery. Further work using different concentrations of VGF-derived peptides could 
be carried out to provide more information to this question. Moreover, there is a 
possibility that VGF-derived peptides only act on a subset of DRG neurons. It is 
possible that the effects of the peptides on the small population of the neurons are 
masked by the background noise, as cultured DRG neurons are highly heterogeneous. 
Future work to investigate the effect of VGF-derived peptides on longer DRG 
neuronal culture supplemented with different neurotrophins can be done. This isolates 
different populations of neurons (such as supplementing NGF to isolate small 
diameter sensory neurons) and hence allows a more reliable conclusion of the effects 
of the VGF-derived peptides on the primary DRG neurons to be drawn. Furthermore, 
as reported by Riedl et al, VGF is upregulated in the cultured DRG neurons within 24 
 107 
hours, it is possible that the cultured DRG neurons were already desensitised by the 
VGF-derived peptides released in the culture prior to the experiment, and hence a 
further response could not be elicited during the calcium imaging. As demonstrated in 
our study, repetitive applications of VGF-derived peptide on the macrophages cause 
cell desensitisation to further stimulation. Unlike macrophage that does not sythesise 
VGF and hence is able to response to the peptide applied during experiment, DRG 
neurons in the culture could potentially be desensitised by the endogenous 
VGF-derived peptides before being used for the experiment. 
 
The functional assay used in this study, calcium imaging, has been widely employed 
as the assay to investigate the neuronal excitability in vitro and in vivo (MacLean and 
Yuste 2009, Grienberger and Konnerth 2012). However, the acquisition time in vitro 
is often at millisecond scale, rather than seconds. Due to technical limitations, the 
measurements of the assay were made every 6 seconds in our investigation. It is 
possible that the VGF-derived peptides-induced calcium responses are rapid and 
transient within seconds, and hence acquiring measurements every 6 seconds may 
miss the detail of such subtle changes. Although, Severini’s observation of 
TLQP-21-induced increase in the CGCs intracellular calcium was performed in 6 
seconds interval, it is still possible that the mechanism involved in the DRG neurons 
are more rapid and different from that of CGCs. A more thorough study using higher 
resolution cameras to increase temporal resolution may further increase the sensitivity 
of the assay and hence further dissect the role of the peptides on the primary DRG 
neurons.  
 
In this study, calcium imaging was used as a functional read out to investigate the role 
of VGF-derived peptides on the DRG neurons. This assumed that VGF-derived 
peptides-induced neuronal activation is a calcium-dependent process, and the calcium 
response is an indicative of the neuronal action potential activity. Although 
depolarization of neurons are often accompanied by a change in the intracellular 
calcium, it is possible that VGF-derived peptides can induce action potential via 
calcium-independent pathway as it has been shown action potential can be modulated 
by calcium-independent process in the sensory neurons (Zhang and Zhou 2002, 
Zheng, Fan et al. 2009). This question can be answered by utilizing the voltage 
sensitive dye, such as DiBAC, in combination with the high temporal resolution 
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imaging or employing the high resolution simultaneous voltage and calcium imaging 
to correlate electrical and chemical activities in the neurons (Vogt, Gerharz et al. 2011) 
upon VGF-derived peptides stimulations.  
 
It is also possible that the VGF-derived peptides tested in this study (i.e. LQEQ-19 
and TLQP-21) are not the biologically active peptides on the sensory neurons. To date, 
there are at least 13 VGF-derived peptides been reported, other peptides could still 
potentially act on the sensory neurons. There is also a possibility that VGF-derived 
peptides do not, at all, signal through DRG neuron itself in an autocrine manner. It is 
likely that VGF derived-peptides are synthesised and released by DRG neurons upon 
depolarisation, and subsequently exert its function on the adjacent cell types such as 
dorsal horn neurons and microglia as suggested by Moss et al and Riedl et al, 
respectively. Nevertheless, the conclusion could not been drawn until the questions 
mentioned are answered. 
 
2.5.2. Effects of VGF-derived peptides on the intracellular calcium level in the 
bone-marrow derived macrophages. 
 
Macrophages play a pivotal role in the immune response and have been implicated in 
the development and/or maintenance of neuropathic pain including injury-induced 
neuropathic pain (Shi, Zekki et al. 2011). It is well established that a change in the 
intracellular calcium concentration is the initiation step of many ordinary macrophage 
cellular processes, including pro-inflammatory mediators productions (Park, Jun et al. 
1996) (Park, Jun et al. 1996, Watanabe, Suzuki et al. 1996), phagocytosis (Gronski, 
Kinchen et al. 2009) (Kruskal and Maxfield 1987) and chemotaxis (Smith, Kessler et 
al. 1982). In the cultured macrophage, the cytosolic calcium concentration of the 
resting cells is kept at low level, ranged from ~50 to 150 nM (Malik, Denning et al. 
2000), which can be evoked to a dramatically high level in response to various stimuli 
and subsequently carries out the ultimate cellular functions. As mentioned, several 
evidences in the literature suggested that VGF-derived peptides act on cells adjacent 
to the sensory neuron terminals in the central nervous system, including dorsal horn 
neurons and microglia. I was interested to elucidate if VGF-derived peptides also 
signal in such paracrine manner at the periphery. Having demonstrated that 
VGF-derived peptides at 1 μM did not elicit a calcium response in the DRG neuron, I 
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further examined if the VGF-derived peptides, which are increased in the gene 
expression and released from the DRG neurons after nerve injuries, signal through the 
primary macrophage in a calcium-dependent manner.  
 
Here I demonstrated, for the first time, a VGF-derived peptide (TLQP-21) acts on the 
bone-marrow derived primary macrophage. Other VGF-derived peptides (LQEQ-19 
and TLQP-62), at the concentration tested, did not induce a change in the intracellular 
calcium, indicating unique calcium-dependent function of TLQP-21 on the primary 
macrophage. Even though LQEQ-19 and TLQP-62 did not elicit a calcium response 
in the macrophages, it cannot be ruled out that these peptides could still act on the 
macrophages by other means such as inducing epigenetic changes. The TLQP-21 is 
functional at concentration as low as 10 nM in the primary macrophage, and the 
percentage of cell responding to this peptide plateaued at 100 nM. Although the 
percentage of cell responding to the peptide did not further increase at concentration 
higher than 100 nM, it does not mean that 100 nM is the saturating concentration as it 
is possible that the amount of calcium flux was different at the higher peptide 
concentrations while the percentages of cell responding remained similar. Future 
experiment can be carried out to quantify the amount of calcium flux in the 
macrophages after high concentrations of TLQP-21 applications using ratiometric 
calcium dye such as Fura-2. This will provide more detailed information on how 
TLQP-21 induces changes in the intracellular calcium level in the macrophages at 
higher peptide concentrations.  
 
As demonstrated in this chapter that TLQP-21 induces a dose-dependent, rapid but 
transient, calcium response in the primary macrophages, this could possibly indicate 
that TLQP-21 acts on the primary macrophage by binding to its target receptor on the 
membrane. Another line of evidence suggesting a receptor is involved is that not all 
cultured macrophage responded to the TLQP-21 peptide. Cultured bone-marrow 
derived primary macrophage is shown to be a mixture of different subtypes of 
macrophages. It is possible that TLQP-21 only acts on the receptor-expressing 
subtypes of macrophages, and hence a small number of cells per experiment did not 
respond to the peptide. It is also possible that the receptor is only expressed on cell 
surface at specific cellular phase, for example the receptor can be internalized during 
cell division and hence no response can be observed. Low concentration of TLQP-21 
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(1 nM) is unable to elicit a calcium-dependent response in the primary macrophage, 
indicating dose-dependent specificity of this peptide on the macrophages and possible 
ligand kinetic on the target receptor.  
 
One issue must be raised here is that the primary macrophages used in this study were 
derived from the bone-marrow pluripotent stem cells, which yield a relatively more 
homogenous cells. Although this is the widely accepted protocol in studying 
macrophage function, it is important to note that they are not like resident 
macrophages in vivo as the resident macrophages themselves are not homogeneous 
where they differentiate according to the environmental cues to suit the 
microenvironment of the tissue and possible pathogens they encountered. The major 
reason bone-marrow derived macrophage was used in this study was that isolation of 
resident macrophages from the animal tissues results significant lower number of cells 
available for the study and the procedure is relatively more complex. Future work 
could be carried out in vitro to further confirm TLQP-21 activity using the resident 
macrophages isolated from animal tissues. Moreover, in vivo study using transgenic 
mice systematically expressing fluorescent calcium sensor can be carried out to 
investigate the TLQP-21 mechanism ex vivo as demonstrated recently (Sasaki, 
Takahashi et al. 2010). 
 
The scrambled control peptide ScrTLQP-21 possesses the same charge, same amino 
acid components (but scrambled in sequence) as TLQP-21 peptide. Here, I 
demonstrated in the study that vehicle control and scrambled peptide control 
(ScrTLQP-21) at physiological concentration did not elicit a calcium response in the 
primary macrophage, this evidence further strengthens the postulation of TLQP-21 
specific action on the primary macrophage. Nevertheless, the scrambled peptide was 
shown to be functional to the primary macrophage at extreme high concentration (50 
μM). The possible explanation for the functionality of ScrTLQP-21 at high 
concentrations could be that the sequence of the scrambled peptide was not 
randomised enough. The TLQP-21 harbours four arginine residues possessing 
positive charges, showing in bold in the sequences below. The four arginine residues 
in the scrambled peptide after randomisation were still in close proximity at the 
C-terminus of the peptide, this could possibly account for the non-specific effect 
observed at extreme high concentration.  
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TLQP-21 sequence   TLQPPASSRRRHFHHALPPAR  
ScrTLQP-21 sequence PSFLLPPHHSRAQHRTPRAAR 
 
It is also possible that the secondary structure of the scrambled peptide remains 
similar though the sequence is not identical from the wild type. Therefore, the ‘active 
domain’ of the peptide was not completely disrupted, which resulted in partial 
functionality of the peptide at extreme high concentration. Furthermore, it is also 
possible that TLQP-21-induced response in macrophage is partially charge-dependent, 
and hence the scrambled peptide possessing the same charge and same amino acid 
component can partially elicit a non-specific effect at extreme high concentration. 
 
2.5.3. The molecular mechanism of actions of the TLQP-21 peptide on the 
bone-marrow derived primary macrophages. 
 
Change in the intracellular calcium level is important in initiating various macrophage 
functions such as recognition of foreign antigens challenges including bacterial 
substances (Hotchkiss, Bowling et al. 1997) (Dewamitta, Nomura et al. 2010) yeast 
component (Kelly, Wang et al. 2010) and viral protein (Hegg, Hu et al. 2000, Lee, Liu 
et al. 2003). Not surprisingly, numerous disease pathogeneses are associated with 
dysregulation in macrophage calcium signalling. For example, mycobaterium 
tuberculosis interferes with macrophage antimicrobial response to achieve immune 
evasion by inhibiting the increase in the intracellular calcium that is required for the 
macrophage phagocytosis (Malik, Denning et al. 2000). Macrophage intracellular 
calcium dynamic is also altered in the pathological conditions such as Sepsis. Deviant 
of calcium signals in the macrophage induced by bacterial lipolysaccharide 
contributes to the aberrant cytokines productions that underlies the consequences of 
organ failure during sepsis (West, Clair et al. 1996, Zhang, Guo et al. 2011). 
Regulated calcium signalling is pivotal for macrophage to ultimately function 
correctly. Thus, understanding the molecular mechanism by which calcium signals 
after TLQP-21 stimulation is important for understating how the cell functions upon 
VGF-derived peptide challenge.  
 
I have demonstrated that TLQP-21 application to the primary macrophage induced an 
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immediate but transient increase in the intracellular calcium. I was interested to 
investigate further the effect of multiple applications of TLQP-21 on the primary 
macrophages to further dissect the mechanism involved in TLQP-21 signalling. It was 
observed that TLQP-21 desensitised the primary macrophage to further TLQP-21 
stimulation without affecting ATP-induced calcium response. In order to eliminate the 
possibility that the lack of response was not due to insufficient time for replenishing 
the intracellular calcium, the cytosolic calcium was allowed to return to the basal 
level before subjecting the cells to another stimulation after first application. In 
addition, I also tested longer time intervals between the two applications up to an hour, 
and the primary macrophages were still desensitised to the second dose of TLQP-21 
treatment one hour after the first stimulation. Moreover, the ATP induced calcium 
response at the end of the experiment was not affected, implying the calcium 
depletion from intracellular store is invalid.  
 
The rapid TLQP-21-induced densitisation of calcium response to the repetitive 
peptide stimulation in the primary macrophage could be explained by several 
mechanisms. As seen in the current study, TLQP-21-induced calcium response in the 
macrophage is rapid but transient, like many responses (including chemokine- and 
complement-induced responses) observed mediating through G protein-coupled 
receptors (GPCRs) that quickly uncouples from G protein-mediated signalling by 
kinase phosphorylation of the receptors (Oppermann, Mack et al. 1999, Rebres, Moon 
et al. 2010). It is possible that TLQP-21 induces an increase in intracellular calcium 
via the GPCRs, and the termination of the signalling is due to the receptor 
internalization or desensitisaiton. There are two documented densensitition forms of 
GPCRs, the homologous- and heterologous-desensitisation (Murakami, Imamichi et 
al. 1993, Capra, Accomazzo et al. 2010). The homologous desensitisation is the 
process of downregulating activated GPCR itself, whereas heterologous 
desensitisation is the phenomenon of activated receptor downregulating a different 
GPCR. In the current study, calcium response was observed after first TLQP-21 
application, the same macrophages were stimulated again with the same amount of 
TLQP-21 peptide. No calcium response was observed to the second dose of TLQP-21, 
but the macrophages still showed the calcium response to ATP stimulation at the end 
of the experiments. This suggests that the desensitisation observed is likely a 
homologous one and that the signal transduction pathway for TLQP-21 is different 
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from that of ATP. The key reaction of GPCR desensitisation is initiated by 
phosphorylation of intracellular domain of the activated receptors by GPCR kinases 
(GRKs), which consequently results in binding of arrestin proteins to the 
phosphorylated receptor. Upon binding of the arrestin adaptor proteins, the 
phosphorylated receptor is prevented from binding to the G proteins, and hence 
disrupting its activation. This mechanism effectively turns off the receptor for a short 
period of time (Lattin, Zidar et al. 2007). The phosphorylation of the GPCRs could 
also results in internalisation of the receptor (Krueger, Daaka et al. 1997, 
Zimmermann, Conkright et al. 1999), although this process is less likely to account 
for the results observed here. As demonstrated by Zimmerman et al. the 
internalisation of GPCR CC chemokine receptor-3 (CCR-3) was merely 76 % and 24 
% after 3 hours of RANTES (reduced on activation T cell expressed and secreted) and 
eotaxin stimulation, respectively. Moreover, the desensitisation described in the 
current study was observed in more than 90% of the cells within minutes of time scale. 
Therefore, the internalisation of receptor is probably not fast enough to account 
entirely for our results. Nevertheless, there is still a possibility that the receptor that 
TLQP-21 targets exhibits a fast kinetic in receptor internalisation and hence account 
for the desensitisation effect seen here.  
 
Another possible mechanism that could account for the absence of the calcium 
response after successive applications of TLQP-21 could be a negative feedback 
mechanism of the macrophage. The first TLQP-21 stimulation on macrophage could 
results in the secretion of certain factor from the cells that, in response to further 
exposure of TLQP-21, acts in an autocrine manner and negatively regulates the cells 
from further activation. In fact, it has been demonstrated such negative feedback 
mechanism exists in primary macrophage. It has been shown that upon LPS challenge, 
activated macrophage secrets nitric oxide that exerts a negative feedback effect on 
production of the downstreatm inflammatory mediator TNF-α in response to further 
activation by LPS (Fahmi, Charon et al. 1995). 
 
I have also showed in the study, pre-treatment of TLQP-62 that possesess TLQP-21 at 
its N-terminus, did not induce heterozygous desensitisation in the primary 
macrophages. This implies TLQP-62 signal transduction pathway is probably 
different from that of TLQP-21. It is also possible that TLQP-62 is not a functional 
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peptide on the primary macrophage at all. More intriguingly, when a high dose of 
ScrTLQP-21 was applied to elicit a non-specific response in the primary macrophage, 
the successive wild type TLQP-21-induced response was not observed. This suggests 
that the scrambled peptide may be acting non-specifically in a similar manner and 
sharing a common calcium flux pathway as wild type TLQP-21. To further elucidate 
the desensitisation mechanism involved in the TLQP-21 calcium flux pathway, the 
experiments could be carried out in the future to test the phosphorylation state of the 
membrane proteins, find the receptor and track the receptor for internalisation.  
 
Having demonstrated that TLQP-21 elicits a calcium response in the primary 
macrophage, I was interested to further investigate what was the source of the calcium 
in the calcium response observed. Is it a result of influx of extracellular calcium or a 
release of calcium from internal store? This was investigated by using a calcium free 
extracellular solution, containing 2 mM calcium specific chelator EDTA, during 
calcium imaging. If the source of calcium is from the extracellular solution, the calcium 
response induced by TLQP-21 will be abolished when extracellular calcium is depleted. 
As demonstrated in the study, the cells still responded to the TLQP-21 when the 
extracellular calcium was excluded, implying the TLQP-21-induced calcium response 
is, at least partly, from the internal stores. The extracellular calcium is not essential for 
initiating the TLQP-21 induced calcium response, as the percentage of responding cells 
in extracellular calcium free condition was not significantly different from that in the 
normal condition. Nevertheless, it is still possible that a small influx of extracellular 
calcium is subsequent to TLQP-21 induced calcium response. This may not be 
observed in our experiment because the magnitude of ATP response was altered in 
calcium free condition. Therefore, the ratio between TLQP-21/ATP induced responses 
may not be directly compared, and hence unable to conclude if the magnitude of 
TLQP-21 induced calcium response was changed in calcium free condition. This 
question can be investigated by future experiment to quantify the absolute calcium 
concentration induced by TLQP-21 in both calcium present and calcium free conditions 
using dyes such as Fura-2 (Invitrogen). The ratiometric calcium dye as such allows 
conversion of fluorescent calcium signals into calcium concentrations, which allows 
direct comparison of calcium response induced by TLQP-21 in different bathing 
solutions. This experiment will allow us to further conclude if the calcium observed in 
TLQP-21 induced calcium response was solely a release of calcium from intracellular 
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store to the cytoplasm, and independent to extracellular calcium. 
 
The data presented here suggested that the calcium source of TLQP-21-induced 
calcium response is, at least partly, from the internal stores of the macrophage. To 
further test if the calcium released from the internal stores is the only calcium source, 
pharmacological agents such as thapsigargin can be used in calcium imaging. 
Tharpsigargin depletes the internal stores of calcium by inhibiting the 
sarcroplasmic/endoplasmic reticulum calcium ATPase (SERCA) family of calcium 
pumps (Rogers, Inesi et al. 1995), which has been shown to be present in a variety of 
organelles including nuclear envelope (Xu, Morita et al. 2001), sarcoplasmic 
reticulum(Arruda, Nigro et al. 2007), endoplasmic reticulum (Papp, Dziak et al. 
2003)and Golgi body(Vanoevelen, Raeymaekers et al. 2004). Pretreatment primary 
macrophages with thapsigargin can block the restoration of calcium that causes the 
internal stores to become depleted. If calcium from internal store is the only core source 
of calcium, pretreatment of thapsigargin would expect to abolish the subsequent 
TLQP-21-induced calcium response. It is established in literature that the major 
pathways that regulate internal store calcium homeostasis involve calcium channels 
such as inositol 1,4,5-trisphosphate (IP3) receptors and ryanodine receptors (RyR), and 
calcium pumps such as SERCAs and PMCAs (plasma membrane calcium ATPases). 
Future experiments can be carried out to dissect which pathway and which calcium 
channel/pump is downstream to TLQP-21 stimulation in macrophage. For example, 
PLC inhibitor, U73122, can be used to check if the TLQP-21 induced calcium 
response involves G-protein activation of phospholipase C and IP3 
production(Mogami, Lloyd Mills et al. 1997). Moreover, inhibitors of RyR such as 
ruthenium red and high concentration of ryanodine can be used to determine the 
involvement of RyR downstream to TLQP-21 activation (Gerasimenko, Maruyama et 
al. 2003). The use of pharmacological agents as such in calcium imaging would not 
only further confirm the source of calcium, but also reveals the nature of the pathway 
that TLQP-21 mediated through. The major intracellular organelles involve in calcium 
dynamic in the cells are the endoplasmic reticulum (ER) and the mitochondria, 
although it must be noted that other organelles, such as Golgi body, nucleus, 
lysosomes and secretory vehicles have also been implicated in modulating 
intracellular calcium level(Michelangeli, Ogunbayo et al. 2005). To further elucidate 
if the internal store of calcium was released from specific organelle(s), studies using 
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calcium sensitive photoprotein, such as aequorin, targeting specific organelle (such as 
mitochondria) can be carried out. Chimeric proteins of aequorin with organelle 
targeting sequences can be generated (Rizzuto, Simpson et al. 1992), and the calcium 
change in these organelles can be specifically monitored upon TLQP-21 application. 
All together, these experiments would provide more evidences to draw a more reliable 
and convincing conclusion on how TLQP-21 acts on the primary macrophage through 
calcium signalling. 
 
After determining that the calcium released from the internal stores plays an 
imperative role in TLQP-21 signalling in the primary macrophage, I was interested to 
next investigate if different subtypes of macrophage response to the peptide 
differently in vitro. Macrophage is established to adapt multiple subtypes and can be 
highly polarised in response to their microenvironment. The polarisation of 
macrophages has been implicated in many disease progressions. For example, 
macrophage is shown to shift from M1 subtype to M2 subtype during tumor 
progression (Sica, Larghi et al. 2008). A shift from an M1 phenotype to an M2 
phenotype is also observed during the course of the disease in animal model of 
muscular dystrophy(Villalta, Nguyen et al. 2009). On the other hand, a change in 
macrophage phenotype from M2 to M1 has been evident in obesity (Suganami and 
Ogawa 2010). The high plasticity of macrophages plays a role in the disease 
development and polarised macrophages may respond to the same stimulus differently. 
To examine whether TLQP-21 acts on different subtypes of macrophage differently, I 
attempted to convert the cultured macrophages into M1 population by LPS treatment, 
M2a population by stimulating with IL-4 and M2c population with IL-10. After 24 
hours stimulations, the polarised populations were able to produce phenotypical 
markers (high iNOS/Arg1 expression for M1 population and low iNOS/Arg1 
expression for M2 populations. M2c also produces high levels of IL-10). In addition, 
the morphologies of M1 macrophages were observed to be more rounded in shape and 
M2 macrophages were more elongated, which are consistence with the literature 
finding (Mills, Kincaid et al. 2000). The data presented in this investigation 
surprisingly suggests TLQP-21-induced calcium response was not affected by the 
polarisation of the macrophages. The percentages of cells responding to TLQP-21 in 
different macrophage subtypes were not significantly different from each other, 
suggesting all subtypes of macrophages responded to TLQP-21 peptide in a calcium 
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dependent manner. However, it is still possible that the pathways downstream to 
calcium increase are different in different macrophage subtypes, and hence result in 
different functional outcomes after TLQP-21 stimulation. Although the percentages of 
responding cell to TLQP-21were not significantly differing between groups, the 
calcium concentrations increased in different subtypes could still be different.  
 
It has been demonstrated that media isolated from activated macrophages show effect 
on DRG neuron axon outgrowth and neurotoxicity in vitro (Gensel, Nakamura et al. 
2009). For this reason and because macrophages are shown to be infiltrated to the 
DRG after peripheral injury (Kim, You et al. 2011), the effect of TLQP-21-stimulated 
macrophage conditioned media (MCM) on cultured DRG neurons were assessed. The 
preliminary data in this study suggests that the 4 hours TLQP-21 treated MCM 
induces about 2 times more DRG neurons to respond when compared to that 
stimulated with 4 hours ScrTLQP-21 treated MCM. This suggests TLQP-21 
stimulated macrophage could possibly release certain functional effectors, which in 
term activates DRG neurons. Nevertheless, the experiment needs to be repeated in 
order to confirm the hypothesis. In addition, MCM from longer treatment with 
TLQP-21 can be tested to examine if the percentage of responding neurons further 
increases.  
 
2.5.4. Effect of TLQP-21 treated primary macrophage on nociception at the 
periphery in vivo.  
 
Having demonstrated VGF-derived peptide, TLQP-21, specifically acts on the primary 
macrophage in a dose-dependent and calcium-dependent manner in vitro. I next sought 
to investigate the effect of TLQP-21-stimulated macrophage in vivo. This is the first 
study that investigates the involvement of VGF-derived peptide-stimulated 
macrophage in the pain modulation. The data presented here suggests that 
TLQP-21-stimulated macrophages exhibited a functional role in eliciting mechanical 
hypersensitivity in rat when injected peripherally. This effect is specific, as the 
hypersensitivity was not observed when ScrTLQP-21-stimulated macrophages were 
injected. The TLQP-21-stimulated macrophages-induced hypersensitivity behaviour 
was demonstrated to be temporary in our study, which was observed in the animals up 
to 3 days post-injection. The paw withdrawal threshold of the animal to the mechanical 
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stimulation on day 5 post-injection of TLQP-21-treated macrophages was not 
significantly different from the baseline before injection. The observed 
TLQP-21-stimulated macrophage effect in vivo is transient could be due to a couple of 
possible reasons. Firstly, it is possible that the injected macrophages may require 
constant exposure to TLQP-21 for a persistent effect. In fact, prolonged upregulations 
of VGF mRNA and protein were observed in the DRG neurons after peripheral nerve 
injury in the Spared nerve injury (SNI) model of neuropathic pain. Such increase in the 
expression is maintained for at least 21 days (Moss, Ingram et al. 2008). Moreover, the 
macrophage is highly polarised, and the polarisation of macrophage can be reversed 
when the polarising stimulus is removed or repolarised when challenged with other 
stimuli (Mosser and Edwards 2008, Ambarus, Santegoets et al. 2012). The animals 
used in this study were naïve, so the VGF derived peptides were most likely not 
presented in the microenvironment surrounding the injected macrophages in vivo. 
Therefore, the injected TLQP-21-stimulated macrophages were removed from its 
stimulus upon delivering to the naïve rats, and hence likely to be reversed to the resting 
state after several days without exposure to TLQP-21. Secondly, it is also possible that 
the turnover rate of TLQP-21-stimulated macrophage is quick, and hence the majority 
of the stimulated macrophages died out before day 5 behavioural assessment. Indeed, 
differentiated and activated macrophage has been evident to have a limited lifespan. It 
is believed that they enter apoptotic death at the site of injury after activation by nature 
ligands/foreign pathogens (Marriott, Bingle et al. 2005). 
 
Another important point derived from this in vivo experiment that needs to be noted is 
that the hypersensitivity effect observed here could be due to the residual TLQP-21, as 
it has been shown to induce hyperalgesic response in mice when inject peripherally 
(Rizzi, Bartolomucci et al. 2008). Although the cultured macrophages were washed 
thoroughly before being harvested for the intraplantar injection, it is still possible that 
some peptide remained in the residual solution, and hence was carried over and injected 
to the animals. Though, the possibility of the carried over peptide inducing the 
nociceptive behaviour is very low, as the concentration of TLQP-21 used to treat the 
culture macrophage was 500 nM and washes were performed before harvesting. 
Moreover, the literature suggested that concentration to elicit a hyperalgesic response 
was 4 mM, and lower doses at 1 mM and 2 mM do not induce a hyperalgesic response 
when injected. Therefore, it is almost unlikely that the residual TLQP-21 carried over 
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could elicit the robust mechanical hypersensitivity as observed. 
 
Summing all the results presented in this chapter, I have demonstrated for the first time 
that a VGF-derived peptide, TLQP-21, acts on the primary macrophage in vitro. The 
mechanism of action of TLQP-21 on the macrophages is dose-dependent. It elicits a 
robust but transient increase in the intracellular calcium, which is resulted from, at least 
partly, the release of calcium from the internal stores. I also demonstrated that 
TLQP-21 desensitises the primary macrophage to further TLQP-21 stimulation and the 
TLQP-21-induced response is observed in both M1 and M2 subtype of macrophages. 
Macrophage conditioned media after TLQP-21 treatment may be able to cause 
excitation of the DRG neurons in vitro, although more experiments need to be carried 
out to confirm the crosstalk in the neuro-macrophage signalling. Lastly, the intraplantar 
injection of TLQP-21-stimulated macrophages induces the mechanical hypersensitivity 
in vivo on POD1 and POD2, suggesting a role of TLQP-21 in the pain pathway both in 
vitro and in vivo. 
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CHAPTER 3: 
GC1QR AS THE POTENTIAL RECEPTOR FOR TLQP-21 ON 
PRIMARY MACROPHAGES 
  
 121 
Synopsis  
 
The data in the previous chapters suggested that TLQP-21 acts on the primary 
macrophages possibly through a receptor-mediated pathway, as desensitisation was 
observed in the TLQP-21-induced response in the macrophages stimulated repeatedly. 
In this chapter, the identification of the potential receptor, GC1qR, for TLQP-21 is 
described. In addition, the verification of GC1qR as the receptor for TLQP-21 on the 
primary macrophages by neutralising antibodies and siRNA approaches has been 
outlined here. I also present and discuss, in the context of neuropathic pain, the effects 
of neutralising GC1qR in vivo in the partial sciatic nerve ligation animal model. 
 
3.1. Introduction 
 
3.1.1. GC1qR 
 
The receptor for the globular head of complement C1q (GC1qR) is a conserved 
eukaryotic protein. The protein homologues have been identified in a wide range of 
eukaryotic species spanning from fungi to mammal. The protein is expressed in 
multiple compartments within a cell and is reported to be expressed in a variety of cell 
types including endothelial cells (Peerschke, Smyth et al. 1996), fibroblast (Deb and 
Datta 1996), immune cells (Ghebrehiwet and Peerschke 2004) and various cell lines at 
high level, such as the Raji and Daudi cell lines (Ghebrehiwet, Lim et al. 1994). The 
molecular weight of GC1qR is 33kDa and is also known as p33, p32, C1qBP, HABP1 
and TAP (Deb and Datta 1996, Yao, Eisen-Vandervelde et al. 2004). In addition to its 
multi-compartmental expression, the protein has also been shown to bind multiple 
ligands and exerts multiple functions (see later ‘function of GC1qR and its interactive 
proteins’).  
 
Cellular Expression of GC1qR 
 
The cellular distribution of GC1qR is detected in several of cellular compartments, 
including the plasma membrane (Ghebrehiwet, Lim et al. 1994, Ghebrehiwet, Lim et 
al. 2001, Mahdi, Madar et al. 2002, Fogal, Zhang et al. 2008), cytoplasm (Laine, 
Thouard et al. 2003), endoplasmic reticulum (ER), mitochondria (van Leeuwen and 
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O'Hare 2001) and the nucleus (Krainer, Mayeda et al. 1991, Laine, Thouard et al. 
2003). Although the cellular expression of GC1qR is still controversial, it is suggested 
that the protein is produced as a full-length pre-pro-protein of 282 amino acids, which 
appears to be directed mainly to the mitochondria by its N-terminus targeting 
sequence (Dedio, Jahnen-Dechent et al. 1998). The 73-residue-long pre-sequence is 
predicted to harbour the mitochondrial targeting sequence (MTS), which leads the 
pre-pro-protein for mitochondrial accumulation. It has been demonstrated that fusing 
of such pre-sequence alone to a green fluorescent protein directs the protein to the 
mitochondria matrix (Dedio, Jahnen-Dechent et al. 1998). Cleavage or modification 
of the first 73-residue-long targeting sequence results in re-targeting of the pro-protein 
to other cellular compartments. Indeed, it has been demonstrated that the addition of a 
short flag tag to the N-terminus of GC1qR results in disrupting the targeting sequence 
and re-directing the protein to the ER and cell surface (van Leeuwen and O'Hare 
2001). GC1qR on the cell surface is proposed to serve as a multifunctional receptor 
for many extra- and intracellular proteins (Lim, Reid et al. 1996, Nguyen, 
Ghebrehiwet et al. 2000, Pupo and Minneman 2003, Yao, Eisen-Vandervelde et al. 
2004).  
 
Although it is expressed on the cell surface, the translated amino acid sequence of 
GC1qR surprisingly lacks transmembrane domains and GPI anchor. Some suggested 
that the protein possibly induces a transmembrane signal via association with other 
transmembrane proteins, such as β1-integrin and DC-SIGN, to channel the 
downstream signalling events inside the cell (Ghebrehiwet, Feng et al. 2003, Hosszu, 
Valentino et al. 2012). Though there is neither predicted transmembrane segments nor 
GPI anchors on GC1qR, strong evidences in the literature demonstrated its expression 
on the cell surface. First, labelling peripheral blood lymphocytes with 
sulfo-NHS-LC-biotin that is impermeable to the cell membrane, showed specific 
incorporation of biotin in the surface expressed GC1qR but not the intracellular 
counterpart (van Leeuwen and O'Hare 2001). Second, western blot analysis on 
membrane proteins purified from Raji cells showed corresponding bands for GC1qR 
protein, implying it membrane localisation. Moreover, confocal laser scanning 
microscopic analysis using GC1qR specific monoclonal antibodies revealed specific 
surface staining on 90-95% of the Raji cells (Ghebrehiwet, Lim et al. 1994). 
Furthermore, the surface expression of GC1qR has also been demonstrated by 
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Fluorescence-activated cell sorting (FACS) analysis on various cell types 
(Ghebrehiwet, Lim et al. 2001, Vegh, Goyarts et al. 2003). Lastly, functionally, the 
membrane expression of gClq-R was shown to be increased by inflammatory 
cytokines (INF-y, TNF-a and LPS) stimulations on endothelial cells (Guo, 
Ghebrehiwet et al. 1999).  
 
Structure of GC1qR 
 
The structure of GC1qR was first reported by Jiang et al in 1999 at 2.25 Å resolution 
(Jiang, Zhang et al. 1999). Except for mutating the Leucine to Methionine on the 
residue at position 74 for expression purpose, the molecule expressed was identical to 
the mature form of GC1qR without the first 73 targeting sequence. 
 
The primary structure of GC1qR contains a protein kinase C (PKC) phosphorylation 
site at residue 207, a tyrosine kinase recognition site at position 268, and three 
consensus N-glycosylation sites at position 114(Asparagine-Glycine-Threonine), 
136(Asparagine-Asparagine-Serine) and 223(Asparagine-Tyrosine-Threonine). As 
mentioned previously, the primary structure of GC1qR does not predict consensus 
amino acid sequence for transmembrane segments and GPI anchors.  
 
The crystal structure revealed the secondary structure of GC1qR monomer, which 
consists seven consecutive β-strands forming an antiparallel β-sheet flanked by 
α-helices (one at N terminus and two at C terminus of the protein). The region 
spanning the second (αB) and the third (αB) α-helice is suggested to be pivotal for 
oligomerisation of the monomers, and is shown to be conserved in homologous 
proteins among different species. Despite the simplicity of GC1qR monomer structure, 
it does not relate to any known structure folding of proteins.  
 
Three tightly bound GC1qR monomers constitute to a doughnut-shaped tertiary trimer 
structure, forming a channel of ~20Å in diameter in between. The channel wall is 
formed by the β-sheets of all three subunits, where each antiparallel β-strands is 
highly twisted, thus arranging into an up-and-down β-barrel structure. The inner and 
outer diameters of the trimer are measured approximately 20Å and 75Å, respectively, 
and the resultant thickness of the trimeric structure is about 30Å. The trimeric structure 
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of GC1qR is suggested to increase the structural integrity of the protein and has been 
postulated to be the physiological structure. Indeed, the postulation is consistent with 
the literature evidences where GC1qR and its homologue in Saccharomyces 
cerevisiae are shown to behave as trimer in gel filtration chromatography 
(Ghebrehiwet, Lim et al. 1994, Seytter, Lottspeich et al. 1998). Moreover, oligomeric 
nature of GC1qR has been suggested to play a pivotal role for its affinity to 
multivalent ligands such as high molecular weight kininogen (HK) and C1q (Herwald, 
Dedio et al. 1996). 
 
The doughnut-shaped structure of GC1qR exhibits characteristic of highly negative 
charged channel and asymmetric surface charge distribution on the sides of the 
doughnut (one side is highly negatively charged and the other is less charged). The high 
net negative charge of the molecule makes the protein to be highly acidic with a 
calculated pI of 4. The distinctive characteristic of different charges on the two sides of 
the doughnut may suggest its asymmetric functional role.  
 
Function of GC1qR and its interactive proteins 
 
GC1qR was first characterised as C1q binding protein with Kd of 50-100 nM. It has 
been demonstrated that GC1qR binds to both non-denatured and denatured C1q on its 
A-chain and, to a less extend, the C-chain. Although GC1qR was originally identified 
as the binding protein to the globular head of C1q, there is growing literature 
suggesting that it is in fact a multi-ligand binding protein that binds to a variety of 
extra- and intracellular proteins, thus exerting multiple cellular functions.  
 
The first group of interactive proteins that GC1qR binds are the plasma/extracellular 
proteins, which includes C1q (Ghebrehiwet, Lim et al. 1994), thrombin (Ghebrehiwet 
and Peerschke 1998), vitronectin(Lim, Reid et al. 1996), high molecular weight 
kininogen (HK), factor XII (Joseph, Ghebrehiwet et al. 1996) and fibrinogen (Lu, 
Galanakis et al. 1999). GC1qR was first isolated from Raji cell and demonstrated to 
bind C1q by solid phase binding assay. 250 ng of full length C1q, globular region of 
C1q, Collagen-like domain of C1q or BSA were coated on a microtiter plate and the 
binding of 
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I-labelled GC1qR to each of these ligands was accessed. It was clearly 
shown that GC1qR binds to C1q and the globular head of C1q with high affinity but 
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not to the collagen-like stalk of C1q or BSA. This suggested the specific binding of 
GC1qR to the globular head of C1q for the first time and lead to the further 
investigation of the role of GC1qR in complement pathway. Indeed, it is demonstrated 
then that GC1qR functions to inhibit complement haemolytic activity by binding to 
C1q, which often triggers the pathway by binding to the immune complexes (Peterson, 
Zhang et al. 1997). It is also demonstrated that GC1qR plays a role in activating C1q 
dependent Classical pathway of the complement system in human blood platelets, and 
hence contributing to the process of inflammation (Peerschke, Yin et al. 2006). In 
addition to activating the classical pathway of the complement system, GC1qR also 
exacerbates inflammatory process by interacting with HK and factor XII in the 
bradykinin-generating cascade, which later exerts proinflammatory effect (Kaplan, 
Joseph et al. 2002). GC1qR has also been evident to interact victronectin alone and 
the vitronectin-thrombin-antithrombin complex to initiate clearance of 
victronectin-containing complexes, thus inhibiting complement-mediated cell lysis 
(Lim, Reid et al. 1996).  
 
Some intracellular proteins have also been shown to interact with GC1qR. This 
includes cC1q-R, which is another receptor to C1q. GC1qR has been suggested to 
form complex with CC1qR and possibly other proteins, and initiates cross talk 
between the associated proteins (Ghebrehiwet, Lu et al. 1997). α1β-adrenergic 
receptor has also been evident to interact with GC1qR via its cytoplasmic domain of 
the Carboxyl-terminus by yeast-two hybrid screening and co-immunoprecipitation 
experiments (Xu, Hirasawa et al. 1999). Recently, the α1-adrenergic receptor has been 
demonstrated to positively regulate cytokine production in human monocytes and 
macrophages (Grisanti, Woster et al. 2011) and GC1qR has been suggested to regulate 
cellular expression of α1β subunit of α1-adrenergic receptor where co-expression of 
GC1qR with α1β reduced the receptor membrane expression (Xu, Hirasawa et al. 
1999). It is therefore plausible that GC1qR controls human monocyte and 
macrophages cellular functions by coupling with α1β and controlling its expression 
and downstream signalling cascades. Furthermore, GC1qR has been identified to 
interact with intracellular PKC-μ. It is demonstrated that GC1qR binds to PKC-μ 
protein via its kinase domain, possibly function to regulate PKC-μ kinase activity, yet 
does not serve as a substrate. Indeed, PKC-μ aldolase phosphorylation, but not 
autophosphorylation, is shown to be inhibited in a dose-dependent manner by 
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presence of GC1qR in the kinase assays (Storz, Hausser et al. 2000). 
 
GC1qR has also been demonstrated to bind to proteins from pathogenic 
microorganisms including viral and bacterial proteins. The strong interactions of 
GC1qR to the viral and bacterial proteins have been implicated in the pathogenicity 
and oncogenicity of these pathogenic microorganisms directly or indirectly. GC1qR is 
shown to bind to the core protein of Hepatitis C virus (HCV) and function to promote 
viral infection and persistence (Kittlesen, Chianese-Bullock et al. 2000, Waggoner, 
Hall et al. 2007). HCV utilised GC1qR to evade the immune response, in which HCV 
core protein interacts with GC1qR and subsequently arrests the proliferation of T cells, 
which is reversible by anti-GC1qR antibody (Yao, Eisen-Vandervelde et al. 2003).  
GC1qR has also been implicated in viral gene expression regulation of HIV-1 and 
herpes simplex virus by interacting with their accessory proteins HIV-1 Tat (Yu, 
Loewenstein et al. 1995), HIV-1 Rev (Luo, Yu et al. 1994) and open reading frame P 
of herpes simplex virus (Bruni and Roizman 1996). It is also evident that GC1qR 
interacts with bacterial proteins such as protein A of Staphylococcus aureus 
(Peerschke, Bayer et al. 2006) and Internalin B of Listeria monocytogenes 
(Pizarro-Cerda, Sousa et al. 2004). In both of the cases, GC1qR functions as the 
initating step of invasion mechanism of the pathogen and enable subsequent 
intracellular growth.  
 
All together, the cellular expression, structure, examples of functions and interactive 
proteins of GC1qR demonstrates its regulatory roles in intracellular and extracellular 
signalling. The localisation of the protein and which ligand it interacts dictate its 
ultimate cellular functions. Thus, GC1qR, as agreed in the literatures, is shown to be a 
multi-ligand binding protein exerting multiple cellular functions. 
 
3.1.2. Animal models of neuropathic pain 
 
Human studies of pain patients and control volunteers provides invaluable information 
towards our understanding of the mechanism of neuropathic pain, which serves as 
strong stepping stone for future research and treatment therapeutic drug developments. 
One example of the importance of human research is the identification of SCN9A as 
one of the ‘pain genes’. SCN9A gene has been mapped to be the gene causing 
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phenotype from patients with complete inability to sense pain in 2006 (Cox, Reimann 
et al. 2006). It encodes the alpha subunit of the voltage-gated sodium channel, NaV1.7, 
which is now one of the major targets for pain drug developments in the 
pharmaceuticals and remained to be the major focus of research by a number of 
international laboratories. Although human studies are essential in the pain research, 
the evaluation of neuropathic pain in human is complex and more than often, the 
stimuli/procedures required to induce neuropathic pain result in permanent damage and 
are all subject to limitation. Moreover, it is difficult to recruit a large number of patients 
with similar symptoms for testing. Therefore, these is a need for reproducible surrogate 
animal models to validate, and in some case guide, human research and broaden the 
knowledge of the mechanism involved in the neuropathic pain development, thus 
shedding the light for better pharmacotherapies development. 
 
The major advantages of the animal models of neuropathic pain include that they allow 
pathophysiological assessment in the nervous system, both centrally and peripherally, 
in the neuropathic state. They also enable neurophysiological, morphological and 
biochemical changes to be evaluated during disease state and allow molecular and 
cellular mechanism underlying the development of such dis-regulated pain to be 
investigated. Moreover, they are invaluable for analgesic pharmacology where they 
could enable drug efficacy to be examined and allow identification of rational targets 
for future analgesic drugs developments.  
 
In this session, some of the most commonly employed animal models of neuropathic 
pain in the pain research will be introduced. The existing animal models of neuropathic 
pain could be divided into two broad categories, nerve injury models of neuropathic 
pain and disease-associated models of neuropathic pain. Common models from both of 
the categories will be presented here. 
 
Never injury model of neuropathic pain 
 
Partial sciatic nerve ligation (PSNL or Seltzer) model 
In my studies I have used the partial sciatic nerve ligation (PSNL) model of peripheral 
injury neuropathic pain model. Seltzer, Dubner and Shir (Seltzer, Dubner et al. 1990) 
developed this model by partially ligating the sciatic nerve, which is one of the most 
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commonly employed animal model of neuropathic pain. In this model, the sciatic 
nerve at upper thigh level of the left hind leg is exposed under anaesthesia. About 
one-third to half width of the sciatic nerve is tightly ligated with non-absorbable 
suture (table 3.1). This procedure results in partial denervation of one of the hind 
paws while keeps some of the sensory input intact. The damage to the peripheral 
nerves results in infiltration of mast cells, macrophages and T lymphocytes that 
produce inflammatory mediators such as proinflammatory cytokines and chemokines, 
which play pivotal roles to the initiation and/or maintenance of neuropathic pain. The 
behavioural alterations of the animal after the surgery includes spontaneous pain in 
forms of wound guarding, excessive licking of the ipsilateral hind paw and avoidance 
of putting body weight on the injured paw. The behavioural changes to the hind paw 
like cold allodynia, hyperalgesia to mechanical, thermal and chemical stimuli have 
been shown to develop within 1 week after the surgery and could persist up to several 
months post-surgery.  The PSNL model produces unilateral peripheral 
mononeuropathy, and symptoms developed after surgery has been suggested to 
manifest those observed in causalgiform pain syndrome in patients. Furthermore, the 
model has been extended to other species like mice (Malmberg and Basbaum 1998, 
Harvey and Dickenson 2009), and it has been demonstrated there is changes in the 
electrophysiological properties of the neuronal activity. It has been noted that 
increases in C-fibre evoked response, spontaneous activity and wind-up of wide 
dynamic range (WDR) neurons have been observed after PSNL surgery. Wind-up is s 
phenomenon where repetitive electrical stimulation of the peripheral C-fibres results 
in progressively increasing response in the corresponding spinal cord WDR neurons. 
Increase in wind up of WDR neurons is correlated to the central sensitisation, 
implying development of central sensitisation in the PSNL model of neuropathic pain. 
 
Spinal nerve ligation (SNL or Chung) model 
The other most commonly employed nerve injury model of neuropathic pain is the 
Spinal nerve ligation (SNL) model. Kim and Chung developed this model with tight 
ligation at the L5 and L6 spinal nerves distal to the dorsal root ganglion (Kim and 
Chung 1992). Briefly, under anaesthesia, a small incision is made at the lower back to 
expose the left posterior iliac crest. The left posterior iliac crest is crushed to expose the 
lumbar spinal nerves. The L5 and L6 spinal nerves are identified, carefully separated 
from L4 and ligated with non-degradable suture (table 3.1). L4 spinal nerve is often 
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kept intact in this model because it consists large amount of motor fibres, ligation to this 
spinal nerve will result in disrupting motor function and hence complicate 
interpretation of the behavioural outcome. Within 48 hours, the operation results in 
long-lasting behaviour change including cold and mechanical allodynia, thermal 
hyperalgesia and persistent pain, which are maintained for up to 16 weeks.  
This is a highly reproducible model and the symptom mimics that of chronic 
neuropathic pain state in human. The SNL model offers a major advantage that the L5 
and L6 spinal nerved are designed to be deneravated, thus the specific spinal segments 
that are damaged/intact are known, allowing subsequent investigation of the spinal cord 
(central) mechanism of neuropathic pain. 
 
Chronic constriction injury (CCI) model 
The chronic constriction injury (CCI) model, developed by Bennett and Xie, is a 
model of mononeuropathy induced by self-strangulation of the sciatic nerve. Unlike 
PSNL in that a single partial ligation is performed on the sciatic nerve, four ligatures 
are loosely tied around the sciatic nerve and result in slight constriction to the nerve  
(Bennett and Xie 1988)(Table 3.1). The constriction of the sciatic nerve is associated 
with intraneural oedema, focal ischemia and Wallerian degeneration. Thus, the actual 
cause of the nerve damage in the CCI model is not resultant from the ligatures, but the 
‘strangulation’ of the nerve caused by oedema-induced nerve swelling. In addition, it 
is suggested the myelinated sensory afferents are affected more severely in this model 
than the unmyelinated fibres (Bennett, Chung et al. 2003). The post surgery 
behaviours of the animals includes decreased threshold in paw withdrawal to thermal 
(both hot and cold), mechanical and chemical stimuli. Spontaneous pain behaviours 
are also observed. These phenotypes can persist for 8-12 weeks post-surgery. 
Moreover, the affected hind paw are shown to be unusually warm/cool in one third of 
the animals and more than half of the operated animals developed overgrown claws 
on the injured side. The CCI model was originally developed in the rats, but it has 
been successfully established in the mice as well (Sommer, Schmidt et al. 1997).  
 
Spared nerve injury (SNI) model 
Spared nerve injury (SNI) model is the latest peripheral nerve injury model of 
neuropathic pain developed by Decosterd and Woolf in 2000. In this model, the rats are 
anaesthised and the sciatic nerve of the left hind leg and its three terminal branches are 
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exposed (sural, tibial and common peroneal nerves). Two of these sciatic nerve 
terminal branches are tightly ligated with non-degradable sutures followed by 2mm 
axotomy (typically the tibial and common peroneal nerves) and the sural nerve is left 
intact (table 3.1), and hence the model was named the ‘spared nerve’ injury model. The 
spared nerve injury model results in mechanical and thermal hyperalgesia. The 
behavioural changes are observed within 24 hours, and could persist up to 6 months. 
The reproducibility of this model is considered to be higher when compared to PSNL 
and CCI models, and it is claimed that all animals are responders after the surgery 
(Decosterd and Woolf 2000).Unlike PSNL, SNL and CCI models result in a mixture of 
intact and degenerating axons and the behavioural testing outcome is a summation 
output of all these nerves, SNI model permits testing of the non-injured skin surface 
where the sural nerve innervates and the denervated areas of the axotomised common 
peroneal and tibial nerves. This allows direct comparison and simultaneous 
investigation of the thermal and mechanical sensitivities between the injured skin 
territories and the neighbouring intact sensory afferents.  
 
Disease-associated model of neuropathic pain 
 
Diabetes-induced neuropathy model 
Diabetic neuropathy is resulted from the nerve damage caused by chronically high 
blood sugar and diabetes. It is estimated about one in five people with diabetes 
develops painful diabetic neuropathy, which is a devastating condition and often leads 
to foot amputation. The clinical conditions of diabetes-induced neuropathy include 
paraesthesia, allodynia, hyperalgesia, spontaneous pain and sensory loss (Calcutt 2002). 
The most common animal model for painful diabetes-induced neuropathy is the 
streptozotocin (STZ) model. In this model, STZ, which is toxic to the insulin-producing 
β cell of the pancreas, is administered intra-peritoneally/subcutaneously/ intravenously 
to the animals (normally between 50-200mg/kg concentration) (Courteix, Eschalier et 
al. 1993, Aley and Levine 2001, Anjaneyulu and Chopra 2003). The behavioural 
symptoms post-injection include thermal and mechanical hyperalgesia and allodynia to 
thermal and mechanical stimuli that often do not elicit pain response. These symptoms 
occur gradually and are observed most prominently 2 weeks after diabetes induction. 
Although the model can be easily induced by solely STZ injection, it presents 
drawbacks such as that the animals develop other symptoms complicating the 
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interpretation of nociception, these include reduced growth and motor activity, fall in 
skin temperature, alterations in lipid metabolism, ketoacidosis, polyuria and diarrhea. 
These complications thus have to be considered when choosing the suitable models for 
neuropathic pain studies. 
 
Cancer treatment-induced neuropathy model 
Chemotherapeutic agents used to treat cancers have been reported to induce sensory 
neuropathy and resulting in neuropathic pain in patients. These chemotherapy drugs 
include Vincristine and Paclitaxel. Cancer treatment-induced neuropathy animal 
models of neuropathic pain have hence been developed in hope to understand the 
pathogenic mechanisms underlying the development of drug-induced neurotoxicity 
and better understand the pathophysiological, morphological and electrophysiological 
changes due to chemotherapeutic agents. The two most commonly utilised 
chemotherapy drug-induced neuropathy models are described here -the 
vincristine-induced and paclitaxel-induced neuropathy model. 
 
Vincristine has been used in current clinic routinely to treat breast cancer, leukemia, 
lymphomas and primary brain tumours. Several toxic effects have been attributed to 
vincristine, including peripheral neurotoxicity and the subsequent resultant 
sensory-motor neuropathy (Hilkens and ven den Bent 1997). Different animal models 
of vincristine-induced neuropathy have been developed in which they differ from the 
dose regimen and the numbers of dosages. The most frequently employed protocol is 
developed by Aley et al (Aley, Reichling et al. 1996) where 100 μg/kg of Vincristine is 
delivered daily intravenously to the tail vein of rats over a period of two weeks. 
Thermal and mechanical hyperalgesia has been reported to develop on the second day 
after vincristine treatment, and persist up to 24 days. However, this model has been 
demonstrated that higher dose (200 μg/kg) of vincristine treatment leads to loss of 
~12.5% body weight during the course of treatment and significant mortality. 
 
Paclitaxel is one of the other chemotherapeutic agents currently used in the clinic, 
which has been extensively used for the treatment of numerous malignancies 
including breast, ovarian, head, neck and non-small cell lung cancers (Jordan and 
Wilson 2004). Like Vincristine, Paclitaxel has been reported to cause adverse side 
effects including peripheral axon neuropathy, cardiotoxicities, gastrointestinal 
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toxicities and mucositis, which may ultimately lead to disabling symptoms and 
resultant in reduced quality of life for the patients. Paclitaxel-induced neuropathy 
model of neuropathic pain has hence been developed to understand not only the 
mechanism underlying neuropathic pain, but also the pathogenesis of 
paclitaxel-induced neuropathy in hope to prevent or delay neurotoxicity. If the 
neurotoxicity side effect could be greatly improved by the better understanding of the 
pathogenesis from the model, it may leads to more effective therapeutic regimens. In 
this model, typically 1-2 mg/kg of paclitaxel is administered intra-peritoneally to the 
animals on four alternate days (day 0, 2, 4 and 6). This dose regimen of paclitaxel 
results in cold and mechanical allodynia and endoneural oedema of the sciatic nerve. In 
addition cold and mechanical hyperalgesia has also been observed on day 5 post- first 
dose injection and persist for almost 3 weeks after the last dose. Intriguingly, this model 
results in little or no alteration to the sensitivity to noxious pain as heat hyperalgesia is 
often not observed (Polomano, Mannes et al. 2001). 
 
Viral infection-induced neuropathy model 
Sensory peripheral neuropathy associated neuropathic pain is frequently observed in 
patients with viral infections, which include the Human Immunodeficiency virus Type 
1 (HIV-1) and Varicella zoster virus (VZV) infection. HIV-induced sensory neuropathy 
is common among infected patients, which has been shown to affect about 35% of the 
hospitalised patients (So, Holtzman et al. 1988). The HIV-induced sensory neuropathy, 
which often associates with devastating neuropathic pain, is reported at high rate 
globally and remains to be a major global health concern. The animal model hence was 
developed to better understand the pathogenesis of HIV-induced sensory neuropathy in 
hope to improve symptom, identify risk factors and develop effective therapeutic 
treatments for affected sufferers. In the HIV infection-induced neuropathy model, the 
rat’s left sciatic nerve is exposed and wrapped with oxidised cellulose (oxycellulose) 
soaked with 200ng HIV-1 envelope protein gp120. The oxycellulose serves as a carrier 
matrix, which slowly release viral protein gp120 ectopically, mimicking physiological 
viral infection (Wallace, Blackbeard et al. 2007). Such perineural administration of 
gp120 results in mechanical, but not thermal or cold, hyperalgesia. This 
hypersensitivity is observed from day 9 post-gp120 treatment, peaked at day 12, and 
persists until day 21 post-surgery. Moreover, the rats also exhibit anxiety-like 
behaviour in the open field behavioural experiment. In addition, the mechanical 
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hypersensitivity observed is shown to be reversible by treatment with gabapentin, 
morphin and cannabinoid. This model not only allows investigation of the mechanism 
underlying HIV-1 induced sensory neuropathy, but also provides invaluable system 
for preclinical testing of drugs available for treatments.  
 
Varicella zoster virus (VZV) is a virulent neurotropic herpesvirus that causes 
approximately 4 million cases of chickenpox annually. After primary infection, the 
virus retrogradely transports along the sensory axon and quiescent in the sensory 
ganglia. The quiescent virus can be reactivated when the immunity is weaken and 
causing acute herpes zoster, also known as shingles. Neuropathic pain is more than 
often associated with relapse of viral infection. Thus, the VZV infection-induced 
neuropathy has been replicated in rats, in which animals are anesthetised and injected 
with VZV infected cells (6-8 x 10
6 
cells in 50 µl) to the left mid-plantar glabrous foot 
pad. 3 days after the viral infected cells injection, the rats develop mechanical allodynia 
and hyperalgesia, which reach the maximal level before day 21 (Hasnie, Breuer et al. 
2007). 
 
Although growing numbers of animal models of neuropathic pain have been 
developed in the recent years, each animal model still presents its drawbacks. For 
example, in the PSNL model, because 30-50% of the sciatic nerve axons are ligated, it 
is impossible to ensure the same amount of axons, and the exact location of sciatic 
nerve, is ligated in different animal. Therefore, resulting in different amount of nerve 
damage in different animals, which may contribute to the variability observed in the 
behaviours among animals underwent surgery. Moreover, over tightening/loose 
tightening of the ligatures in the CCI models could lead to complete axotomy/no 
nerve constriction. Hence, the model required researchers with extensive experience 
to perform minimal but appropriate constriction to the sciatic nerve. Furthermore, 
most of the disease-associated models of neuropathic pain are limited with dosage 
cytotoxicity. Apart from these technical drawbacks, it is impossible for a single 
animal model to manifests all the symptoms from human patients and exhibits the 
whole spectrum of neuropathic pain mechanisms. Therefore, comparisons between 
animals models and combined used of the models are essential in the pain research 
and would benefits the future research for better understanding of the mechanism of 
neuropathic pain.
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 Nerve Injury models of Neuropathic pain  
 Name Procedure Schematic diagram Reference 
Partial sciatic nerve 
ligation (PSNL or 
‘Seltzer’ Model) 
Tightly ligate 30-50% of the sciatic nerve of 
the left hind at upper thigh level 
 (Seltzer, Dubner et al. 
1990) 
 
 
Spinal nerve ligation 
(SNL or ‘Chung 
model’) 
Tight ligation of the L5 and L6 spinal nerves 
distal to the dorsal root ganglia 
 (Kim and Chung 
1992) 
 
 
Chronic constriction 
injury model (CCI) 
Four ligatures are loosely tied around the 
sciatic nerve of the left hind leg resulting in 
chronic constriction to the nerve 
 (Bennett and Xie 
1988) 
 
 
Spared nerve injury 
model (SNI) 
The common peroneal and Tibial nerves are 
ligated followed by axotomy transection while 
the sural nerve is left intact (Spared nerve) 
 (Decosterd and Woolf 
2000) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spinal cord 
 
Spinal cord 
 
Spinal cord 
 
Spinal cord 
L6 
L6 
L6 
L6 
L5 
L5 
L5 
L5 
L4 
L4 
L4 
L4 
DRG 
DRG 
DRG 
DRG 
Sciatic Nerve 
Sciatic Nerve 
Sciatic Nerve 
Sciatic Nerve 
Partial ligation 
Tight ligations 
4x ligatures 
Sural 
    
Tibial 
Common peroneal 
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Table 3.1. Summary of the procedures, schematic diagrams and original references for different animal models of neuropathic pain. 
 
 Diseases-associated models of neuropathic pain  
 Name Procedure Schematic diagram Reference 
Diabetes induced 
neuropathy model 
Subcutaneous injection of streptozocin 
(STZ) 
 
 (Courteix, Eschalier et al. 
1993) 
Cancer 
treatment-induced 
neuropathy model 
Paclitaxel and vincristine injection   (Aley, Reichling et al. 1996, 
Polomano, Mannes et al. 
2001) 
HIV-1 induced 
neuropathy model 
Perineural administration of gp120 
glycoprotein of HIV-1 by wrapping 
oxidised cellulose soaked with gp120 
around the left sciatic nerve. 
 
 
 
(Wallace, Blackbeard et al. 
2007) 
Varicella zoster virus 
(VZV)-induced 
neuropathy model 
Injecting VZV infected cells (6-8 x 10
6 
cells in 50 µl) to the left mid-plantar 
glabrous foot pad. 
 
 
 (Hasnie, Breuer et al. 2007) 
 
 
 
 
 
 
 
 
 
Streptozocin 
 
Paclitaxel/Vincristine 
 
 
VZV infected cells 
(CV-1 cells) 
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3.1.3. Identification of VGF receptor – GC1qR 
 
I have demonstrated in the previous chapter that macrophage is one of the target cells, 
if not the only one, for VGF-derived peptide TLQP-21. Despite the results in the 
previous chapter suggesting TLQP-21 acts on primary macrophage in a 
dose-dependent and intracellular calcium-dependent manner, the receptor for 
TLQP-21 and other VGF derived peptides still remain unknown in the current 
literature. Recently in our laboratory, an attempt was made to identify the receptor(s) 
for TLQP-21. To identify the receptor for TLQP-21, two approaches were employed.  
 
The first method exploited was the chemical cross-linker in combination with mass 
spectrometry techniques. Sulfo-EMCS amine-to-sulfhydryl heterobifunctional 
cross-linker was used in this experiment, which contains N-hydroxysuccinimide 
(NHS)-ester and maleimide reactive groups at each end as shown in figure 3.1. The 
NHS-ester functional group and the maleimide functional groups react with primary 
amine and sulfhydryl group, respectively, and are separated by a medium-length 
spacer arm (9.4 angstroms). For receptor identification, a synthetic TLQP-21 peptide 
(>95 % purity, Peptide Synthetics, PPR Ltd) was generated with an extra cysteine 
added to the C-terminus and a biotin covalently attached to the N-terminus via the 
amine bond (see figure 3.1). TLQP-21 naturally consists no cysteine in the protein 
sequence, and the extra cysteine added to the C-terminus allows Sulfo-EMCS 
cross-linker to be utilized in the receptor identification experiment. In addition, the 
extra biotin at the N-terminus allows the ease for detecting the receptor/ligand 
complex (e.g. using streptavidin-HRP). Moreover, this modification disrupted the 
primary amine structure on the TLQP-21 peptide, which prevents the 
TLQP-21-conjugated cross-linkers reacting with the peptide itself or the adjacent 
peptides. This eliminates the concern of the multiple cross-linkers joining TLQP-21 
peptides together, and the NHS-ester reactive arms are left to only react to the primary 
amines groups on the potential receptor(s).  
 
The synthetic peptide was conjugated to the sulfo-EMCS cross-linker via the 
maleimide reactive arm, which reacts with the sulfhydryl group on the cysteine at the 
C-terminus. To confirm the peptide was successfully conjugated to the cross-linker, 
the mixture was analysed by MALDI-TOF mass spectrometry. Figure 3.2 A shows the 
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result from the MALDI-TOF analysis. The predicted monoisotopic mass of the 
synthesised TLQP-21 conjugated to Sulfo-EMCS is 3147.46 Da. The most abundant 
peak observed in the spectrum was the conjugated form at m/z 3148.4, which 
corresponds to the (TLQP-21+cross-linker+H)+ form of the conjugate. Although the 
unconjugated peptide was also observed in the spectrum at m/z 2764.6, the intensity 
of such peak is much weaker than the conjugated peptide+cross-linker peak. To 
identify the receptor, the peptide-conjugated cross-linker was mixed with membrane 
proteins prepared from adult rat brains and spinal cord. The free NHS-ester reactive 
group covalently reacted with the primary amine of receptor protein(s) that binds to 
TLQP-21+cross-linker conjugate. Western blotting using streptavidin-HRP was 
employed to detect the receptor/peptide complex. Figure 3.2 B reveals a ~30 kDa 
band was detected when the conjugated peptide was applied to the membrane proteins. 
This band was barely visible in the control lane loaded with same amount of 
membrane proteins, suggesting the specificity of the reaction and the presence of a 
receptor at ~30 kDa for TLQP-21.  
 
 
Figure 3.1 Schematic diagram illustrating the experiment procedure exploited for the 
identification of TLQP-21 receptor by chemical cross-linker. 
Sulfo-EMCS crosslinker with a medium-length spacer arm was used. The crosslinker was 
conjugated to the synthesised biotin-TLQP-21 peptide via the sulfhydryl group on the 
cysteine at the C terminus of the peptide. The reaction was carried out in MES buffer at pH 
6.5 for 30 minutes at room temperature to allow stable formation of thioether bonds between 
the crosslinkers and sufhydryl group of the cysteine residue. The reaction was stopped by 
adding excess amount of DTT to react with the free crosslinkers. The conjugations were 
confirmed by MALDI TOF mass spectrometry. The conjugated peptides were then incubated 
with membrane proteins homogenates prepared from CNS tissue (whole brain and spinal cord) 
in boric acid buffer at pH 8 with 150mM NaCl for 3 hours on ice to allow identification of the 
potential receptor. The reaction was terminated by adding 50mM Tris buffer, and the samples 
were resolved on a Tricine-PAGE and analysed by Western immunblotting. 
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Figure 3.2 Receptor identification by chemical crosslinker method (Data generated by Dr 
Mahmood Ayub, see thesis for more methodology detail). 
A. The chemical structure of the conjugated TLQP-21 with sulfo-EMCS is illustrated, and the 
predicted monoisotopic mass is calculated to be 3147.458151 Da. The TLQP-21 conjugates 
were cleaned-up and eluted from a C18 resin Zip Tip, followed by MALDI-TOF mass 
spectrometry analysis to confirm conjugation. MALDI-TOF mass spectrometry result 
confirmed successful in conjugation and the major peak observed was the 
Sulfo-EMCS-conjugated TLQP-21 species. The major peak with m/z of 3148.4 represents the 
species of TLQP-21 conjugated to sulfo-EMCS, and that with m/z of 1572.9 represents the 
double protonated form of such conjugate. Unconjugated TLQP-21 in protonated form is 
shown at the peak of m/z 2764.6 B. Western blotting revealed a distinct band at ~30kDA 
(indicated by an arrow) in the TLQP-21 crosslinking reaction compared to its corresponding 
control. 
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This is the first time, to our knowledge, a receptor was identified for TLQP-21 
peptide. To elucidate the identity of this receptor and confirm the binding of the 
complex without covalent chemical reaction, a second methodology was employed: 
affinity chromatography combined with mass spectrometry (figure 3.3). The synthetic 
TLQP-21 (10 µM) was attached to a monomeric avidin resin via the N-terminus 
biotin, and membrane proteins prepared from the rat brains was applied through the 
column. The potential receptor that bound to the TLQP-21 peptide would be retained 
in the column after several washes, while others were washed away. The potential 
receptor bound to TLQP-21 was subsequently eluted and resolved by SDS-PAGE. A 
control experiment was carried out in parallel, where the same chromatography was 
performed without attaching TLQP-21 peptides to the monomeric avidin column. Any 
protein eluted after washes in the control chromatography experiment would be those 
interacted with the resin non-specifically, such as the endogenous biotinylated 
proteins. Figure 3.4A shows the result of a silver-stained SDS-PAGE gel from the 
affinity chromatography experiment. A ~30 kDa band was observed in the elution 
from TLQP-21 attached avidin column (indicated by arrow), but not in the elution 
from control. To reveal the identity of this ~30 kDa proteins, which appeared in both 
chemical cross-linking based and affinity chromatography based experiment, the band 
was excised from the silver-stained gel, followed by de-staining and in-gel digestion 
with trypsin. The resulting peptide was analysed by nanoLC-MS/MS Orbitrap. Figure 
3.4 B shows the result from nanoLC-MS/MS Orbitrap experiment. The identity of the 
band was revealed to be a multimeric, multi-functional protein – GC1qR, with three 
unique peptide coverage shown in the ion-assignment spectra and highlighted in red 
in the protein sequence. To further verified the identity of the ~30 kDa band is GC1qR 
(as revealed in the mass spectrometry analysis), Western blot analysis was performed 
on the elutions from affinity-chromatography experiment using GC1qR specific 
antibody. A monoclonal antibody from Abcam that targets amino acids 76-93 at 
GC1qR N-terminus was used in the analysis. It was found that a visible band at ~30 
kDa was apparent in the lane corresponds to the elution from TLQP-21 packed 
column (Figure 3.4C). The band is barely visible in the adjacent lane corresponding to 
the elution from negative control. The data here validates the LC-MS/MS data that 
indicates TLQP-21 binds to GC1qR and suggests the identity of the ~30 kDa band we 
observed in the cross-linker experiment was most likely to be GC1qR. All together, 
these experiments suggest GC1qR could be the potential receptor for TLQP-21 
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peptide and the function of TLQP-21 could possibly be mediated via pathways 
downstream to this receptor. 
 
 
 
Figure 3.3 Schematic diagram illustrating the experiment procedure exploited for the 
identification of TLQP-21 receptor by monoavidin affinity chromatography. 
10 µm of synthesised TLQP-21 was attached to the monomeric avidin (monoavidin) column, 
via their biotin tag, and the membrane proteins were applied to the column. The membrane 
proteins were prepared from cerebral hemispheres of post natal day 4 rats prior to the 
experiment. Any membrane protein that binds to TLQP-21 peptide would be retained in the 
column after a number of washes, while others would be washed away. The potential 
TLQP-21-bound receptor is then eluted from the column, resolved by SDS-PAGE, followed by 
silver staining. A negative control chromatography without TLQP-21 peptide attached to the 
column would also be performed. The proteins eluted in the control would be non-specific 
interactive proteins to the resin/column itself. Any protein that is eluted specifically in 
TLQP-21 attached column would be TLQP-21 specific interactive protein, and hence, the 
potential receptor for TLQP-21. The identity of such potential receptor would then be revealed 
by LC-MS/MS, followed by confirmation using western blot analysis with the target specific 
antibody. 
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Figure 3.4 Receptor identification by monoavidin affinity chromatography method (Data 
generated by Dr Mahmood Ayub, see thesis for more methodology detail). 
A. The sample eluted from TLQP-21 packed monoavidin column and monoavidin only column 
were analysis by SDS-PAGE, which were subsequently silverstained by SilverQuest Silver 
staining kit (Invitrogen, mass spectrometry analysis compatible). A band at ~30kDa was 
observed in the eluents from the TLQP-21 attached monoavidin column (as indicated by an 
arrow), indicating TLQP-21 interacts with a ~30kDa protein. The band was not observed in the 
eluent from the monoavidin only column (negative control), suggesting the specificity of 
interaction. B. LC-MS/MS analysis revealed three unique peptide coverages (as shown in red) 
for GC1qR. The LC-MS/MS analysis from a second independent affinity chromatography 
experiment was repeated and GC1qR was identified in both analysis. The fragmentation spetra 
indicates the three fragment ions assignments for the GC1qR peptides identified. C. Western 
blot analysis using GC1qR specific antibody confirmed the identity of the ~30 kDa protein that 
interacted with TLQP-21 was GC1qR (as indicated by an arrow). 
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3.2. Aim 
 
Despite the accumulative evidences shown in the previous chapter and the literatures 
suggesting the involvement of VGF-derived peptide in the pain pathway, the receptors 
for all VGF-derived peptides still remain unknown. Recently in our laboratory, a 
potential receptor for TLQP-21 was identified. The aim of this chapter is, therefore, to: 
 
1. Verify, functionally, if GC1qR is the potential receptor for TLQP-21 on 
macrophage by using neutralising antibody in combination of calcium imaging. 
 
2. Establish siRNA transfection into the primary macrophage to aid to verify 
involvement of GC1qR in the molecular mechanism of TLQP-21 signalling in 
macrophage. 
 
3. Clone and overexpress murine GC1qR in cells that don’t respond to TLQP-21, 
and to investigate such overexpression could aid TLQP-21 signalling in these 
cells. 
 
4. To better understand the involvement of GC1qR in the development of 
neuropathic pain in vivo by localised treatment of neutralising antibody against 
GC1qR after partial sciatic nerve ligation. 
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3.3. Material and method 
 
3.3.1. Transfection of siRNA oligonucleotides into rat primary macrophages 
 
RNA interference was carried out using double-stranded short interference RNA 
oligonucleotides purchased from Qiagen (listed in table below). The differentiated 
macrophages were transfected using either the Neon capillary electroporation system 
(Invitrogen) or the GenePulser cuvette electroporation (BioRad). The bone marrow 
derived primary macrophages were cultured and differentiated for 6 days as 
previously described (section 2.2.3). On the day of transfection, the cells were 
washed three times with PBS and harvested using 5ml of non-enzymatic 
dissociation buffer (Sigma). The conditions used for Neon Capillary electroporation 
system is listed in table 3.2 in the result section. The pulse condition for GenePulser 
cuvette electroporation were performed at 50V, 100V, 200V or 400V with constant 
resistance (100 Ω) and capacitance (150 μF). The electroporation was performed in 
an electroporation cuvette (gap width 0.2 cm). For each electroporation, 1,000,000 
cells in 50 µl of optiMEM medium (Invitrogen) and 3 µg of double-stranded siRNA 
were used. Immediately after electroporation, 2 ml of warmed 10 % FBS in DMEM 
(no antibiotics) was added to the cells. The mixture was plated onto a 6 well plate 
and cultured for up to 48 hours. The transfected cells were lysed at 24 or 48 hours 
post-transfection for total RNA and protein lysates preparation (see later for detail). 
 
Short interference RNA Sequence (5’-3’) 
siRNA1 UAGGUGGUCAUACAAGGCCCA 
siRNA2 UUCUCCGGCAACUUUGCGCAA 
siRNA3 UAAUUUAGCCUCCGUGCCGTT 
siRNA4 UAAAUGGAGGUGUAACGGCGA 
siRNA oligonucleotide sequences used for transiently knock-down GC1qR 
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3.3.2. Trypan blue viability assay 
 
The cell survival after electroporation was evaluated by dye exclusion assay using 
trypan blue. Non-viable cells will be stained blue and the viable cells will exclude 
the dye and remain unstained. The electroporated cell suspension (or untreated cells) was 
topped up to 1 ml by complete media. 10µl of the cell samples were diluted 1:1 with a 
sterile filtered 0.4 % Trypan Blue solution. The dilution was carefully pipetted into a 
hemocytometer, which was allowed to stand for 2 minutes at room temperature. The cells 
were counted under the microscope in four 1 x 1 mm squares and the average number of 
cells per square was determined. The number of trypan blue positive cells were also counted 
and the cell viability was access by the percentage of trypan blue positive cells (Number of 
trypan blue positive counted ÷ total number of cells counted x 100%).  
 
3.3.3 Quantitative real time polymerase chain reaction 
 
Total RNA extraction from cultured cells, cDNA synthesis and Quantitative RT-PCR 
was performed as described in the previous chapter (section 2.2.5). To obtain the total 
RNA for the ex vivo investigation of vgf expression in the PSNL model study, the L4 
and L5 DRGs were removed from both ipsilateral and contralateral sides of injured 
rats on post-operative day 1, 3 and 5. The total RNAs were extracted from the 
harvested DRGs using Qiashedders (Qiagen) and RNAeasy extraction kit (Qiagen) 
according to the protocols provided by the manufacturer. The primers used in the 
qRT-PCR studies of this chapter are listed below:  
 
Targets Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
Beta-actin TCCTGTGGCATCCATGAAACT AACGTCACACTTCATGATGGAATT 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
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Cyclophilin A GCAAGACCAGCAAGAAGATC TCAGTGAGAGCAGAGATTACAG 
Vgf ACTTCCTGGTCCCAAACGG GGCTGGGAGACAGACACTTCA 
GC1qR 1 GTATTGGGCGCCTGGTCACC CGCTCCTGGAAGATGGTGATGG 
 
3.3.4. Western blot analysis 
 
48 hours after siRNA electroporation, the transfected macrophages were harvested for 
western blot analysis to check the GC1qR protein expression level. 
 
Sample lysis and preparation 
 
The cell culture dish were placed on ice and washed with ice-cold PBS three times to 
remove residual serum proteins in the culture. The PBS was aspirated and cells were 
lysed in 100 µl ice-cold Radio Immuno Precipitation Assay (RIPA) lysis buffer with 
protease inhibitors. The RIPA buffer comprised 150 mM NaCl, 0.1 % Triton X-100, 
0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulphate (SDS) and 50 mM 
Tris-HCl, which is adjusted to pH 8.0. The lysed cells were scraped and transferred to 
a pre-chilled 1.5 ml eppendorf tube, where the cell suspensions were incubated with 
agitation at 4 ºC for 2 hours, followed by centrifugation at 16,000 x g for 20 minutes 
at 4 ºC in a refrigerated centrifuge. The lysate supernatants were carefully removed 
and transferred to a pre-chilled eppendorf tube and the pellets were discarded. The 
protein concentrations were determined by BCA protein assay (Pierce). 10 µg of 
proteins from each sample were mixed with 5X Laemmli buffer (10 % SDS, 50 % 
glycerol, 25 mM DTT, 0.01 % bromphenol blue, 0.312 M Tris-HCl, pH 6.8) and 
incubated for 1hour at room temperature.  
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SDS poly-acrylamide gel electrophoresis (SDS-PAGE), transfer and blotting 
 
Equal amounts of protein were subjected to SDS-PAGE. Samples along with protein 
marker were loaded into the wells of the 12.5 % poly-acrylamide gel. The proteins 
were separated at constant voltage at 80 V until the marker was well separated. After 
SDS-PAGE, the proteins were transferred onto polyvinylidene fluoride (PVDF) 
membrane (Amersham) using the iBlot
TM
 dry transfer system (Invitrogen). The blot 
was then incubated with 5 % blocking solution, consisted of 5 % dried fat-free milk 
in phosphate buffered saline supplemented with 0.1 % Tween-20 (Sigma) (PBS-T), 
at 4 ºC overnight to block the non-specific sites. The membrane was subsequently 
incubated with primary antibody anti-GC1qR 60.11 (ab24733, Abcam) diluted 
1:1000 for 2 hours at room temperature. Following three 15 minutes washes with 
PBS-T, the membrane was incubated with anti-mouse secondary antibody (DAKO) 
conjugated to Horseradish Peroxidase (HRP) at 1:1000 dilution for 1 hour at room 
temperature. The membrane was washed for three times, 15 minutes each, with 
PBS-T, followed by signal development. The enhanced chemiluminescence western 
blotting detection system kit (Applichem) was used for the signal development and 
signal detection was performed using Fujifilm LAS-3000 Imaging System.  
 
The membrane was stripped with stripping buffer (2 % SDS, 100 mM β- 
mercaptoethanol, 50 mM Tris-HCl, adjusted to pH 6.8) at 50 ºC for 30 minutes with 
constant agitation. Following three washes in PBS-T, the membrane was blocked in 
5 % blocking solution overnight at 4ºC and subsequent re-probing with second 
primary antibody (beta-actin) at 1:1000 dilution for 1 hour at room temperature. The 
anti-rabbit HRP antibody was used at 1:1000 dilution and the signal was detected as 
previously described. All signal quantification and analysis was performed using 
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ImageJ image analysis software (http://rsbweb.nih.gov/ij/). 
 
3.3.5. Molecular cloning of recombinant GC1qR 
 
Polymerase Chain Reaction 
 
The primer sequences used in the PCR reaction are shown in the below table. The 
final concentrations of the following components were mixed: 1x PCR Master Mix 
(Promega) consisting Taq DNA polymerase/dNTP/MgCl2, 1.5 µM of each primer and 
100 ng of rat macrophage cDNA templates. The polymerase reaction was activated 
95ºC for 2 minutes, followed by 30 cycles of reaction at 95 ºC for 30 seconds, 60 ºC 
for 30 seconds and 72 ºC for 1 minute.   
 
Primer Sequence (5’-3’) 
Forward (BamHI site) ATGGATCCACCATGGTCCCTCTGCTGCG 
Reverse (XhoI site) GGCTCGAGCCCTGACTCTTGACAAAGC 
Primer sequences used for GC1qR gene amplication by PCR 
 
DNA gel electrophoresis, purification and TA cloning 
 
The PCR reaction products were separated by gel electrophoresis according to the size 
of the amplified fragments. The PCR products were run on a 1.5 % w/v agarose gel 
along with 10 μl of TrackItTM 1 Kb Plus DNA Ladder (Invitrogen, UK) at 100 volts 
for 45 minutes. The expected size of the product is 840 bp. The correct size bands 
were excised and the DNA was purified from the gels using gel purification kit 
(Qiagen). The concentration of recovered DNA was then determined using nanodrop; 
purified PCR products were subsequently ligated with 50 ng pGEM-T easy vector at 
3:1 ratio overnight at 16 ºC. The ligated clones were then transformed into XL1Blue E. 
Coli cells, and plated on LB plates supplemented with 100 μg/ml Ampicillin (Amp), 
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1mg of Xgal in DMF and 1mg of IPTG. The plates were incubated overnight at 37 
o
C. 
To check if cloning was successful, white colonies were selected and inoculated the 
next day, and incubated at 37 
o
C with agitation overnight. Restriction enzyme 
digestion with BamHI and XhoI was then carried out on the plasmids purified from 
the overnight culture using mini-prep kit (Qiagen), followed by DNA gel 
electrophoresis analysis of the digestion reaction. The clones with the correct insert 
sizes were then sent to be sequenced using Eurofins MWG operon's DNA sequencing 
service, followed by checking the sequence using BLAST software 
(http://blast.ncbi.nlm.nih.gov/).  
Subcloning into expression vector 
 
The insert was cut out from the pGEM-T vector and the expression vector 
pDG1-MN1 was linearised by BamHI and XhoI restriction enzyme digestion at 37 ºC 
for 2 hours. The digestion reactions were run on 1.5% agarose gel to separate the 
digested insert from vector backbone and separate the digested pDG1-MN1 from the 
undigested. The 840 bp insert and 4.7 kb vector bands were excised from the gel and 
purified using Gel purification kit (Qiagen). The insert was ligated to pDG1-MN1 
vector at 3:1 ratio at 16 ºC overnight. The ligation reaction was then transformed to 
XL1blue competent cells and the colonies were picked the next day to check the 
success in subcloning (as described previously). The molecular cloning of GC1qR 
construct was done with help of a undergraduate student, Mr Yosuke Hamada, during 
his final year project.  
 
3.3.6 HEK293T cell transfection 
 
HEK293T cells were cultured in DMEM supplemented with 10 % FBS, penicillin 
 149 
and streptomycin. The cells were re-plated one day before cell transfection. 1x10
5
 
cells were plated on glass-bottom plate and allowed to divide overnight. On the day 
of transfection, 1 µl of lipofectamine was added to 25 µl of OptiMEM and 250 ng of 
dronpa-GC1qR DNA construct was mixed with 25 µl. Both mixtures were allowed 
to stand for 5 minutes at room temperature, followed by mixing both mixtures 
together and incubate for further 20 minutes to allow DNA-lipofectamine complexes 
to form. Meanwhile, the cell cultures were washed 3 times with OptiMEM. The 
DNA-lipofectamine complexes (50 µl total) was subsequently added to the plates of 
cells. The cells were transfected overnight with 10% FBS supplemented to the cells 
6 hours after transfection. The cells were washed and replaced with fresh media 
(DMEM + 10% FBS and penicillin and streptomycin) the next day.  
 
3.3.7 Rhodmine 3 calcium imaging  
 
The Rhod-3AM imaging kit (Invitrogen) was used to allow investigation of calcium 
level changes. Briefly, the cells were washed 3 times in balanced extracellular 
solution (140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1.8 mM CaCl2, 10 mM D-Glucose 
and 10 mM HEPES buffer, pH 7.4) and incubated with 2 ml of loading buffer 
(consisting 20 µl of 100x PowerLoad concentrate, 2 µl of 10mM Rhod-3AM and 20 
µl of 250 mM probenecid, topped up to 2 ml with balanced extracellular solution) for 
30 minutes. The cells were washed twice in balanced extracellular solution, followed 
by incubation with 2 ml of incubation buffer (balanced extracellular solution 
containing 2.5 mM probenecid) in the dark for 30 minutes. The cells were washed 
twice and live-cell imaging was performed subsequently using confocal microscopy 
with HeNe543 laser. The emission wavelength was captured at 570-630 nm. This 
protocol was used because of the emission wavelength of Dronpa protein overlapped 
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with Fluo-4 calcium dye. Calcium imaging of dronpa-GC1qR transfected cells was 
hence carried out using Rhodamine 3 calcium dye instead. The calcium imaging 
experiment of Dronpa-GC1qR transfected HEK293T cells were carried out 1 day 
and 3 days post transfection. 
 
3.3.8. In vivo surgery and behavioural assessment 
 
Three weeks old male Wistar rats were used for the in vivo experiment. The partial 
sciatic nerve ligation was performed under general anaesthesia. About 50 % of the 
sciatic nerve on the left hind leg was tightly ligated using 7.0 non-absorbable silk 
suture (Mersilk, Ethicon). Immediately after ligation, the injured sciatic nerve was 
wrapped loosely with oxidized regenerated cellulose soaked with 25 µg of GC1qR 
neurtalising antibody, 25 µg control IgG antibody or PBS only. The mechanical 
sensitivity of the ipsilateral and contralateral hind paws were examined using 
electronic Von Frey filaments as previously described in section 2.2.6. The 
experimenter was blinded to the treatment each animal group received and the 
experimental groups of the animals were randomised. The behavioural assessment 
was carried out on the post-operative day 1,3 and 5. The described in vivo study was 
done in collaboration with Dr Alessandro Pristera. The behaviour assessment was 
kindly performed by Dr Alessandro Pristera 
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3.4. Results 
 
3.4.1. Verification of GC1qR as the receptor for TLQP-21 on primary 
macrophage by neutralising antibodies 
 
In the previous chapter, it was observed that TLQP-21 induced an increase in 
intracellular calcium, in a dose-dependent manner, in the primary macrophage. It is 
also suggested in our laboratory that GC1qR is the potential receptor for TLQP-21. 
Here I sought to understand if TLQP-21 induced increase in calcium level in 
macrophage was mediated via this potential receptor. Two experimental approaches 
were employed here, blocking the receptor by neutralising antibodies and knock 
down the receptor by siRNA, in combination with calcium imaging to examine if 
interfering GC1qR signalling affects TLQP-21 induced calcium response in the 
primary macrophage. This enables us to further verify if GC1qR is the receptor for 
TLQP-21 on primary macrophage. 
 
Effect of GC1qR neutralising antibodies on TLQP-21 induced calcium response 
in primary macrophages 
 
Two monoclonal antibodies neutralise GC1qR were used in conjunction with 
calcium imaging. One of which targets the N terminus of GC1qR at amino acid 
76-93 (MAb60.11) and the other targets the C terminus at amino acid 204-218 
(MAb74.5.2). The MAb60.11 antibody recognises the mature form (74-282) of 
GC1qR on the putative C1q binding site. The MAb74.5.2 antibody, on the other 
hand, reacts with both the mature and truncated forms (lack residues 74-95) of 
GC1qR. The interactive side of this antibody on GC1qR is the portion where 
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high-molecular-weight kininogen (HK) and Factor XII (FXII) bind.  
 
The neutralising antibodies were incubated with cultured primary macrophages, 
either singly or combined, at 3 μg/ml for 15 minutes prior to calcium imaging. 
Figure 3.5 A shows the averaged fluorescence profile of all cells recorded during 
calcium imaging after treatment with both antibodies. The previous observed 
TLQP-21 induced increase in intracellular calcium was abolished in the majority of 
the cells after neutralising antibodies treatment, whereas, the 1 mM ATP was able to 
elicit a robust increase in calcium level, indicating the cells were viable after 
antibodies treatment. To further elucidate the effect of neutralising GC1qR on the 
cell responsiveness to TLQP-21 in the calcium imaging, I further quantified the 
percentages of cells responding to the peptide after treatment of MAb60.11 only, 
MAb74.5.2 only, or both antibodies together. Figure 3.5B shows that after treatment 
of both antibodies for 15 minutes, the percentage of cells responding to 100 nM 
TLQP-21 peptide significantly decreased from 67.04 ± 2.24 % to 10.56 ± 3.97 % 
(p< 0.01, n = 3, One way ANOVA, Tukey post hoc test), indicating there was a 
decrease in responsiveness to TLQP-21, at 100 nM, by 84.25 %. Moreover, when 
the cells were pre-treated with MAb60.11 or Mab74.2.5 antibody only, the 
percentages of cells responding to the peptide also significantly decreased to 18.46 ± 
7.84 % and 32.45 ± 6.67 %, respectively (p< 0.05, n = 3 for both treatments), 
indicating a drop of 72.46 %, and 51.60 % in responsiveness to the peptide. Together 
these data suggest neutralising, or blocking, GC1qR interferes the responsiveness of 
primary macrophages to TLQP-21, at least at the concentration tested (100 nM) here. 
This implies the GC1qR is likely to be the potential receptor for TLQP-21, and the 
function of TLQP-21 was signaled, at least partly, via GC1qR. 
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Figure 3.5. 15 mins pre-incubation of anti-GC1qR antibodies attenuates the TLQP-21 
induced calcium response and reduces the percentage of cells responding to the peptide.  
A. Represented averaged fluorescence trace from calcium imaging of macrophage pre-treated 
with both GC1qR neutralising antibodies (3 µg/ml). The averaged fluorescence demonstrated 
the calcium levels were not increased after 100 nM TLQP-21 application. Yet, the positive 
control at the end of experiment, 1 mM ATP, induced a robust increased in intracellular 
calcium, indicating the cells were viable and able to respond. B. Pre-incubation with GC1qR 
specific antibodies MAb60.11, MAb74.5.2 or both antibodies together (3 µg/ml) significantly 
reduced the percentage of cells responding to 100 nM TLQP-21 peptides (*p<0.05, **p<0.01, 
One way ANOVA, Tukey post hoc test, n = 3) 
 
Table 3.1 Table listed the number of cells analysed and responded to 100nM TLQP-21 in 
each experiment (A minimum of 80 cells analysed for each experiment). 
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3.4.2. Verification of GC1qR as the receptor for TLQP-21 on primary 
macrophage by siRNA approach 
 
To further confirm that TLQP-21 signals through GC1qR to exert its function on the 
primary macrophage, a second method was employed, small interfering RNA 
(siRNA) gene manipulation, to interfere with this pathway. siRNA is a method of 
‘silencing’ gene expression in vitro and could be used to down-regulate endogenous 
GC1qR expression. Although the silencing effect will only be transient and the level 
of knock-down in gene expression may be incomplete, it may still be enough to 
deliver a functional change in response to TLQP-21. Here we sought to silence 
GC1qR expression in the primary macrophage by siRNAs, and examine the 
subsequent cell responsiveness to TLQP-21. To achieve this, a protocol to introduce 
siRNAs into the primary macrophage needed to be first established. 
 
Primary macrophage siRNA transfection optimisation 
 
Delivering siRNAs to primary macrophage using lipid-based transfection method 
has been evident to alter macrophage physiology and often yield low transfection 
rate (Zhang, Edwards et al. 2009). To attempt delivering siRNA into the primary 
macrophage, I employed two electroporation systems, the Neon capillary 
electroporation system (Invitrogen) and the GenePulser cuvette electroporation 
(BioRad). The GenePulser cuvette electroporation allows a higher electric field to be 
delivered, which could be advantageous for cells hard to be trasfected. On the other 
hand, the capillary electroporation system is suggested to generate a more uniform 
electric field that results in better cell survival and allows better maintenance. 
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Alexa Fluor 546- tagged control siRNA, that does not show any homology to any 
mammalian gene, was introduced to the cells to aid visual determination of 
successful transfection. The electroporation conditions tried using the Neon system 
failed to deliver siRNA into the primary macrophage (table3.2), except for one cell 
which was transfected using 2200V voltage, 20ms Pulse width with 2 
electroporation pulses condition. Nevertheless, cuvette electroporation using 
GenePulser system successfully showed positive transfection in three of the 
conditions tested, 100V:150μF:100Ω, 200V:150μF:100Ω and 400V:150μF:100Ω 
(voltage: resistance: capacitance, figure 3.6). Keeping the siRNA concentration 
constant (3µg), 400V:150μF:100Ω appeared to produce the greatest number of 
transiently transfected cells. The number of cells transfected with siRNA in the 
200V:150μF:100Ω condition was high as well. However, 100V:150μF:100Ω 
condition showed relatively lower number of transfected cells. The untreated control 
showed no background fluorescence, indicating the fluorescence observed in the 
transfected cells were not derived from cell autofluorescence. Moreover, the same 
amount of siRNA was used for electroporation for 50V:150μF:100Ω condition, and 
the result shows little fluorescence, indicating the success transfection using other 
three conditions were not due to residual siRNAs in the media.  
 
Furthermore, I tested the cell viability in the three conditions that shows positive 
transfections by using trypan blue. As shown in figure 3.7, the percentages of trypan 
blue positive cells after electroporation were 4.47%, 10.71%, 11.21% and 28.73%, 
for untreated control, 100V, 200V and 400V conditions, respectively. It is worth 
noting that there was a low percentage of cells showed trypan blue positive staining 
even in the untreated control, which may possibly indicates some cells became 
unhealthy during the harvesting procedure. Nevertheless, electroporation of the cells 
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caused further increase in numbers of trypan blue positive cells with a particular 
high percentage when using 400V voltage. Together with these data, in terms of both 
cell survival and transfection efficiency, 200V:150μF:100Ω was shown to be the 
optimal condition for high transfected cell number and cell survival. It was hence 
chosen to be the condition used for all the subsequent work involved siRNA 
transfection into primary macrophage.  
 
 
Table 3.2 Table listed all the conditions tested using the Neon capillary electroporation 
system. 
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Figure 3.6 GenePulser electroporation system successfully introduced siRNA into the 
primary macrophages. 
Alexa Fluor 546 tagged non-targeting siRNA was used to optimise the electroporation 
conditions for primary macrophage siRNA transfection. The fluorescent images and its 
corresponding bright field images were taken, and the success in transfection was monitored 
by the red fluorescence observed inside the cells. Condition 100V:150μF:100Ω, 
200V:150μF:100Ω and 400V:150μF:100Ω (voltage: resistance: capacitance) showed 
successful transfection of siRNA as indicated by the red florescence. The untreated control 
showed no fluorescent, indicating the fluorescence observed in the mentioned conditions 
were derived from the Alexa Fluor 546 tagged, not from the auto-fluorescence of the cells. 
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Figure 3.7 Cell viability assay by Trypan blue after electroporation. 
Primary macrophages were transfected with non-targeting siRNA by electroporation 
(1,000,000 cells per electroporation) using the following conditions: 100V:150μF:100Ω, 
200V:150μF:100Ω and 400V:150μF:100Ω (voltage: resistance: capacitance). The untreated 
cells were harvested under the same, but did not underwent electroporation. The cell 
suspension was topped up to 1ml by complete media after electroporation. 10µl of the cell 
samples were diluted 1:1 with a sterile 0.4% Trypan Blue solution. The dilution was filled 
into a hemocytometer and allowed to incubate for 2 minutes at room temperature. The 
non-viable cells would be blue and the viable ones would be unstained. The cells were 
counted under a microscope and the percentage of trypan blue positive cells was calculated. 
In the untreated cells that underwent the harvesting procedure, about 4.47% of the cells 
were non-viable, and the percentage of non-viable cells increased to 10.71%, 11.21% and 
28.73% after electroporation using 100V:150μF:100Ω, 200V:150μF:100Ω and 
400V:150μF:100Ω settings, respectively. The error bar was expressed as standard deviation 
between the two independent experiments carried out. 
 
Percentage of Trypan blue +ve cells %(no. of +ve cells/total cells) 
Condition Untreated 100V 200V 400V 
 
4.08 (4/98) 8.16 (8/98) 9.09 (8/88) 30.43 (21/69) 
 
4.85 (5/103) 13.25 (11/83) 13.33 (12/90) 27.03 (30/111) 
Average 4.47 10.71 11.21 28.73 
Table 3.3 Table listed the number of blue cells (non-viable cells), total number of cells 
counted and the percentage of trypan blue positive cells in the hemocytometer for each 
experiment. 
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Validation of downregulation by qRT-PCR 
 
Having established the optimal electroporation condition for siRNA transfection into 
the primary macrophages, the cells were transfected with different siRNAs targeting 
GC1qR. To explore the changes in GC1qR expression levels, real-time quantitative 
PCR was employed as the readout assay. The two most commonly used analyses for 
qRT-PCR are the absolute quantification (standard curve method) and relative 
quantification (2
-ΔΔCT method). The absolute quantification allows the input copy 
number to be determined and a standard curve for each gene target is essential to 
relate the PCR signal. On the other hand, instead of measuring the absolute amount 
of gene expression, the relative quantification compares the PCR signal of the target 
gene in a control group to that of the treatment groups. The relative quantification, 
i.e. 2
-ΔΔCT method, is a convenient analysis to determine the relative changes in gene 
expression after siRNA knock down experiment, where the absolute expression of 
the gene is not as important, and hence was used here as the analysis method.  
 
In order to perform the relative quantification from the qRT-PCR experiment, and 
for the 2
-ΔΔCT calculations to be valid, the amplification efficiencies for the target 
gene primer and house keeping gene primer must be approximately equal. Therefore, 
the primers efficiencies were first verified by performing qRT-PCR on a range of 
dilutions of the macrophage cDNA. The amplification curves and the melt curves for 
the target genes (GC1qR 1 and GC1qR 2) and house keeping genes (CyclophilinA, 
Beta actin, GAPDH) were monitored (figure 3.8). The amplification curves show all 
the primers tested, at all template concentrations, increased in the fluorescent 
detected, implying the success in PCR amplification. Moreover, all the amplification 
curves showed good CT values, suggesting detectable copy numbers of gene at the 
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dilation made. The melt curve for GC1qR 1 and Cyclophilin A show perfect single 
peak curve, indicating only one product was generated and the primer specificities. 
On the other hand, beta actin (at high concentration only), GC1qR 2 and GAPDH all 
show additional product peak at higher melting temperature, implying multiple 
products were produced. The additional peaks in the melt curve for beta actin and 
GC1qR 2 were minimal when compared to the main product peak, which could 
possibly optimised by reducing primer concentration used, and hence were still used 
for the subsequent test of the primer efficiencies. However, the GAPDH primer 
shows strong amplifications of more than one product, which may make the 
interpretation of primer efficiency difficult.  
 
The differences in efficiencies between the target and house keeping genes primers 
were calculated (ΔCT), and the log cDNA concentrations were plotted against the 
resultant ΔCT. The slope of the linear trendline was the indicator of the variability 
between the efficiencies of the primers. If there were no differences in the 
efficiencies of the two primers, it will result a slope value of 0. If the slope values 
were good (<0.1), this indicates there were minimal variations between the 
amplification efficiencies using the two primers compared, and hence are suitable for 
the use in 2
-ΔΔCT analyses. However, if the slope value is >0.1, the primers should not 
be used together for the 2
-ΔΔCT analysis to prevent false interpretation of the qPCR 
results.  
 
The validation experiment for the GC1qR primers and the house-keeping gene, beta 
actin was performed, which resulted a slope of 0.0019 (GC1qR 1) and 0.0546 
(GC1qR 2), confirming comparable primer efficiencies between the two GC1qR 
primers to beta actin primer (figure 3.9A). Figure 3.9B also shows minimal 
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variations in efficiencies between the two GC1qR primers and the GAPDH primer, 
as the resultant slope were 0.0022 and 0.0549 for GC1qR 1 and GC1qR 2, 
respectively, when compared to GAPDH. Comparable efficiencies were also 
observed between the two GC1qR primers and Cyclophilin A primer (figure 3.9C), 
as indicated by the slope of 0.0448 (GC1qR 1) and 0.0879 (GC1qR 2). These data 
confirmed the primer efficiencies between the primers for target gene (GC1qR 1 and 
GC1qR 2) and that for house-keeping genes (Beta actin, GAPDH and Cyclophilin A) 
were similar with minimal variations. However, when the primers were tested in a 
no-template reaction, GC1qR 2 primer showed an increase in amplification curve 
with CT value around 27. This indicates the primer could amplify in a qPCR reaction 
without template, which could lead to wrong interpretation of gene expression, and 
hence was not suitable for subsequent studies.  
 
From the results obtained here, GAPDH primer resulted in multiple products 
generated (as indicated in melt curve) and GC1qR 2 primer exhibited 
self-amplification property in no-template reaction, and hence both primers were 
discarded from use in the later studies. Nevertheless, GC1qR 1 primer shows good 
amplification efficiency and the efficiency showed minimal variation to beta actin 
and cyclophilin A primers, thus were utilised in the subsequent experiments.  
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Figure 3.8 Amplification plot and Melt curve of the primers tested using qPCR revealed 
successful amplifications after serial dilutions. 
The GC1qR, Cyclophilin A, Beta actin, GAPDH and GC1qR2 primers sets were tested for 
suitability to be used in qPCR experiment. The primers tested by qPCR experiments on a 
range of dilutions of the macrophage cDNA. The melt curves of all primer tested showed 
desirable CT values, and the melt curves showed a major single peak for majority of primers 
tested, except for GAPDH. Beta actin and GC1qR2 primers also showed a small additional 
peak at higher melting temperature (additional peaks indicates by red circles.) 
 
       
     GC1qR         Cyclophilin A        β-actin           GAPDH          GC1qR 2 
 GC1qR         Cyclophilin A        β-actin           GAPDH          GC1qR 2 
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Figure 3.9 The slopes of the primers efficiencies tests revealed there were only minimal 
variations between the primers for target gene and that for reference genes. 
Primer efficiencies test between A. GC1qR1/GC1qR2 and beta actin. B. GC1qR1/GC1qR2 
and GAPDH C. GC1qR1/GC1qR2 and Cycliphilin A. D. Primer sets tested in the absence 
of cDNA template revealed self annealing property of GC1qR2. 
D. 
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Having determined the suitability of the primers being used, the siRNA-mediated 
down-regulation of GC1qR was validated by qPCR. The GC1qR expressions were 
examined in untreated cells, non-targeting siRNA transfected cells and 
GC1qR-siRNAs transfected cells. Figure 3.10 shows the amplification plot and 
melting curve for GC1qR, beta-actin and cyclophilin A in the 24 hrs–post 
transfection samples. The amplification curve of the house-keeping genes (beta actin 
and cyclophilin A) showed similar CT values in all samples, indicating reliability in 
pipetting and cDNA synthesis. A shift in amplification curve of GC1qR was 
observed, implying there was a difference in GC1qR expression between samples. 
The melt curves showed single peaks for all products generated, confirming good 
PCR quality and amplification specificity. To quantify the changes in GC1qR 
expression between samples, 2
-ΔΔCT calculations were performed. Figure 3.11A and 
3.11B show the percentage of GC1qR expression in all samples at 24 hrs- and 48 
hrs-post transfection, respectively (the raw data are listed in table 3.4). 24 hrs- post 
transfection, GC1qR mRNA expressions decreased 73.5%, 22.6%, 77.6%, 81.8%, 
36.1%, and 47.6% by siRNA1, siRNA2, siRNA3, siRNA4, siRNA mix and 
modified siRNA, respectively, when compared to the non-targetting siRNA 
transfected (nt-siRNA) control. It is worth noting that untreated control (without 
electroporation) showed similar expression to the nt-siRNA control 24hrs after 
transfection (101.7% and 100% for untreated and nt-siRNA, respectively), 
indicating the electroporation treatment itself did not alter GC1qR expression. 48hrs 
post transfection, all samples showed at least 60% decreased in GC1qR expression 
at mRNA levels when compared to nt-siRNA control (reduced in GC1qR expression 
by 64.1%, 85.9%, 75.6%, 79.3%, 78%, 63.2% for siRNA1, siRNA2, siRNA3, 
siRNA4, siRNA mix and modified siRNA transfected samples, respectively). Still, 
the GC1qR expression in the untreated control was similar to nt-siRNA control 48 
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hours after transfection (84.7% and 100% for untreated and nt-siRNA, respectively). 
Together, these data show robust down-regulation of GC1qR at mRNA level by all 
the siRNA tested.  
 
 
 
Figure 3.10 qPCR results from the siRNA transfected cells versus untreated control.  
Amplification plot showed consistency of CT values on reference genes amplifications across 
all samples. Whereas, changes in CT values were observed in GC1qR amplifications (as 
indicated by red and blue arrows). The melting curves demonstrated all amplifications were 
resulted from a single amplified product, as indicated by a single peak produced. 
 
 
 
 
 
 
 
 
 
β-actin                   Cyclophilin A               GC1qR          
 
         
     β-actin/Cyclophilin A/GC1qR          
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Figure 3.11 qPCR revealed downergulation of GC1qR mRNA in primary macrophage 
24 hours- and 48 hours- post-transfection. 
Transfection of siRNA against GC1qR (siRNA 1-4, mixed siRNA and modified siRNA with 
Alexa Fluor 546) into primary macrophage successfully reduced GC1qR mRNA expression 
A. 24 hours and B. 48 hours after transfection when compared to both untreated and 
non-targeting siRNA transfected controls. The data presented were normalised to 
Cyclophilin A house-keeping gene, and were expressed as percentage of non-targeting 
siRNA control. 
 
 
Table 3. 4 Table listed the raw data of all qPCR experiments carried out for figure 3.11.  
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Validation of downregulation by Western blotting 
 
Although the GC1qR expressions were shown to be downregulated at mRNA level 
by siRNA tested, the changes in GC1qR protein expressions still need to be 
examined as mRNA expression level does not always correlate to its protein 
expression level. It was observed after electroporation, there were much debris in the 
culture, and such debris possibly made the cells more restless as spontaneous 
increase in calcium were observed 24 hours after electroporation in the majority of 
the cells in the later calcium imaging experiment. The spontaneous activations of the 
cells made the calcium imaging analysis difficult, as it would be hard to interpret if 
the increase in intracellular calcium was due to peptide stimulation or spontaneous 
activity of the cells. For this reason, the cultures were washed twice and the media 
were changed 24 hours after electroporation, and the cells were allowed to settle for 
another 24 hours before being used for calcium imaging. GC1qR protein expressions 
were hence quantified and compared, by western blotting, 48 hours after transfection. 
Figure 3.12A shows the GC1qR protein expressions in the nt-siRNA control, 
siRNAs-transfected samples and the untreated control in all western blotting 
experiments. The percentages of GC1qR protein expressions to nt-siRNA control 
significantly decreased to 50.6±10.2%, 40.5±13.1%, 58.7±9.9% and 55.5±14.5% by 
siRNA1, siRNA2, siRNA3 and siRNA4, respectively (figure 3.12B *p<0.05, 
**p<0.01, raw data listed in table 3.5). The GC1qR protein expressions in nt-siRNA 
controls did not significantly differ from that of untreated controls (98.3±4.0%). The 
data here suggests all four siRNAs tested showed successful downregulation of 
GC1qR at protein level 48 hours post transfection. 
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Figure 3.12 Western blot analysis demonstrated the downregulation of GC1qR protein 
in primary macrophages 48 hours after transfection. 
Transfection of siRNA against GC1qR (siRNA 1-4) into primary macrophages significantly 
reduced GC1qR protein expression after 48 hours. Non-targeting siRNA (negative control) 
and untreated control did not show alteration in GC1qR expression. A. Western 
immunoblots from three independent experiments B. Quantification of the bands intensity 
from part A by ImageJ analysis. Error bar expressed as standard error means. *p<0.05, 
**p<0.01, One way ANOVA Fisher’s post hoc test, n=3 
 
 
Table 3.5 Raw data for the quantification of the band intensities from immunoblots. 
Protein expression is normalised to the non-targeting control for comparison. 
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Effect of GC1qR knock-down by siRNAs on TLQP-21 induced calcium response 
in primary macrophage 
 
To elucidate if knocking down GC1qR by siRNA alters the TLQP-21 induced 
calcium response in the primary macrophage, calcium imaging was performed on 
siRNA-transfected cells, nt-siRNA transfected control cells and untreated cells. The 
percentages of cells responding to 100nM were determined for each condition, and 
the averages of the percentages of cells responding for each condition was 
normalised to the nt-siRNA control. As shown in figure 3.13, the percentage of cells 
responding to 100nM TLQP-21 was significantly reduced by 27.7%, 43.5%, 33.8% 
and 29.3% 48 hours after transfection of siRNA1, siRNA2, siRNA3 and siRNA4, 
respectively, when compared to nt-siRNA control (*p<0.05, **p<0.01, n=4). The 
percentage of cells responding to the peptide in nt-siRNA transfected cells did not 
significantly differ from that in untreated control. The raw data of each experiment 
was summarised in table 3.6.  
 
Figure 3.13 GC1qR knock-down by siRNA significantly reduced the percentage of cells 
responding to 100nM TLQP-21 48hours post-siRNA transfection. 
Error bars expressed as standard error means. *p<0.05, **p<0.01, One way ANOVA 
Fisher’s post hoc test (n=4). A minimum of 183 cells were analysed per experiment. 
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Table 3.6 Table summarises the results the percentage of cells responding to 100nM 
TLQP-21 after GC1qR knockdown by siRNA. 
 
3.4.3. Overexpression of GC1qR-dronpa fusion protein in HEK-293T cells 
 
Whilst having demonstrated that TLQP-21 induced response on primary macrophage 
was reduced when GC1qR was ‘blocked’ or ‘downregulated’, over-expressing 
recombinant GC1qR in cells that are naturally unresponsive to TLQP-21 and examine 
its effect would provide us with further evidence on the involvement of GC1qR in the 
TLQP-21 pathway. HEK-293T cells, as had been demonstrated by Dr Mahmood 
Ayub previously, are unresponsive to TLQP-21 peptide by using the calcium imaging. 
Here, I aimed to clone and overexpress recombinant GC1qR with Dronpa fluorescent 
protein at its C terminus in HEK-293T cells, followed by examining the effect of 
TLQP-21 peptide on the GC1qR overexpressed HEK-293T cells. 
 
Cloning and overexpressing GC1qR in the HEK-293T cells 
 
For obtaining the GC1qR clone, T/A cloning was first employed. The rat 
macrophage cDNA was used as template for PCR amplification using Taq 
polymerase, which allowed the resultant PCR product to harbor 3’ A-overhangs. The 
PCR product was ran on a DNA gel to confirm the size. As shown in figure 3.14A, 
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the resultant PCR products had an expected size of 840bp, which were subsequently 
purified from the gel and ligated with pGEM®-T Easy (pGEM-T) vectors. Positive 
clones were selected by blue-white colony screening in the presence of IPTG and 
Xgal. The plasmid DNA was purified from the selected positive clones, and 
subsequently treated with restriction enzymatic digestion to confirm the insert sizes. 
The two positive clones selected showed expected sizes of 840bp and 3015bp for 
GC1qR insert and pGEM-T vector respectively, after enzymatic digestion (Figure 
3.14B). The insert was excised from the pGEM-T cloning vector using BamHI and 
XhoI restriction enzyme and subcloned into the CoralHue® Dronpa-Green 
expression vector. The success in subcloning was confirmed by restriction enzymatic 
digestion followed by resolving fragments on a DNA gel. As indicated in figure 
3.14C, the two fragments resulting from the enzymatic digestion showed correct 
sizes of 840bp and 4696bp for GC1qR insert and pDG1-MN1 vector, respectively. 
The sequence of GC1qR in this clone was confirmed by DNA sequencing. 
 
Having obtained the desire construct, the HEK-293T cells were transfected with the 
either the Dronpa-GC1qR construct or Dronpa (vector only) control using 
lipofetamine based method. The Dronpa protein is a photochromic version of the 
Green fluorescent protein (GFP). The transfected cells were hence observed under a 
fluorescence microscope 1 day- and 3 days- post transfection. The cells transfected 
with Dronpa control showed homogeneous green fluorescence in the whole cell 
without particular compartment accumulation of fluorescence (figure 3.15). 
Interestingly, most of the Dronpa-GC1qR transfected cells exhibited ‘ring-shape’ 
green fluorescence in the cell 1 day after transfection. Such expression was observed 
in the majority of the transfected cells 3 days post-transfection, suggesting specific 
compartmentalisation of GC1qR expressed in the HEK-293T cells. 
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Figure 3.14 Successful recombinant DNA construct was generated for GC1qR 
expression with Dronpa fluorescent protein tag at the C-terminus. 
DNA gel revealing A. Successful amplification of GC1qR sequence from macrophage cDNA 
B. Successful cloning of GC1qR sequence into pGEM-T vector and C. Successful inserted 
GC1qR coding sequence into Dronpa vector. 
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Figure 3.15 Microscopic images revealed successful transfection of HEK-293T cells with 
Dronpa-GC1qR and Dronpa only constructs. 
Representative fluorescence pictures of HEK-293T cells transfected with Dronpa only 
(control construct) or Dronpa-GC1qR construct are shown. The green fluorescence picture, 
bright field and the overlay of the two channels are displayed. Scale bars represent 100μm. 
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Effect of GC1qR overexpression in HEK-293T on its responsiveness to TLQP-21 
 
In order to examine the functionality of TLQP-21 peptide on Dronpa-GC1qR 
overexpressed HEK-293T cells, calcium imaging using Rhod-3 calcium indicator was 
employed. In these experiments, Rhod-3 was used instead of Fluo-4 calcium dye 
because the emission wavelength of Fluo-4 dye overlapped with the green 
fluorescence emitted from Dronpa. Rhod-3 with longer excitation/emission maxima 
of 556/579 nm allowed simultaneous investigation on calcium level change in dronpa 
transfected cells emitting green fluorescence. Prior to the HEK-293T experiment, the 
experiment protocol was first established using the primary macrophage. Primary 
macrophage was stained with Rhod-3 calcium dye and tested to see if TLQP-21 
induced increase in calcium could be observed in the modified calcium imaging 
protocol (a positive control experiment to test the experimental set up). Figure 3.16 
shows all the primary macrophages within the field of view were stained with Rhod-3 
using the described staining protocol, and 100nM TLQP-21 stimulation induced an 
expected immediate increase in intracellular calcium. The subsequent application of 
1mM ATP also elicited an instant increase in intracellular calcium, indicating cell 
viability. The result here demonstrated that the Rhod-3 staining protocol and the 
experimental set up in calcium imaging were good for the investigation of TLQP-21 
induced calcium response.  
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Figure 3.16 Calcium imaging with Rhod3 calcium indicator revealed that primary 
macrophages were able to respond to 100nM TLQP-21 peptide and 1mM ATP under 
the RhoD3 staining protocol and the modified experiment procedure. 
 
Having established the experiment protocol and staining condition, I next examined 
the effect of TLQP-21 on Dronpa-GC1qR transfected HEK-293T cells 1 day after 
transfection. Figure 3.17 shows the majority of cells were transfected with 
Dronpa-GC1qR, and the cells expressed notable green fluorescence indicating 
successful expression. 100nM TLQP-21 was applied to the transfected cells, no 
significant increase in fluorescent intensity was detected, indicating no change in 
intracellular calcium level after peptide application. Since HEK-293T cells do not 
endogenously express P2X subtype receptors for ATP (Morelli, Chiozzi et al. 2003), 
Ionomycin was used as a positive control at the end of the experiment instead. 
Ionomycin induced the increase in intracellular calcium by stimulating the release of 
calcium from intracellular stores and enhancing calcium influx by activation of 
endogenous entry pathways (Morgan and Jacob 1994). Positive control with 2µM of 
ionomycin applied at the end of the imaging experiment elicited a robust increase in 
intracellular calcium in Dronpa-GC1qR expressing HEK-293T cells immediately 
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after stimulation, indicating the capability of the cells to elicit a calcium response. 
 
The effect of TLQP-21 on Dronpa-GC1qR/Dronpa only transfected HEK-293T cells 
was also tested on post-transfection day 3. 100nM TLQP-21 application was shown to 
elicit no increase in intracellular calcium in both Dronpa-GC1qR transfected and 
Dronpa only transfected HEK-293T cells on post-transfection day 3 (as shown in 
figure 3.18A and 3.18B, respectively). Nevertheless, 2µM ionomycin at the end of 
the experiment demonstrated that the cells were viable and were able to response to 
the positive control stimulation. Together, these data failed to demonstrate 
overexpression of GC1qR in HEK-293T cells enable a functional response of 
TLQP-21 peptide on these cells on post transfection day 1 and 3. 
 
 
Figure 3.17 Calcium imaging using RhoD3 demonstrated HEK-293T cells transfected 
with Dronpa-GC1qR construct did not respond to 100nM TLQP-21 1 day after 
transfection. Ionomycin positive control, however, induced a robust response. 
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Figure 3.18 Calcium imaging using RhoD3 calcium dye illustrated the cells were not 
responsive to TLQP-21 peptide 3 days after transfection. 
HEK293-T cells transfected with A. Dronpa only control construct and B. Dronpa GC1qR 
construct, failed to demonstrate a TLQP-21 stimulated calcium response 3 days after 
transfection. Nevertheless, the positive control with ionomycin elicited a sustained increase in 
intracellular calcium level after application. 
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3.4.4. VGF expression in Partial Sciatic Nerve Ligation (PSNL) model 
 
The presented in vitro data together suggested that GC1qR is the potential receptor for 
TLQP-21 on primary macrophages. Macrophages were shown to infiltrate to the site 
of injury and dorsal root ganglion (DRG) after peripheral nerve injury (Hu and 
McLachlan 2003, Dubovy, Tuckova et al. 2007, Komori, Morikawa et al. 2011), 
where vgf has been shown to be released and upregulated in expression (Riedl, Braun 
et al. 2009). It was hence hypothesised that the recruited macrophages after nerve 
injury were stimulated by TLQP-21 via GC1qR at the periphery, which affects the 
excitability of sensory neurons and resulting in a change in the nociception. To 
validate this hypothesis, I first sought to demonstrate if vgf expression is upregulated 
in the partial sciatic nerve ligation (PSNL) model of neuropathic pain, followed by 
elucidating if interfering TLQP-21/GC1qR pathway in vivo alters the hypersensitivity 
to the mechanical stimulation seen in this rat animal model of neuropathic pain (see 
next section). 
 
Vgf has been demonstrated to be upregulated in a variety of animal models of 
neuropathic pain, including spinal nerve ligation (SNL) model, chronic constriction 
injury (CCI) model, spare nerver ligation (SNI) model, HIV-1 gp120 model, varicella 
zoster virus (VZV) model (Maratou, Wallace et al. 2009, Riedl, Braun et al. 2009). 
However, its expression has not been monitored in the rat PSNL model of neuropathic 
pain, and hence was investigated in this study. The experimental animals were divided 
into two groups; one group underwent PSNL surgery and the other received sham 
surgery. The sham surgery was necessary to isolates the specific effects of PSNL 
surgery as opposed to that caused by anaesthesia, incisional trauma, or pre- and 
postoperative care. Figure 3.19A shows the immunohistochemistry image of the 
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sciatic nerve in Sham animal and that of PSNL animal. The nerve sections were 
stained with neuronal tubulin and Hoechst to reveal neuronal fibres and nuclei, 
respectively. As observed in the PSNL picture, a great number of cells were infiltrated 
to the side of injury where the suture was made, presumably including macrophages 
as evident in literature. The immunohistochemistry confirmed the successful ligation 
and revealed cell infiltration in PSNL models. 
 
Both the ipsilateral and contralateral dorsal root ganglions were collected from the 
two groups of animals on post operative day 1 (POD1), post operative day 3 (POD3) 
and post operative day 5 (POD5). The vgf mRNA expressions were measured by 
quantitative RT-PCR and the data were expressed as percentage of vgf expression in 
ipsilateral DRG over the contralateral DRG. As shown in figure 3.19B, the vgf 
expressions were at approximately the same level in the ipsilateral and contralateral 
DRGs of the sham animal on POD1, POD3 and POD5 (shown as blue bars), as the 
percentages of expression (ipsi/contra) were close to 100% (119.3± 7.8% 
144.2±15.7% and 121.0±19.5% for POD1, POD3 and POD5, respectively). However, 
in the animals underwent PSNL surgery, the vgf expressions were robustly increased 
by 3.2±0.2, 3.4±0.4, 2.8±0.5 folds on the ipsilateral DRG on POD1, POD3 and POD5, 
respectively, when compared to the contralateral DRG. Moreover, the percentages of 
vgf expression (ipsi/contra) on POD1, POD3 and POD5 were significantly different in 
the PSNL animals when compared to Sham (n=3, p<0.01 for POD1 and p<0.05 for 
POD3 and POD5). The presented data here confirmed the vgf expression was 
upregulated in the ipsilateral DRG, up to post-operative day 5, after PSNL surgery and 
the expression was not altered in the sham-operated animals. 
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Figure 3.19 Vgf expression was significantly upregulated at mRNA level in PSNL animal 
models of neuropathic pain on post operative day 1, 3 and 5. 
A. Immunohistochemistry illustrating the staining of neuronal tubulin (green) and cell 
nuclei (blue) at the ipsilateral side of sciatic nerve in Sham and PSNL operated animal. B. 
qPCR data showed significant upregulation of vgf mRNA in DRG of PSNL rats(red bars) 1 
day (POD1, **p<0.01), 3 days (POD3, *p<0.05), and 5 days (POD5, *p<0.05) post 
operation when compared to sham operated rats (blue bars) (n=3, Student’s t-test vs sham). 
 
3.4.5. Effect of blocking GC1qR on mechanical hyperalgeia of the PSNL 
neuropathic pain animal model 
 
The data so far has demonstrated that TLQP-21 can robustly activate bone-marrow 
derived macrophages and result in the release of the intracellular calcium from the 
internal stores. In vitro antibodies neutralisation and siRNA knock-down of GC1qR 
on the primary macrophage interfered the TLQP-21 signalling and reduced the 
percentage of cells responding to the peptide. In addition, vgf expression has also been 
demonstrated to be upregulated in vivo at the periphery of the PSNL animal model of 
Sham 
Nuclei 
nTub 
PSNL 
Nuclei 
nTub 
A. 
B. 
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neuropathic pain. To validate the results presented in vitro and that the culture models 
tested were biologically relevant and to implicate the GC1qR/TLQP-21 pathway in 
macrophage to neuropathic pain, the effect of neutralising GC1qR in vivo was 
examined, in the PSNL animal model of neuropathic pain. 
 
The in vivo experimental set up is shown in figure 3.20. Here I sought to investigate if 
there is a change in the mechanical hypersensitivity that is often observed in animal 
model of neuropathic pain, after topical application of GC1qR neutralising antibody 
at the ligation site. The rats were divided into three groups receiving equal volume of 
PBS vehicle, control IgG, or anti-GC1qR neutralising antibody, after partial sciatic 
nerve ligation surgery. The treatments were soaked in oxidised regenerated celluloses, 
which were wrapped around the suturing ligature after ligation to allow slow release 
of treatments. The mechanical sensitivity to electronic Von Frey was measured on the 
hind paws before (baselines) and after the surgery (POD1, POD3 and POD5), and the 
resulting paw withdrawal threshold data were expressed as percentage to baseline.  
 
Figure 3.20 Schematic diagram illustrating the experimental set up for in vivo study. 
The treatments (vehicle, control IgG or anti-GC1qR) were soaked in an oxidised 
regenerated cellulose, which were wrapped around the ligation sutures. The paw withdrawal 
thresholds to mechanical stimulation were assessed by electronic von Frey on post operative 
day 1, 3 and 5. 
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Figure 3.21A shows that the animals received PBS vehicle control after PSNL 
developed typical hypersensitivity to mechanical stimulus as seen in the animal model 
of neuropathic pain. The paw withdrawal threshold to the mechanical stimulus 
significantly dropped by 33.5±9.1% (n=8, p<0.05) on POD1, which is further reduced 
to 48.2±7.4% and 42.2±10.3% of the baseline on POD3 and POD5, respectively, 
indicating a development of mechanical hypersensitivity in animals receiving vehicle 
control after surgery. Animals receiving control IgG treatment was also demonstrated 
to develop hypersensitivity to the mechanical stimulus (figure 3.12B), as the paw 
withdrawal threshold was significantly reduced by 36.9±6.1%, 49.4±3.6%, 
47.8±7.6% (n≥7, p<0.001) on POD1, POD3 and POD5, respectively, compared to the 
baseline. This indicates that the animals received control IgG after PSNL surgery still 
developed mechanical hypersensitivity as observed in the vehicle control, suggesting 
the treatment of control IgG did not interfere with the development of hyperalgesia in 
the animal model of neuropathic pain. Interestingly, the animals received anti-GC1qR 
treatment after surgery showed a delayed in development of mechanical 
hypersensitivity. As shown in figure 3.21, the paw withdrawal threshold on POD1 
was not significantly differed from that of the baseline (74.2±6.8% for POD1 
compared to 100±8.9% of baseline), even though there was a trend of reduction. 
Nevertheless, the paw withdrawal thresholds on POD3 and POD5 were significantly 
reduced by 40.7±6.9% and 37.8±13.3% (n≥5, p<0.001), indicating a development of 
mechanical hypersensitivity on POD3 and POD5. It is worth noting though when the 
percentages reduction in withdrawal threshold were compared for day 1 between PBS, 
control IgG and anti-GC1qR groups, the results were statistically insignificant 
(P=0.535, One Way ANOVA). This indicates the possibility that the lack of 
significance in the day 1of the GC1qR antibody treated group could likely be driven 
by the big variations in response between animals or the higher than normal 
 183 
variability in the baseline of the animals.  
 
The data presented here may suggest that topical treatment of GC1qR neutralising 
antibody after PSNL surgery could potentially delay the development of mechanical 
hypersensitivity in the rat PSNL model of neuropathic pain. Although future 
experiments with larger n numbers should be carried out to draw a more reliable 
conclusion, the data presented here may implicate a role of GC1qR in the 
development of neuropathic pain in vivo. 
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Figure 3.21 Anti-GC1qR neutralising antibody, but not the vehicle nor control IgG 
antibody, attenuated mechanical hypersensitivity on post-operative day 1 in PSNL 
animal model of neuropathic pain. 
Ipsilateral paw withdrawal threshold to electron von Frey were examined on post operative 
day 1, 3 and 5 on PSNL rats treated with A. Vehicle, PBS (n=8) B. 25 μg Control IgG (n≥7) C. 
25 μg Anti-GC1qR neutralising antibody (n≥5). The ipsilateral paw withdrawal threshold for 
each n number in all experiments is listed in the table. The animals treated with vehicle and 
control antibody showed reductions in mechanical thresholds one day after PSNL surgery 
(*p<0.05 and **p<0.01 vs. BL for POD1 vehicle and POD1 control IgG, respectively.). In 
contrast, the PSNL rats treated with GC1qR antibody exhibited higher mechanical threshold 
to the electronic von Frey when compared to the control antibody treated rats and the 
vehicle treated rats. Moreover, the paw withdrawal threshold POD1 GC1qR treated PSNL 
rats were not statistically differing from the baseline (not significant, p = 0.12, for POD1 
anti-GC1qR). *p<0.05, **p<0.01, Two way ANOVA Tukey’s post hoc test. D. The 
percentages reduction in withdrawal threshold of PBS, control IgG and anti-GC1qR treated 
groups. The percentage reduction between groups were statistically insignificant (p = 0.53515, 
One way ANOVA). Error bar expressed as standard error means. 
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3.5 Discussion 
 
In the previous chapter, it was demonstrated that macrophage is one of the target 
cells, if not the only one, for TLQP-21 in the periphery. TLQP-21, at the 
concentration as low as 10nM, acts on the primary macrophage and induce a 
pronounced increase in the intracellular calcium level. Intriguingly, TLQP-21 
stimulation on the primary macrophage desensitised the cells from responding to the 
second dose of TLQP-21, implying the presence of a receptor for this peptide on the 
primary macrophage. This potential receptor for TLQP-21 was identified as GC1qR 
in our laboratory by two independent experiments, chemical crosslinking and 
affinity purification in combination with mass spectrometry. In this chapter, I aimed 
to verify, functionally, if GC1qR is the receptor for TLQP-21 on the primary 
macrophage in vitro, and examine its involvement in the neuropathic pain 
development in vivo.  
 
3.5.1. Effect of GC1qR neutralisation and downregulation on TLQP-21 induced 
calcium response in the primary macrophage in vitro 
 
I first demonstrated in this chapter that neutralisation of the receptor using two 
monoclonal antibodies specifically targets GC1qR (MAb60.11 and MAb74.5.2) and 
results in a reduction of calcium response induced by TLQP-21 in the primary 
macrophages. The effect is seen most pronounced when the antibodies were used 
together at the concentration of 3µg/ml (of each antibody). Though there is no 
statistical significance between the percentages of cells responding to TLQP-21 after 
MAb60.11 and MAb74.5.2 pre-incubation, there is a trend of more cells being able 
to respond after MAb74.5.2 treatment. The possible reason for this could be that 
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MAb60.11 only recognises the mature form of GC1qR, whereas MAb74.5.2 
interacts with both mature and truncated forms of GC1qR. It is possible that 
TLQP-21 interacts with the mature forms of GC1qR with higher affinity and 
subsequently exerts its function upon binding, and hence the effect of MAb74.5.2 
treatment was diluted as it also recognised the truncated form. Moreover, MAb 
60.11 and MAb74.5.2 target specific GC1qR epitopes at amino acids 76-93 and 
204-218, respectively, where they block distinctive functional domains of GC1qR. It 
is also plausible that blocking of the functional domain that MAb74.5.2 targets is 
less effective in disrupting the interactions between GC1qR and TLQP-21 
stoichiometrically. Nonetheless, blocking of GC1qR using either neutralising 
antibodies or combined, showed significant reduction of percentage of cells 
responding to TLQP-21 in the primary macrophage. This indicates that GC1qR is, at 
least partly, involved in TLQP-21 induced calcium signalling in the primary 
macrophage.  
 
This finding is in line with the GC1qR downregulation experiment by siRNA 
oligonucleotides, where the GC1qR downregulation in the primary macrophage also 
showed to reduce the percentage of cells responding to TLQP-21. It is worth noting 
though, the abolishment in calcium response effect caused by GC1qR 
downregulation was not as pronounced as that of GC1qR neutralistion by antibodies. 
This could be explained by that the siRNA oligonucleotides used in the experiment 
not completely eliminating all the endogenous GC1qR, and the residual proteins 
expressed in some of the cells could still exert functions. Indeed, the Western blot 
analysis 48 hours after siRNA transfection showed the downregulation efficiency of 
GC1qR was about 50% at protein level on average. Although, the percentage of 
knockdown at the mRNA level was achieved between 70-80%, it is possible that 
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GC1qR has a long protein half-life. As a result of this, though the mRNA was 
knocked down to a significant level, the protein remained stable inside cells and 
hence partially masking the siRNA effect in some of the cells. Future experiments 
could be carried out using different siRNA sequences or carrying out extensively 
optimisation on concentration used and time point for the current siRNAs to achieve 
better knock down at protein level. This achievement would be relevant to achieve a 
more pronounced functionality change in macrophage upon TLQP-21 stimulation.  
 
3.5.2. Effect of GC1qR overexpression on TLQP-21 stimulation of the 
HEK293T cells in vitro 
 
Having demonstrated GC1qR receptor neutralisation and knockdown both affect the 
ability of primary macrophage responding to TLQP-21, I intended to proof the 
functionality and involvement of GC1qR in the TLQP-21 induced calcium signalling 
on primary macrophage by a third experimental approach. Other than knocking down 
of the target gene by RNAi technology, one of the most common ways to dissect the 
function of a gene in a pathway is to overexpress the gene. One of the main concerns 
associated with RNAi experiment is the off-target effect on other genes. However, if 
result obtained from the overexpression experiment shows the opposite functional 
read out to siRNA, it is less likely the results of siRNA-mediated reduced in 
percentage of cell responding were due to non-specific off target effects. For this 
reason, the GC1qR construct was cloned and transfected into a cell line which did not 
respond to TLQP-21. It was thus hypothesised that overexpression of GC1qR into a 
cell line that does not normally respond to TLQP-21 could potentially allow them to 
become responsive, at least in terms of calcium response, to the peptide. The human 
embryonic kidney cell line 293 (HEK293T) has been demonstrated previously in our 
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laboratory by Dr Mahmood Ayub to be unresponsive to TLQP-21 stimulation in the 
calcium imaging and was hence chosen to be the in vitro system for overexpression 
experiment. Unexpectedly, it was demonstrated in this chapter that HEK293T cells 
overexpressed GC1qR failed to induce an intracellular calcium response when 
TLQP-21 was applied. The possibility that HEK293T cells were unable to elicit a 
calcium response was eliminated as ionomycin positive control induced a robust 
transient calcium response after its application to the cells. These cells failure to 
respond could be for a number of reasons. It is possible that HEK293T cells may not 
have the correct downstream molecular components to process the interaction of 
GC1qR and TLQP-21, as HEK293T cells are human embryonic kidney cells, the 
endogenous molecular machinery is likely to be very different from macrophage. It is 
also plausible that HEK293T cells may have the correct machinery, but the GC1qR 
construct transfected was a rodent clone, which failed to interact or weaken the 
interaction with the endogenous downstream signalling molecule so that the 
subsequent functional outcome cannot proceed. Although this possibility exists, it is 
very unlikely to be the case as the rodent sequences of GC1qR are 89.9% identical to 
the human sequence and the essential amino acids at functional domains are often 
conserved among different species. Furthermore, it is worth noting that GC1qR lacks 
consensus sequence for a predicted transmembrane segment, it is hence hypothesised 
to initiate downstream signalling by coupling with transmembrane proteins. Here, I 
cannot formally rule out other factors such as cell type specific 
accessory/adaptor/transmembrane proteins might be needed and are involved to 
dictate the cell type specific response to be induced following TLQP-21 stimulation. 
Although, the complete signalling mechanism has yet to be determined, the finding 
that TLQP-21 and GC1qR interact and interfering with this interaction, either by 
siRNA genetic manipulation or antibody neutralisation, results in reduced 
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TLQP-21-induced calcium response, suggests a role of GC1qR in the 
TLQP-21-mediated cellular response in the primary macrophage. Future experiments 
could be carried out to consolidate the finding of the involvement of GC1qR in 
TLQP-21 signalling in primary macrophages, where siRNA targeting of the 
untranslated region of GC1qR mRNA could be designed and used to downregulate the 
endogenous GC1qR in the primary macrophage. The percentage of cells responding to 
TLQP-21 after GC1qR knock down by such siRNA will be expected to reduce. An 
investigation could be carried out subsequently to examine if overexpressing 
exogenous GC1qR could rescue the siRNA-mediated effect (i.e. rescue the percentage 
of cell responding to TLQP-21). 
 
3.5.3. Effect of GC1qR neutralisaiton in vivo on pain behaviour in the PSNL 
animal model of neuropathic pain 
 
Despite that the evidences demonstrated in this chapter linking GC1qR in the 
TLQP-21 induced calcium-dependent signalling pathway in the macrophage in vitro, 
its involvement in vivo in neuropathic pain development had not yet been examined, 
and hence was investigated. As demonstrated in figure 3.21, a single dose of local 
anti-GC1qR antibody treatment, but not control IgG or vehicle treatment, after PSNL 
surgery delayed the neuropathic pain-like behaviour in the animal model, suggesting 
neutralisation of GC1qR at the site of injury may result in delay in the development of 
neuropathic pain. This indicates that GC1qR may play an important role in initiating 
and/or maintenance of neuropathic pain after nerve injury.  
 
If GC1qR is pivotal to neuropathic pain development, why is the effect observed 
transient? There could be a number of reasons for this. Firstly, in the experimental set 
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up, the antibody was only delivered to the animal as a single dose of 25µg. It is 
possible that the concentration of the antibody was not high enough to neutralise all 
the GC1qR readily available at the site of injury, as mentioned previously that large 
number of macrophages infiltrate to the injured nerve after periphery nerve injury. 
The concentration of the antibody delivered in the experiment was already the highest 
possible from the commercial available purchase. For future experiment to optimise 
the antibody dose in the in vivo experiment, a higher-titer MAbs could be produced 
through commercial source, and be used at higher concentration to increase 
neutralisation effect in vivo. The second possible reason for the transient effect 
observed in the in vivo study could be that the antibody was delivered as a single dose. 
Antibodies are proteins, which exhibit distinctive half-life. It is possible that the 
antibody has a short half –life and the stability of the antibody in vivo was one of the 
reasons, if not the only one, contributing to the transient effect. Although it has been 
demonstrated by Moreell et al. (Morell, Terry et al. 1970) that the average biological 
half-life of IgG antibodies were 21 days for G1, G2 and G4 subtypes, while IgG3 
was only 7.1 days. The monoclonal antibody used in the in vivo experiment was 
IgG1 subtype, and hence the possibility that the antibody exhibit a short half-live in 
vivo is less likely to the reason. Although this possibility cannot be firmly ruled out 
as it has been demonstrated binding of endogenous antibody to the ‘therapeutic’ 
antibody, as an immune response to eliminate the foreign antibody, forms immune 
complexes that could shorten the half-life of the therapeutic antibody and 
compromise its effectiveness (Chan and Carter 2010). To overcome this problem, 
future experiment could be design to deliver antibody at multiple dosage using 
technology such as osmotic minipump, which allows constant and long-term 
delivery of the antibody at the site of injury, which has been shown successful in the 
literature (Krum, Mani et al. 2008, Clausen, Hanell et al. 2009). Moreover, 
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production of a rat monoclonal neutralising antibody against GC1qR may improve 
the possibility that cross species immune response resulting in shortening of 
antibody stability in vivo. 
 
Moreover, it is worth noting that macrophages infiltrate into the injured nerve 1 day 
after nerve injury, and GC1qR on these macrophages proximal to the treatment wrap 
could possibly be neutralised. However, 2 days after PSNL surgery, another wave of 
M2 macrophage infiltrate the dorsal root ganglia (DRG), where the sensory neurons 
cell bodies lied (Komori, Morikawa et al. 2011). The ectopic application of the 
anti-GC1qR antibody at the site of injury distal to the DRG ganglia may be 
insufficient to neutralise the function of the receptors on this second wave infiltrated 
macrophages, and hence the development of neuropathic pain was delayed but not 
abolished. There is also a complication where the endogenous macrophages are 
constantly being replenished and replacing the ‘neutralised’ macrophages. Therefore, 
the existence of endogenous circulating macrophage may mask the effect of ectopic 
application of the GC1qR antibody. To overcome these problems, future experiments 
could be carried out to deliver the antibody systemically. Though the required 
antibody for systemic injection would be much higher and it could possibly cause a 
secondary effect, it could allow a more distinctive phenotype to be observed as the 
neutralisation condition is more stringent and multiple dosages by systematic 
injection would be experimentally possible. To help dissecting further if neutralising 
GC1qR on macrophage could delay/abolish the development of neuropathic pain in 
vivo, an experimental global macrophage depletion could be carried out in the future 
experiment. This could be done by either total body irradiation (Matute-Bello, Lee et 
al. 2004) or clodronate liposomes technique (Van Rooijen and Sanders 1994). 
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Clodronate liposomes techniques rely on the nature that macrophages are phagocytic 
and ingestion of clodronate (toxin) packed liposome could kill the host cells. Both of 
these methods selectively deplete circulating monocytes and macrophages, as 
microglia in the CNS are not phagocytic and proliferate very slowly, thus making 
them more resistant to these treatments. After systemic depletion of endogenous 
macrophages, in vitro cultured macrophages treated with either anti-GC1qR or IgG 
control could be transplanted to the animal after PSNL surgery. If the anti-GC1qR 
treated macrophage-transplanted animals fail/delay to develop neuropathic pain and 
that of the IgG group develop neuropathic pain normally, this data will draw a more 
convincing result to support the involvement of GC1qR in the development of 
neuropathic pain. 
 
Another weakness of the in vivo experiment that should be noted is that neuropathic 
pain animal models often exhibit characteristic thermal and mechanical hyperalgesia 
and in the in vivo experiment set up, only the mechanical hypersensitivity was 
monitored after neutralising antibody treatment. There is a possibility that a more 
dramatic effect, in terms of delaying/abolishing neuropathic pain development, could 
be observed in the noxious heat read out assay using Hargreaves’s apparatus.  
 
Summing all the results presented in this chapter, I have demonstrated for the first 
time that GC1qR could be the potential receptor on primary macrophage for VGF 
derived peptide, TLQP-21. The interaction between GC1qR and TLQP-21 is essential 
for TLQP-21 induced calcium response in macrophage, as shown in this chapter that 
disrupting this interaction by GC1qR downregulation/neutralisation results in reduced 
percentage of cells responding to TLQP-21 in calcium imaging. I also demonstrated 
that vgf was significantly upregulated in the DRG of PSNL animal model of 
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neuropathic pain, and this upregulation was sustained at least until POD5. Lastly, I 
demonstrated in this animal model, interfering the TLQP-21/GC1qR pathway by 
neutralisation of GC1qR in vivo results in a delay of neuropathic pain development. 
Together, this chapter presents the data examining and verifying the involvement of 
GC1qR in the TLQP-21 signalling pathway and suggests TLQP-21 provokes the 
intracellular calcium response in the primary macrophage, at least partly, via GC1qR. 
Though further optimization is still required, GC1qR is suggested here to play a role 
in the development of neuropathic pain in vivo, and this involvement is likely to be 
downstream of TLQP-21 stimulation.  
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CHAPTER 4: 
INVESTIGATION OF TLQP-21 DOWNSTREAM SIGNALLING 
PATHWAY IN THE PRIMARY MACROPHAGES BY GENETIC 
APPROACHES 
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Synopsis  
The work presented in this chapter aims to investigate the downstream mechanisms 
underlying the TLQP-21 signalling in the primary macrophages. Individual 
inflammatory mediators that are common produced from the macrophages and the 
GC1qR receptor has been tested for their changes in gene expression by qRT-PCR 
following TLQP-21 treatment. In addition, PCR array is utilised to investigate if the 
common transcription factors involved in various biological processes are 
dis-regulated in the primary macrophages after TLQP-21 stimulation. Genome-based 
approach has been also been employed, such that the microarray analysis of the 
transcriptomes of primary macrophage treated with TLQP-21/scrambled peptide are 
compared at different time points. 
 
4.1. Introduction 
 
4.1.1. Methods of differential gene expression detection for investigating gene 
function. 
 
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
 
Polymerase Chain Reaction (PCR) is a revolutionary technology developed by Saiki 
et al. in 1985 (Saiki, Scharf et al. 1985). Ever since then, this technique has been 
widely employed in the field of molecular biology for cloning, genetic engineering 
and sequencing. This technology allows exponential amplification of small DNA 
fragments, which requires a pair of primers (usually ~ 20 nucleotides) complementary 
to, and flanking, the sequence of interest. In addition, thermo-stable DNA polymerase 
is essential to perform the sequence extension from the primers by utilising the 
deoxynucleotide triphosphates supplemented in the reaction. The amplification can be 
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repeated for multiple cycles, which results in an exponential amplification of the 
target sequence. Quantitative Real Time PCR (qRT-PCR) is an advance development 
from such PCR technology, in which the products generated during each cycle of 
amplification can be precisely detected and measured (Freeman, Walker et al. 1999). 
Because the reliable quantification of the product could be measured, qRT-PCR has 
been widely employed in the quantification of gene expression, differential gene 
expression analysis, quantifying pathogen loads such as bacterial, fungal and viral 
infections (Deepak, Kottapalli et al. 2007). The principle of qRT-PCR derived from 
that of PCR, in which sophisticated detection and quantification methods differentiate 
them from the conventional PCR and hence enable reliable “real-time” measurement 
of gene expression. 
 
The most common detection methods in qRT-PCR are the fluorescent 
double-stranded DNA(dsDNA) dye and the fluorescent reporter probes consisting of 
a reporter and a quencher. In the first method, a fluorescent DNA-binding dye (such as 
SYBR green) non-selectively and preferentially binds to any double-stranded DNA in 
the PCR, resulting in fluorescent emission. The binding ability of the dye to the 
single-stranded DNA (ssRNA) is often much lower than that to the dsDNA (at least 11 
folds less for SYBR green dye)(Zipper, Brunner et al. 2004). As the dsDNA is 
amplified during the qRT-PCR cycles, the fluorescent intensity is increased along the 
reaction cycles. The quantification of the PCR product can be made by exciting the 
fluorophore at certain wavelength (λmax = 488 nm for SYBR green) and subsequently 
measures the fluorescent emission (λmax = 522nm for SYBR green) after each cycle of 
the PCR, thus monitoring the gene amplification in “real-time”. A major drawback of 
this detection method is that fluorescent dsDNA dye could bind to all dsDNA, 
including the primer-dimers and the off-target amplified products in the reaction. 
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Such non-specific products could contribute to the output fluorescent intensity and 
prevent accurate quantification of the gene of interest. In order to overcome this 
problem, a melt curve analysis is often performed after the qRT-PCR reaction. During 
the analysis, all dsDNA PCR products are denatured with increasing temperature, 
which results in a reduction in fluorescent intensity. The temperature where 50% of 
the dsDNA is dissociated is known as the melting temperature. Different dsDNA PCR 
products will have different melting temperatures as the sequences are not identical. 
This helps to assess if undesirable multiple products are generated during the 
qRT-PCR reaction and if repeated qRT-PCR reaction could generate the same melting 
temperature for the gene of interest (Ririe, Rasmussen et al. 1997). The latter 
quantification method involves oligonucleotide probes consisting DNA labelled with 
fluorescent reporter at the 5’ end and a quencher at the 3’ end (Holland, Abramson et 
al. 1991). The most widely used fluorescent reporter probes are the TaqMan probes. 
During qRT-PCR cycles, the probe hybridises to the complementary target sequence 
and the fluorescent reporter is cleaved during PCR due to the 5’nuclease activity of 
Taq polymerase. The cleavage releases the fluorophore from the quencher and hence 
permitting fluorescent emission to allow subsequent quantification of the PCR 
product. The detected fluorescent in the qRT-PCR using TaqMan probes is, therefore, 
directly proportional to the fluorophore released from the sequence specific probe and 
the amount of target DNA generated. Non-specific amplification signal is hence 
reduced as no signal will be generated from any background amplification that may be 
formed. In addition, the probes can be labelled with different fluorescent dyes to 
permit detection of different target sequences in a single reaction. However, the 
synthesis of the reporter-and-quencher-labelled probes is required for all the targets of 
interest, which results to a higher experiment cost of this detection method compared 
to others. 
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The quantification methods performed in a qRT-PCR can be either an absolute or a 
relative quantification. The absolute quantification of qRT-PCR data involves 
calibrating the experiment with a standard curve generated from serial dilution of a 
sample with known concentration (Bustin 2000), while the relative quantification 
measures the relative changes in gene expression level of the target gene to a reference 
gene. Relative quantification is generally easier to perform than absolute quantification 
because the generation of a standard curve is not needed. However, a good 
reference/housekeeping/control gene with stable expression is essential for the relative 
quantification to be carried out, as the quantification is heavily relied on comparing the 
expression levels of the target gene to the housekeeping gene and it is often necessary to 
normalise the expression of the gene of interest over the consistently expressed 
reference gene (Radonic, Thulke et al. 2004). The data from relative quantification 
method are often analysed by the ΔΔCt method (Livak and Schmittgen 2001). In this 
method, it is assumed that the primers for the target gene and the reference gene exhibit 
the same efficiency and the amplification of the genes results in similar productivities. 
The 2−∆∆CT algorithm is implemented in the ΔΔCtq quantification method. The data 
analysed are expressed as a fold change to the corresponding control and the absolute 
amount of gene expression in the control remains unknown. 
Microarray as tools in genetic research to investigate gene function 
 
Microarray is a chip-based technique that allows simultaneous measurement of a 
large number of genes. The microarray chip is made by attaching small fragment 
DNA probes to a solid surface. An array can contain thousands of DNA probes, and 
hence enabling the survey for the expression of thousands of genes at the same time. 
The principle of the microarray relies on the phenomenon that complementary nucleic 
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acid sequences are able to bind to each other via hydrogen bonds formations between 
Watson-Crick nucleotide base pairing. The total mRNA is often extracted from the 
sample of interest, followed by labelling with fluorescent detector. The common 
fluorescent dyes used for cDNA labelling are Cy3 and Cy5, which emit fluorescence 
at 570nm (green fluorescence) and 670 nm (red fluorescence), respectively. The 
labelled target sequences are then hybrdised to the probes on the array. The perfect 
complementary sequences exhibit tight associations via strong non-covalent bindings, 
which remain hybridised while non-specific annealing is washed. The gene 
expression level is detected from the fluorescent emission, where the total amount of 
fluorescent signals corresponds to the amount of dye-tagged sequence hybridised to 
the probes on the chip (Gibson 2003). The level of expression can hence be quantified 
by comparing the intensities of all the genes of a sample to those of another sample.  
 
Because of its advantage to investigate the changes in expression of large numbers of 
genes in one experiment, microarray analysis has become popular choice for 
identifying differential gene expression in different disease states. Once identified, the 
varying expression levels of specific gene can be confirmed and further investigated 
for its functional roles in the disease. Indeed, such an approach was found to be useful 
in the field of pain research for investigating changes in gene expression of the 
neuropathic pain animal model compared to naïve animal (Costigan, Befort et al. 
2002), examining common genes that are dis-regulated among different animal 
models of neuropathic pain (Maratou, Wallace et al. 2009), identifying inflammatory 
mediators produced in the sensory ganglia during neuropathic pain development 
(Strong, Xie et al. 2012), and comparing gene profile between different type of pain 
(neuropathic versus inflammatory pain(Rodriguez Parkitna, Korostynski et al. 
2006)) .  
 200 
4.2. Aim  
 
Having demonstrated that VGF-derived peptide, TLQP-21, acts on the primary 
macrophage in a dose- and calcium-dependent manner, and the calcium response 
evoked by TLQP-21 is, at least partly, via GC1qR. In vivo studies in the previous 
chapters also showed that TLQP-21-activated macrophages significantly induced 
mechanical hyperalgesia in the naïve animal and interfering with the GC1qR pathway 
delayed the neuropathic pain development in the PSNL animal model of neuropathic 
pain. Despite these novel findings allowed better understanding of the TLQP-21 
signalling and its involvement, together with GC1qR receptor, in the neuropathic pain 
development, the molecular mechanism downstream to TLQP-21-evoked calcium 
response in the primary macrophage is largely unknown. Thus, the aim of this chapter 
is to investigate in vitro, the downstream signalling event following the 
TLQP-21-induced calcium response in the primary macrophages by: 
 
1. Quantitative RT-PCR to investigate if the characteristic cytokines, 
inflammatory mediators and receptor GC1qR are dis-regulated after 3 hours of 
100nM TLQP-21 treatment. 
 
2. PCR array to investigate if any differential gene expression of the 84 common 
transcription factors can be detected after 30 mins/3 hours of 100nM TLQP-21 
exposure. 
 
3. Microarray analysis to investigate, in the genome wide level, the differential 
gene expression in the macrophages after 30 mins/3 hours/24 hours of 
TLQP-21 stimulation. 
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4.3. Material and method 
 
4.3.1. Sample preparation 
 
Primary macrophage cultures were established as outlined previously in section 
2.2.3. The differentiated cells were isolated from the undifferentiated cells 48 hours 
prior to the experiment by re-plating ~1,000,000 cells/90mm culture dish. For 
quantitative real-time PCR, PCR array and microarray experiment, the media of the 
culture were changed to serum free IMDM 24 hours prior to the treatment. The cells 
were then treated with either 100nM wild type TLQP-21, 100nM scrambled 
TLQP-21 or vehicle (same volume of sterile water) for 30 minutes 3 hours or 24 
hours. Total RNA was extracted from the cells after corresponding peptide/vehicle 
treatment, followed by subsequent procedures to perform qRT-PCR, PCR array and 
microarray (see later). 
 
4.3.2. Quantitative Real-time PCR 
 
Total RNA extraction from cultured cells treated with either scrambled TLQP-21/wild 
type TLQP-21, cDNA synthesis and quantitative RT-PCR was performed as described 
in the previous chapter (section 2.2.5). The primers used in the qRT-PCR studies of 
this chapter are listed below:  
 
Targets Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’) 
Beta-actin TCCTGTGGCATCCATGAAACT AACGTCACACTTCATGATGGAATT 
Cyclophilin A GCAAGACCAGCAAGAAGATC TCAGTGAGAGCAGAGATTACAG 
TNF-α ATCCGAGATGTGGAACTGGCA CCGGACTCCGTGATGTCTAAGT 
IL-1β CACCTCTCAAGCAGAGCACAG GGGTTCCATGGTGAAGTCAAC 
IL-6 TCCTACCCCAACTTCCAATGCTC TGGATGGTCTTGGTCCTTAGCC 
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iNOS CACCTTGGAGTTCACCCAGT ACCACTCGTACTTGGGATGC 
BDNF AAGGCACTGGAACTCGCAAT AACCGCCAGCCAATTCTCTT 
Arg1 TATCGGAGCGCCTTTCTCTA ACAGACCGTGGGTTCTTCAC 
Cox2 TGTATGCTACCATCTGGCTTCGG GTTTGGAACAGTCGCTCGTCATC 
GC1qR  GTATTGGGCGCCTGGTCACC CGCTCCTGGAAGATGGTGATGG 
 
4.3.3. NanoDropTM spectrophotometer 
 
For checking the RNA quantity and quality, the NanoDropTM ND-1000 
spectrophotometer (Thermo Scientific) was used following the manufacturer’s 
instructions. Briefly, the instrument was initialised by 2µl of RNase free water. A 
blanking cycle was performed using 2µl of pure RNase free water before any 
measurements were performed. 1.5µl of RNA from the samples was loaded onto the 
sample loading platform and the concentration of the RNA was obtained in ng/µl. 
The 260/280 absorbance ratio as well as the 260/230 ratio were also obtained from 
the measurement. For 260/280 ratio, a value greater than 2.0 generally indicate 
sufficient quality in the RNA purity. If the value is lower than 2.0, it is likely the 
RNA was contaminated with proteins. 260/230 ratio with value greater than 1.7 
indicates minimal contamination with solvent (such as ethanol). 
 
4.3.4. Assessment of RNA integrity 
 
The RNA integrity assessment was performed using the Agilent Total RNA Nano 
6000 Labchip
TM 
kit and Agilent Bioanalyser according to the manufacturer’s manual. 
Briefly, all reagents from the Nano 6000 Labchip kit were allowed to equilibrate at 
room temperature for 30 minutes prior to be used. 550µl of the Agilent RNA 6000 
Nano gel matrix was placed into the top of the spin filter provided, which is then 
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centrifuge at 1500g for 10 minutes. The filtered gel was then divide into 65µl 
aliquots in 0.5ml RNase-free tubes, and stored at 4ºC. 1µl of well-mixed RNA 6000 
Nano dye concentrate from the kit was added to a 65µl aliquot of the filtered gel, 
followed by thorough vortex and centrifugation at 13000g for 10 minutes at room 
temperature. The mixture of filtered gel and dye was allowed to equilibrate at room 
temperature for 30 minutes in the dark. The gel/dye mixture was loaded to the chip 
via a plunger system on the chip priming station. The RNA samples used were at 
concentrations between 158-492ng/µl. Prior to the RNA samples loading, 5 μl of the 
RNA 6000 Nano marker was loaded into all the wells. 2µl of the RNA samples were 
denatured at 70ºC for 2 minutes to minimise secondary structure. 1µl of the heated 
samples/RNA ladder were loaded into the corresponding wells. The chip was placed 
into the IKA vertex mixer and vortex at 2400rpm for 1 minute. The chip was then 
placed into the Agilent 2100 Bioanalyzer and analysed by the Eukaryote Total RNA 
Nano series II programme. 
 
4.3.5. Transcription factor PCR array 
 
cDNA sample for PCR array was synthesized from 3µg of the total RNA using RT
2
 
First strand reverse transcription kit (SABiosciences, Qiagen) according to the 
manufacturer’s instruction. Briefly, 8µl of total RNA was mixed with 2µl of 5x 
genomic DNA elimination buffer. This Genomic DNA elimination mixture was 
incubated at 42ºC for 5 minutes, followed by chilling on ice for another 5 minutes. 
While incubation, reverse transcription cocktail was prepared by mixing 4µl of 5x RT 
buffer 3, 1µl of Primer & External control mix, 2µl of RT enzyme mix 3 and 3µl of 
RNase/DNase free water. The 10µl of Genomic DNA elimination mixture was then 
mixed with the 10µl reveres transcription cocktail. The mixture were mixed well and 
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incubated at 42ºC for 15 minutes exactly and terminating the reaction immediately 
after by heating at 95ºC for 5 minutes. 91µl of RNase/DNase free wter was added to 
the 20µl cDNA synthesis reaction, which is chilled on ice for 5 minutes. To run the 
RT² Profiler transcription factor PCR Array (PARN-075ZC, SABiosciences, Qiagen), 
102 µl of the diluted first strand cDNA synthesis reaction was mixed with 1350µl of 
2x SABioscience RT2 qPCR mater mix and 1248µl of RNAse/DNase free water. 25µl 
of the experimental cocktail was loaded into each well of the array by using a eight 
channels pipettor. After a brief spin at 1000g, the array was run on Applied 
Biosystems 7500 fast Real-Time PCR machine using the following cycling 
programme: 95ºC for 10 minutes followed by 40 cycles of 95ºC for 15 seconds and 
60ºC for 1 minutes. The raw Ct values were analysed by the comparative expression 
2
-∆∆Ct
 method, and the relative fold changes were normalised to five endogenous 
house-keeping genes; β-actin, β-2 microglobulin, Hypoxanthine 
phosphoribosyltransferase 1, Lactate dehydrogenase A, Ribosomal protein large P1, 
and assessed relative to either the scrambled peptide treated control or the vehicle 
control. Where expression was undetermined in the real-time PCR reaction, the 
sample was given a default Ct of 35. 
 
4.3.6. Microarray 
 
The RNA samples for microarray were prepared as described in the section 4.3.1. The 
preliminary microarray work investigating the downstream signalling upon TLQP-21 
stimulation in the primary macrophages used the whole genome expression profiling 
Affymetrix RG230.2 arrays. The quality control of the RNA samples, hybridisastion 
and the microarray analysis were performed by the commercial company AROS. The 
differential gene expression analysis were performed by Pfizer Neusentis, in which the 
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statistical analysis was performed using the Linear Models for microarray analysis 
from the Limma package (Smyth, G.K., et al., Limma: linear models for microarray 
data, in Bioinformatics and Computational Biology Solutions using R and 
Bioconductor. 2005, Springer, New York. p. 397-420). The differential expressions 
was compared between the TLQP-21 treated and scrambled TLQP-21 treated groups 
at all time points. The p-values were uncorrelated and p values below 0.01 were 
considered to be significant. The significant probe lists were generated. 
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4.4. Results 
 
Despite macrophage has been known to upregulate expression of many 
pro-inflammatory mediators upon activation in the neuropathic pain state, the 
molecular event downstream to TLQP-21 stimulation in the macrophage still remains 
unknown. Having demonstrated in the previous chapters that primary macrophage is 
the target cell, if not the only one, for VGF-derived peptide TLQP-21 and TLQP-21 
acts on the primary macrophage, at least partly, via GC1qR, eliciting a 
dose-dependent increase in intracellular calcium level, here I sought to investigate the 
TLQP-21 downstream signalling pathway in the primary macrophage. The 
investigation here will help to address the following questions: are the gene 
expressions of the characteristic cytokines, chemokines and metabolites produced by 
macrophages in the pain state altered upon TLQP-21 stimulation? Does TLQP-21 
induce changes in gene expressions of other genes after eliciting the calcium response 
in the primary macrophages?  
 
To examine the TLQP-21 downstream signalling event, three experimental 
approaches were employed. The first method employed was the quantitative real-time 
PCR to investigate if the common mediators secreted by macrophages are changed in 
expression levels after TLQP-21 treatment. Secondly, I employed PCR array to assess 
if the expression levels of the common transcription factors are altered following 
TLQP-21 exposure. Lastly, microarray was employed for a high throughput 
assessment to the genome-wide gene expression changes. 
 
4.4.1. Examining in vitro gene expression of the characteristic mediators 
produced from macrophages after TLQP-21 stimulation by Quantitative 
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Real-Time PCR. 
 
Macrophages secrets many cytokines, chemokines and metabolites in the pain state, 
which are important mediators of hyperalgesia (Sommer and Kress 2004). These 
mediators include tumour necrosis factor α (TNF-α)(Miller, Jung et al. 2009), 
interleukin 1β (IL-1β)(Kiguchi, Kobayashi et al. 2012), interleukin 6 (IL-6)(Kiguchi, 
Maeda et al. 2009), inducible nitric oxide synthase (iNOS)(Levy, Kubes et al. 2001, 
Purwata 2011), brain-derived neurotropic factors (BDNF)(Wong, Liao et al. 2010, 
Salegio, Pollard et al. 2011), arginase 1 (Arg1)(Kigerl, Gensel et al. 2009), and 
cyclooxygenase 2 (Cox2)(Ma, Chabot et al. 2010). Targeting some of these mediators 
has been proposed to be the potential treatment for neuropathic pain (Ma and Quirion 
2006). 
 
TLQP-21 has been demonstrated in the literature to play a role in modulating 
inflammatory pain in vivo (Rizzi, Bartolomucci et al. 2008). However, it was 
demonstrated in chapter 2 that TLQP-21 is likely not acting directly on the sensory 
neuron, at least not in the functional assay tested. In addition, TLQP-21 was shown in 
the same chapter to act on primary macrophage in vitro and intraplantar injection of 
TLQP-21-stimulated macrophages elicited pain-like behaviour in vivo. These 
accumulating data enables us to hypothesise that TLQP-21 could potentially exert its 
function by modulating activity of the primary macrophages at the periphery upon 
nerve injuries. It could possibly indirectly modulate the neuronal excitability/activity 
by inducing the release of effectors from the stimulated macrophages. Nevertheless, 
the possibility that the TLQP-21 peptide acts directly on neurons could not be firmly 
eliminated, as it is possibly that the process is a calcium independent process, and 
hence was not picked up in our functional assay.  
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The mentioned mediators play important roles in the initiation and/or maintenance of 
neuropathic pain, it is hence our interest to investigate if the expression of these 
mediators are altered in the macrophage upon TLQP-21 stimulation, and if any of 
these mediators are the downstream effectors of TLQP-21 in the macrophages, which 
transduces the signal to specific functions and ultimately alters sensory neuronal 
activity. 
 
To investigate if any of these mediators are involved in the downstream event of 
TLQP-21 in the primary macrophages, I examined the gene expressions of these 
common macrophage mediators following 100nM TLQP-21 stimulation by 
quantitative real-time PCR. In addition, the expression level of the TLQP-21 receptor, 
GC1qR, was also examined in parallel to investigate if the TLQP-21 
positively/negatively regulate the expression of its receptor in the macrophage. 
Specific primers for TNF-α, IL-1β, IL-6, iNOS, BDNF, Arg1, Cox2 and GC1qR were 
designed. The expression level of these mediators, along with housekeeping genes 
β-actin and cyclophilin A, were accessed by qRT-PCR. Three hours treatment was 
selected as the time point for the experiment because it has been demonstrated in the 
literature that the maximal expressions for most of the inflammatory mediators peak 
at about 6 hours (Wollenberg, DeForge et al. 1993, Chacon-Salinas, Serafin-Lopez et 
al. 2005). The cultured macrophages were re-plated to 90mm plates at 1,000,000 cells 
per plate one day prior to treatment. On the day of treatment, the cells were treated 
with either 100nM TLQP-21 or 100nM scrambled TLQP-21 as control for 3 hours, 
followed by total RNA extraction, reverse transcription and qRT-PCR analysis. The 
result was analysed by comparative 2^
- ΔΔCt 
method. The data for each gene after 
TLQP-21/scrambled TLQP-21 was normalised against to the house keeping gene 
(β-actin), and the gene expression after TLQP-21 treatment was normalised to that 
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after scrambled TLQP-21 treatment (expressed as percentage of expression to 
scrambled TLQP-21 treated control). Figure 4.1 shows the expression of house 
keeping gene cyclophilin A is not significantly altered in expression, indicating 
treatment of TLQP-21 and scrambled TLQP-21 did not interfere with normal 
expression of the house keeping genes. Moreover, it was found, rather unexpectedly, 
none of the common inflammatory mediators implicated in the pain pathway were 
significantly altered in expression level. This was found to be consistent with either 
β-actin or cyclophilin A as control.  
 
 
 
Figure 4.1 Result of quantitative Real-Time PCR shows 100nM TLQP-21 did not 
induce a significant change in gene expression of common macrophage inflammatory 
mediators or the GC1qR receptor.  
The expression levels of the characteristic macrophage inflammatory mediators were not 
significantly altered after treating the cells with 100nM TLQP-12 for three hours. Error bars 
presents as standard deviation. 
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Experiment 
1 
Experiment 
2 
Experiment 
3 
Experiment 
4 
Average 
 
Standard 
Deviation 
TNF alpha 87.5 87.9 88.2 74.4 84.5 6.7 
iNOS 120.0 156.2 107.9 146.2 132.6 22.4 
IL1beta 93.7 85.9 77.3 87.4 86.1 6.8 
IL6 92.1 90.8 82.8 99.3 91.3 6.8 
BDNF 103.5 100.8 96.1 undetermined 100.1 3.8 
Arg1 103.8 69.6 91.4 94.1 89.7 14.5 
Cox2 112.1 108.3 98.2 104.3 105.7 5.9 
GC1qR 81.3 92.5 83.3 91.6 87.2 5.7 
Cyclophilin A 104.6 54.4 95.0 56.1 77.5 26.0 
Beta actin 100.0 100.0 100.0 100.0 100.0 0.0 
Table 4.1 Data of the percentage of gene expression after TLQP-21 treatment from the 
four quantitative real-time PCR experiments (expressed as percentage to the scrambled 
TLQP-21 treated control). 
 
4.4.2. Investigation of transcription factors expressions following TLQP-21 
treatment by Transcription factor PCR array. 
 
Macrophages are cells with diverse function. To fulfill these functions, macrophages 
possess the ability to express, produce and release of more than one hundred of 
different soluble substances that subsequently influence diverse functional pathways 
(Pollard 2009). The expressions of these effector substances, or change in the 
expression levels of these substances upon stimulation, are largely dictated by the 
transcription factors control of macrophages. Here, I ask the question if the 
expression levels of the common transcription factors in the primary macrophages 
are altered upon TLQP-21 stimulation. If any of the common transcription factors is 
shown to be dis-regulated in the expression level after TLQP-21 treatment, it will 
enable us to narrow down, and further dissect, the TLQP-21 downstream signalling 
pathway in the macrophages.  
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To achieve this, I utilized the RT² Profiler transcription factor PCR Array 
(PARN-075ZC) to simultaneously perform gene expression analysis of 84 common 
transcription factors, along with 5 house keeping genes (full gene list please refer to 
Table 4.2). The primary macrophages were cultured in serum-free media for 24 
hours prior to the treatment with either vehicle control (same value of water), 
100nM TLQP-21, or 100nM Scrambled TLQP-21. The cells were exposed to the 
treatments for either 30 minutes or 3 hours and the total RNA was immediately 
extracted, followed by reverse transcription for cDNA synthesis. The cDNA was 
used to run the real-time PCR cycling program and the analysis of the array was 
performed (see figure 4.2 for experimental outline).  
 
 
Figure 4. 2 Schematic diagram showing experimental outline of transcription factor 
PCR array experiment. 
 
 
 212 
GeneBank Symbol Gene Name Also known as 
 NM_012502  Ar  Androgen receptor  Andr, Tfm 
 NM_012780  Arnt  Aryl hydrocarbon receptor nuclear translocator  Arnt1 
NM_001100895 Atf1 Activating transcription factor 1 Atf-1 
 NM_031018  Atf2  Activating transcription factor 2  - 
 NM_012912  Atf3  Activating transcription factor 3  LRF-1, LRFI 
 NM_024403  Atf4  Activating transcription factor 4   - 
 NM_012524  Cebpa  CCAAT/enhancer binding protein (C/EBP), alpha  DBPCEP 
 NM_024125  Cebpb  CCAAT/enhancer binding protein (C/EBP), beta  Il6dbp, LAP, NF-IL6, TCF5 
 NM_012831  Cebpg  CCAAT/enhancer binding protein (C/EBP), gamma  C, EBP, CEBPRNA 
NM_001024294  Clasrp  Clk4-associating serine/arginine rich protein  Sfrs16, Srsf16 
 NM_031017  Creb1  CAMP responsive element binding protein 1  Creb 
 NM_133381  Crebbp  CREB binding protein  CBP, RSTS, RTS 
 NM_053357  Ctnnb1  Catenin (cadherin associated protein), beta 1  Catnb 
NM_001011914  Dr1  Down-regulator of transcription 1  - 
NM_001100778  E2f1  E2F transcription factor 1  - 
 XM_233986  E2f6  E2F transcription factor 6  - 
 NM_012551  Egr1  Early growth response 1  Krox-24, NGFI-A, Ngf1, Ngfi 
 NM_012689  Esr1  Estrogen receptor 1  ER-alpha, Esr, RNESTROR 
 NM_012555  Ets1  V-ets erythroblastosis virus E26 oncogene homolog 1   Ets-1, Etsoncb, Tpl1 
NM_001107107  Ets2  V-ets erythroblastosis virus E26 oncogene homolog 2   - 
 NM_022197  Fos  FBJ osteosarcoma oncogene  c-fos 
 NM_012743  Foxa2  Forkhead box A2  Hnf3b 
 NM_012560  Foxg1  Forkhead box G1  BF1A, Fkhl1, RATBF1A 
 NM_012764  Gata1  GATA binding protein 1  Eryf1 
 NM_033442  Gata2  GATA binding protein 2  - 
 NM_133293  Gata3  GATA binding protein 3  - 
 NM_031041  Gtf2b  General transcription factor IIB  - 
NM_001007711  Gtf2f1  General transcription factor IIF, polypeptide 1  MGC94148 
 NM_021592  Hand1  Heart and neural crest derivatives expressed 1  MGC114332, eHand 
 NM_022696  Hand2  Heart and neural crest derivatives expressed 2  - 
NM_001025409  Hdac1  Histone deacetylase 1  - 
 NM_024359  Hif1a 
 Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor)  MOP1 
 NM_012669  Hnf1a  HNF1 homeobox A  HNF1, LF-B1, Lfb1, Tcf1 
 NM_022180  Hnf4a  Hepatocyte nuclear factor 4, alpha  Hnf4, Hnf4alpha 
XM_001059031  Hoxa5  Homeo box A5  - 
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 NM_024393  Hsf1  Heat shock transcription factor 1  - 
 NM_012797  Id1  Inhibitor of DNA binding 1  ID125A, Idb1, MGC156482 
 NM_012591  Irf1  Interferon regulatory factor 1  - 
 NM_021835  Jun  Jun oncogene  - 
 NM_021836  Junb  Jun B proto-oncogene  - 
 NM_138875  Jund  Jun D proto-oncogene  MGC72300 
 NM_145095  Kcnh8 
 Potassium voltage-gated channel, subfamily H (eag-related), member 
8  ELK3, Elk1, Ets-1 
 NM_022210  Max  MYC associated factor X  MGC124611 
NM_001014035  Mef2a  Myocyte enhancer factor 2a  - 
NM_001017507  Mef2b  Myocyte enhancer factor 2B  - 
 XM_574821  Mef2c  Myocyte enhancer factor 2C  RGD1563119 
NM_012603  Myc  Myelocytomatosis oncogene  MGC105490, c-myc, mMyc 
NM_001106783  Myf5  Myogenic factor 5  - 
 NM_176079  Myod1  Myogenic differentiation 1  MGC156574 
NM_001108908  Nanos2  Nanos homolog 2 (Drosophila)  RGD1562436 
NM_001107425  Nfat5  Nuclear factor of activated T-cells 5  Nfat, TonEBP 
NM_001107805  Nfatc2 
 Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 2  - 
NM_001108447  Nfatc3 
 Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 3  NFAT4 
NM_001107264  Nfatc4 
 Nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 4  - 
 XM_342346  Nfkb1  Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1  NF-kB 
 NM_031553  Nfyb  Nuclear transcription factor-Y beta  CBF-B, CBFB, Nfya 
 NM_012576  Nr3c1  Nuclear receptor subfamily 3, group C, member 1  GR, Gcr, Grl 
 NM_013001  Pax6  Paired box 6  - 
NM_001109599 Pou2af1  POU class 2 associating factor 1  - 
 NM_013196  Ppara  Peroxisome proliferator activated receptor alpha  PPAR 
 NM_013124  Pparg  Peroxisome proliferator-activated receptor gamma  - 
 NM_017045  Rb1  Retinoblastoma 1  - 
 XM_223688  Rel  V-rel reticuloendotheliosis viral oncogene homolog   - 
 NM_199267  Rela  V-rel reticuloendotheliosis viral oncogene homolog A  NFkB 
XM_001058445 
RGD1560
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 Similar to nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 1  - 
 NM_013130  Smad1  SMAD family member 1  Madh1 
 NM_019275  Smad4  SMAD family member 4  Madh4 
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 NM_021692  Smad5  SMAD family member 5  Madh5 
 NM_138872  Smad9  SMAD family member 9  Madh9, Smad8 
 NM_012655  Sp1  Sp1 transcription factor  - 
XM_002726189  Sp3  Sp3 transcription factor  - 
 NM_032612  Stat1  Signal transducer and activator of transcription 1  - 
NM_001011905  Stat2  Signal transducer and activator of transcription 2  - 
 NM_012747  Stat3  Signal transducer and activator of transcription 3  MGC93551 
NM_001012226  Stat4  Signal transducer and activator of transcription 4  - 
 NM_017064  Stat5a  Signal transducer and activator of transcription 5A  Stat5 
 NM_022380  Stat5b  Signal transducer and activator of transcription 5B  - 
NM_001044250  Stat6  Signal transducer and activator of transcription 6  - 
NM_001004198  Tbp  TATA box binding protein  MGC93994, TFIID 
XM_001054844  Tcf7l2  Transcription factor 7-like 2 (T-cell specific)  - 
 NM_001107345  Tcfap2a  Transcription factor AP-2, alpha  Tfap2a 
NM_001015020  Tgif1  TGFB-induced factor homeobox 1 
 MGC109104, MGC156525, 
Tfig, Tgif 
 NM_030989  Tp53  Tumor protein p53  MGC112612, Trp53, p53 
 NM_173290  Yy1  YY1 transcription factor  NF-E1, UCRBP 
 NM_031144  Actb  Actin, beta  Actx 
 NM_012512  B2m  Beta-2 microglobulin  - 
 NM_012583  Hprt1  Hypoxanthine phosphoribosyltransferase 1  Hgprtase, Hprt, MGC112554 
 NM_017025  Ldha  Lactate dehydrogenase A  Ldh1 
 NM_001007604  Rplp1  Ribosomal protein, large, P1  MGC72935 
 U26919  RGDC  Rat Genomic DNA Contamination  RGDC 
 SA_00104  RTC  Reverse Transcription Control  RTC 
 SA_00104  RTC  Reverse Transcription Control  RTC 
 SA_00104  RTC  Reverse Transcription Control  RTC 
 SA_00103  PPC  Positive PCR Control  PPC 
 SA_00103  PPC  Positive PCR Control  PPC 
 SA_00103  PPC  Positive PCR Control  PPC 
Table 4. 2 Full gene list for the RT² Profiler transcription factor PCR Array 
(PARN-075ZC). 
A total of 84 common transcription factors were analysised along with 5 house-keeping genes 
(highlighted in orange). Quality controls were monitored at the same time to check for the 
genomic DNA contamination (highlighted in green) and efficiency of the reverse 
transcription (highlighted in blue). Moreover, positive controls were performed (highlighted 
in yellow) to ensure the real-time PCR reaction was at its optimal. 
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Total RNA quality, integrity assessment and quantification.  
 
Although the quantitative real-time PCR array allows easy and reliable analysis of 
the expression of a focused group of genes, the technique is highly sensitive and a 
minute change during the experiment, such as the RNA quality, efficiency of reverse 
transcription and efficiency of the PCR cycling, could greatly affect the final result. 
Thus, the initial total RNA quantification and its quality and integrity were carefully 
assessed prior to the cDNA synthesis. For RNA quantification, the Thermo Scientific 
NanoDropTM ND-1000 spectrophotometer was use. The concentration of the RNA 
(in ng/µl) was measured as well as the 260/280 absorption ratio. The 260/280 ratio 
absorbance indicates the purity of the RNA, a ratio of >2.0 is generally regarded as 
sufficient ‘pure’ for RNA. If such ratio is shown to be lower than 2, it possibly 
indicates that there is protein contamination in the RNA, which absorbs strongly 
near 280nm wavelength. As shown in figure 4.3B, all samples prepared for PCR 
array are at good concentration and the 260/280 absorption ratio are all greater than 
2.0, indicating the total RNA extracted are with good purity.  
 
All samples were then assessed for the RNA integrity using an Agilent RNA Nano 
6000 electrophoresis Labchip
TM
 and Aligent bioanalyser. The ribosomal RNAs 
(rRNAs) comprise more than 90% of the mass of total RNA, and the most abundant 
rRNAs are the 18S rRNA and 28S rRNA. The chip-based nucleic acid analysis 
system performs capillary electrophoresis of the samples along with a reference 
marker in the Agilent 2100 bioanalyser. The two abundant peaks shown in 
electrophoresis result in figure 4.3A (left) are the 18S and 28S rRNAs. The 
electropherograms of the electrophoresis result of each sample was generated (figure 
4.3A right), where sharp single peaks for rRNAs indicate good RNA integrity. The 
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RIN software algorithm of the bioanalyser then analyse the entire electrophoretic 
trace and generates a RNA integrity number (RIN) scoring form 1 to 10. The RIN 
values allows non-subjective interpretation of the RNA integrity from the 
electropherogram, where value10 indicates the RNA is at good purity and 1 suggests 
the RNA is totally degraded. The total RNAs use for sensitive technique such as 
PCR array and microarray generally require RIN values great than 7. As shown in 
the figure 4.3A, the RIN values of all samples prepared are greater than 8.8, 
indicating minimal RNA degradation in these samples and the purity and integrity of 
the total RNAs are at good quality. 
 
3µg of the total RNAs were hence used to synthesise the cDNA using RT
2
 First strand 
reverse transcription kit (SABiosciences, Qiagen). The RT
2
 First strand kit enables 
elimination of genomic DNA, the efficiency of the reverse transcription to be assessed 
and examines if there is enzyme inhibitors contamination in the RNA samples. These 
steps are essential for PCR array quality controls as they could alter the final result 
greatly. The reverse transcription efficiency and enzyme inhibitors contamination are 
tested with a built-in external RNA control. A last quality control was monitored at the 
PCR cycling step where a built-in external cDNA was tested for positive control to 
inspect the PCR efficiency. The Positive PCR Control (PPC) and Reverse 
Transcription Control (RTC) were repeated three times in the array, and the average 
Ct and standard deviation between the three repeats were calculated for both RTC and 
PPC. The PCR reaction reproducibility was assessed by the standard deviation of the 
three repeats. The smaller the standard deviation between three RTC and PPC 
indicates better reproducibility of the reaction. To ensure the PCR array is comparable, 
the standard deviation between RTC and PPC has to fall below 0.1 (0.1 cycle indicates 
about 7% deviation in gene expression between two repeats). As indicated in figure 
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4.4 (panel 1), the standard deviations between the three replica of RTC and PPC are 
lower than 0.8, indicating less than 5% deviation in gene expression between the 
repeats, and hence suggesting good PCR array reproducibility.  
 
The change in Ct valules was calculated between the averaged RTC and PPC, which is 
an arbitrary number to assess the reverse transcription efficiency. The reverse 
transcription efficiency is regarded as good efficiency when the ΔCt (average RTC- 
average PPC) is less or equal to 5. As shown in figure 4.4 (panel 2), the ΔCt (average 
RTC- average PPC) from all samples are less than 3.87, indicating a good efficiency at 
the first strand reverse transcription step. Lastly, the genomic DNA contamination 
was assessed by using genomic DNA specific primers in the PCR array, the Ct value 
of these wells should be undetermined or greater than 35 cycles. In all the samples 
prepared, the genomic DNA contamination controls are greater than 35, indicating 
minimal contamination of genomic DNA in the samples. Thus, all the signal 
amplified and interpreted in the experiment are derived from the first strand cDNA 
amplified from the total RNA. 
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Figure 4.3 RNA integrity and quality validation using Agilent Bioanalyzer and 
NanoDrop spectrophotometer.  
A) The RNA integrity was validated using Agilent RNA nano 6000 chip and Agilent 
Bioanalyzer. The micocapillary electrophoresis was run on the chip (top left) and the two 
28S and 28S ribosomal RNA bands are shown to be visible in all samples. The 
electropherogram traces (right) of all the samples were generated from laser-induced 
fluorescence (LIF) detection of the microcapillary electrophoresis gel. The two peaks for 
18S and 28S ribosomal RNAs are detected as distinct sharp peaks in all the samples, 
indicating good RNA integrity. The RNA integrity number (RIN) scorings of all samples 
were calculated from RIN software algorithm (bottom left), Samples with RIN value greater 
than 7 are considered to possess good RNA integrity. B) The RNA quantification and quality 
were accessed by Thermo Scientific NanoDrop
TM
 ND-1000 spectrophotometer. The 
concentration was highlighted in red column (ng/µl) and the 260/280 ratio of all samples are 
shown to be greater than 2.0, indicating good RNA quality with minimal protein 
contamination in all the samples. 
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Figure 4.4 Quality controls for the PCR arrays. 
1. PCR array reproducibility control 2. Reverse transcription efficiency control 3. 
Genomoc DNA contamination control. 
 
PCR array scatter plot: fold regulation comparison between the treatment and 
control 
 
Following validating quality controls for reverse transcription efficiency, genomic 
DNA contamination and PCR array reproducibility, the gene expression of the 84 
focused panel of transcription factors were analysed. A 2-fold cut off threshold was 
set for the PCR array dada analysis. The changes in the gene in the primary 
macrophages after 30 minutes/3 hours peptide incubation were accessed by 
comparing the gene expression levels between TLQP-21 treatment group and 
scrambled TLQP-21 treated group. As shown in Figure 4.5, none of the 84 genes 
tested were shown to be differentially expressed after 30 minutes of 100nM TLQP-21 
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and 100nM Scrambled TLQP-21 treatment. However, it is shown that the 
transcription factor Nuclear factor of activated T-cells calcineurin-dependent 2 
(Nfatc2) was upregulated by 2.56 folds after TLQP-21 stimulation when compared to 
its expression in the cells treated with scrambled TLQP-21. The raw Ct data of Nfatc2 
in all three groups were listed in Table 4.3. 
 
Although it is shown Nfatc2 transcription factor is upregulated by 2.56 folds after 
TLQP-21 treatment when compared to that treated with scrambled TLQP-21, there 
remains a possibility that the Nfactc2 expression was downregulated by 2.56 folds 
instead after scrambled TLQP-21 treatment, and hence a seemly increased in 
expression was observed when compared TLQP-21 treated cell to scrambled 
TLQP-21 treatment. For this reason, the PCR array data was also analysed against the 
expression in the vehicle control, where equal volume of water was added to the 
culture medium (without peptide). 
 
As indicated in figure 4.6, it was found that the scrambled peptide showed no 
differential expression after 30 minutes treatment when compared to the vehicle 
control (figure 4.6A), and Nfatc2 was, in fact, down-regulated after 3 hours of 
scrambled peptide treatment (figure 4.6B). The Nfatc2 expression after 3 hours of 
wild type TLQP-21 peptide treatment was, on the other hand, not differentially 
expressed when compared to the vehicle control (figure 4.6B). In addition, GATA 
binding protein 2 (GATA2) was demonstrated to be downregulated by 2.43 and 2.69 
folds after 30 minutes and 3 hours stimulations with TLQP-21, respectively. The raw 
data of the Ct value of GATA2 expressions in all three conditions were listed in the 
table 4.3. 
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Figure 4.5 Transcription factors PCR array data shows only one gene expression level is 
altered after 3 hours TLQP-21 treatment when compared to that of scrambled 
TLQP-21 group. 
The raw Ct data from the PCR array experiments were analysed using a 2-fold threshold with 
2^
=ΔΔCt
 comparative expression analysis method. The analysed data is represented in scatter 
plots showing the boundary line of 2-fold cut off from the scrambled TLQP-21 treated group 
(control). Genes with more than 2 folds increases in the expression relative to the control fall 
into the up-left area of the scatter plot. On the other hand, genes with more than 2 folds 
decreases in the expression relative to the control fall into the bottom right area of the scatter 
plot. For the genes that are not differentially expressed between the treatment and control (i.e. 
expression differences are less than 2 folds), they are represented within the two boundary 
lines along the diagonal line. The genes expressions of all 84 genes tested are not 
differentially expressed after 30 minutes TLQP-21 treatment and scrambled TLQP-21 
treatment (left scatter plot) and Nfatc2 is upreguated by 2.56 folds after 3 hours of TLQP-21 
treatment relative to the control.  
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Figure 4.6 Transcription factors PCR array data of changes in gene expressions after 
TLQP-21/Scrambled TLQP-21 treatment when compared to the expression in the 
vehicle control. 
The scatter plots show only one gene, Gata2, expression level is down-regulated after 30 
minute TLQP-21 treatment relative to the vehicle control, which remains at lower expression 
in the 3 hours TLQP-21 treatment condition. Nfatc2 is shown to be down-regulated after 3 
hours treatment with scrambled TLQP-21, and no gene is shown to be differentially expressed 
relative to vehicle control after 30 minutes of scrambled peptide treatment. 
 
Gene 
symbol 
Vehicle 
30mins 
TLQP-21 
30mins 
Scrambled-TLQP-
21 30mins 
Vehicle 
3hours 
TLQP-21 
3hours 
Scrambled 
TLQP-21 3hours 
   Nfatc2 32.10 31.66 31.83 32.07 32.61 34.09 
   Gata2 33.32 34.76 33.97 33.73 34.93 34.80 
Table 4.3 Raw Ct data for Nfatc2 and Gata2 in all 6 arrays. 
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4.4.3. Microarray: high-throughput assessment of gene expression changes in 
the primary macrophages upon TLQP-21 stimulation. 
 
In order to expend our investigation of TLQP-21 downstream signalling pathway and 
examine if TLQP-21 stimulation affected the expression of specific genes in the 
primary macrophages, whole-genome expression analysis was carried out in triplicate 
for primary macrophages treated with scrambled TLQP-21 and TLQP-21. In order to 
catch the changes of immediate early genes and late response genes, three time points 
were selected for the treatments, 30 minutes, 3 hours and 24hours, to cover a wider 
range of treatment time. It was observed during the incubation period, the 
macrophages treated with wild type TLQP-21 peptide drastically change the 
morphology after 12 hours of incubation. The morphology of the cultured primary 
macrophage changed from irregular ramified ‘resting’ shape into a more elongated 
morphology with long processes (figure 4.7). This indicates that the downstream 
signalling of TLQP-21 induces a morphological change to the primary macrophage, 
possibly to adapt for its functional outcome.  
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Figure 4.7 Representative pictures in bright field of primary macrophages treated with 
either Scrambled TLQP-21 or TLQP-21 for 12 hours. 
The primary macrophages were treated with 100nM of either scrambled TLQP-21 or wild type 
TLQP-21. It is observed after long incubation with the wild type peptide, the morphology of the 
primary macrophages changed to a more elongated morphology (top) from the usual ramified 
shape in the resting state. The cells treated with scrambled peptide, however, retained the 
ramified cell morphology (bottom). 
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After treating the cells with TLQP-21/Scrambled TLQP-21 for corresponding 
incubation time, the total RNA was extracted from the cells using Qiagen RNAeasy 
extraction kit. The quality control of RNA was performed by commercial company 
AROS, using Bioconductor QualityMetrics array, where no significant outliners 
were detected. The Affymetrix RG230.2 arrays were used for microarray analysis, 
and the differential gene expression analysis of the raw microarray data was 
performed by AROS. Briefly, the raw data was first normalised to the corresponding 
control by robust multi-array analysis (RMA) package (bioconductor), and the data 
were pre-filtered to remove probes that had little variation across all arrays. This 
decreases the number of probes taken forward into the differential analysis step and 
increases the sensitivity for identifying probe sets that significantly altered in 
expression.  
 
To perform the differential analysis, a less stringent direct modeling of the batch 
structure with removeBatchEffect function was performed using the linear model in 
Limma package from Bioconductor. The contrast of interest was formulated to 
compare TLQP-21 treated sample versus its corresponding Scrambled TLQP-21 
treated controls. Figure 4.8 shows the numbers of differential expressed genes in the 
primary macrophages after 30 minutes, 3hours and 24 hours TLQP-21 treatments 
compared to their corresponding Scrambled TLQP-21 treated controls. It was found 
that 22, 5 and 19 genes were significantly down-regulated (p<0.01) after 30 minutes, 
3 hours and 24 hours TLQP-21 treatments, respectively, compared to the 
corresponding scrambled peptide treated controls. In addition, 12, 15 and 25 genes 
were significantly up-regulated (p<0.01) in the 30 minutes, 3 hours and 24 hours 
TLQP-21 treatment group, respectively, compared to the corresponding controls 
treated with same concentration of scrambled TLQP-21. Table A.1, Table A.2 and 
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Table A.3 (see appendix) show the summary of all the differentially expressed genes 
with an uncorrected p-value cutoff of <0.01 for 39 minutes, 3 hours and 24 hours 
treatments, respectively. 
 
 
 
TLQP-21 vs. Scrambled-TLQP-21 
 
30 minutes 3 hours 24hours 
Number of genes down-regulated 22 5 19 
Number of genes with no change in expression 9825 9839 9815 
Number of genes Up-regulated 12 15 25 
Figure 4.8 Number of genes differentially/constantly expressed after 30 minutes, 3 hours 
and 24 hours of TLQP-21 stimulation relative to that treated with same concentration 
of Scrambled TLQP-21. 
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4.5. Discussion 
 
4.5.1. TLQP-21 peptide treatment and the differential gene expression analysis 
by qRT-PCR, PCR array and Microarray. 
 
Having demonstrated in the previous chapters that TLQP-21 acts on the primary 
macrophage in a dose-dependent and calcium-dependent manner, macrophages are 
desensitised to multiple TLQP-21 treatments, and the signalling of TLQP-21 on the 
primary macrophages are, at least partly, via the potential receptor GC1qR, several 
attempts were made in this chapters to elucidate the subsequent downstream 
signalling event in the primary macrophages upon TLQP-21 stimulation. 
 
The first strategy to investigate the downstream signalling event after 
TLQP-21-induced calcium response employed the qRT-PCR to investigate the change 
in expression of the common pro-inflammatory mediators and the receptor. It is 
evident in the literature that the change in the intracellular calcium level is associated 
with the macrophage activation (Petricevich, Reynaud et al. 2008, Kelly, Wang et al. 
2010). In addition, the activation of another lineage of macrophage in the brain, 
microglia, has also been coupled downstream to the calcium signalling (Hoffmann, 
Kann et al. 2003). The subsequent signalling event after the initial calcium response 
often results in the release of the pro-inflammatory mediators and ultimately leading 
to the changes in the corresponding gene expressions, which have been evident to 
peak between 2-6 hours (Wollenberg, DeForge et al. 1993, Brown, Donaldson et al. 
2004, Chacon-Salinas, Serafin-Lopez et al. 2005). Using these as guidance, the 
downstream signalling event of TLQP-21 was first investigated by qRT-PCR as a 
preliminary investigation. Based on the assumption that the maximal 
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pro-inflammatory mediators gene expression levels could be reached after 3 hours 
exposure to TLQP-21 and the scrambled TLQP-21 control peptide would not 
non-specifically elicit the same response as the wild type, the primary macrophage 
cultures were stimulated for 3 hours with either 100nM scrambled TLQP-21 or wild 
type TLQP-21. The gene expression changes of the common pro-inflammatory 
mediators produced from the macrophages were assessed subsequently using 
qRT-PCR.  
 
For all the primer sets designed for the qRT-PCR experiment (TNF-α, IL-1β, IL-6, 
iNOS, BDNF, Arg1, Cox2 and GC1qR), none of the gene was shown to be 
significantly dis-regulated after 3 hours treatment of 100nM TLQP-21 versus 100nM 
scrambled TLQP-21 treatment. There could be a number of reasons for the absence in 
gene expression alteration. The first reasons could simply be that the target genes 
investigated here were indeed not involved in the downstream signalling event of 
TLQP-21 in the macrophages, and hence the changes in gene expressions were not 
observed after TLQP-21 stimulation. The targets that investigated here are mainly the 
pro-inflammatory mediators secreted by M1 subtype of macrophages. While there are 
other different subtype classifications, it is possible that the TLQP-21 downstream 
signalling event is different from the classical M1 signalling pathway. Indeed, it has 
been demonstrated that different subtype of macrophages often gave rise to a 
subtype-specific increase in expression of genes and different stimuli could elicit 
different subtype macrophage responses (Shalhoub, Falck-Hansen et al. 2011, Engler, 
Robinson et al. 2012). It is also possible that TLQP-21-induced response is not as 
robust as other stimuli, such as LPS, which leads to immense up-regulations of 
various pro-inflammatory effectors. The possibility that TLQP-21, as an endogenous 
neuropeptide, may induce a more subtle response, which requires a longer stimulation 
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time, still remains to be further evaluated and cannot be exclusively eliminated. 
Future experiments could be carried out to optimise for longer time points of 
TLQP-21 stimulation. Furthermore, there is also a possibility that macrophages may 
adapt to some immediate physiological responses, such as chemotactic response and 
increase/inhibit in proliferation, instead of being pro-inflammatory activated. Thus, 
the changes in expression of the pro-inflammatory mediators were absent. Future 
experiments could be carried out to investigate the chemotactic effect of TLQP-21 on 
the primary macrophage using techniques such as Boyden chamber assay, and the 
proliferative/anti-proliferative effect of TLQP-21 can also be further assessed.  
To understanding the downstream signalling pathway following the TLQP-21 
stimulated calcium response in the macrophage better, a high throughput PCR array 
technique was employed to investigate the changes in transcription factor expression. 
Only one out of the 84 transcription factors tested in the array was dis-regulated after 
3-hours TLQP-21 treatment when compared to the corresponding scrambled peptide 
treated control. It was shown that the expression of Nfatc2 in the sample treated with 
100nM TLQP-21 for 3 hours was 2.56 folds higher than that treated with 100nM 
scrambled peptide control. 2.56 folds higher expression could equally mean there was 
a 2.56 folds up-regulation in Nfatc2 after 3 hours of TLQP-21 treatment, or a 2.56 
folds down-regulation in Nfatc2 in the 3 hours scrambled peptide treated group. 
Indeed, the raw Ct value indicates that the Nfatc2 expression was similar in the 
vehicle control (32.07) and TLQP-21 treated sample (32.61), whereas the Ct value 
altered after scrambled TLQP-21 treatment to 34.09, indicating a down-regulation of 
gene expression after scrambled peptide 3 hours treatment. This suggests that the 
scrambled peptide could potentially elicit non-specific effects, therefore, comparisons 
of the differential expression between treatment groups to the vehicle control was 
hence important. When comparing to the vehicle control, Gata2 was the gene shown 
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to be down-regulated by 2.43 and 2.69 folds after 30 minutes and 3 hours of TLQP-21 
treatments, respectively. However, the Ct value for this gene is very high (between 33 
- 34), which is very close to the default value (35) set for undetermined gene, and it 
indicates the gene was expressed at very low level even before the treatment, and was 
not further investigated. Here, the transcription PCR array was not particularly 
successful in identifying potential transcription factors downstream to the TLQP-21 
signalling in the primary macrophages. The first possible reason for this could be that 
TLQP-21 may not change in an alternation in the transcription factors gene 
expressions, instead, it could alters the transcription factor activity at the epigenetic 
levels. Post translational modifications of the transcription factors has been shown to 
modulate the transcription factor activity significantly (Gill 2003, Saxe, Tomilin et al. 
2009), and hence it is plausible that though the transcription factor expression level 
was not changed, the activity of the transcription factors was in fact altered after 
TLQP-21 stimulation. Moreover, the PCR array monitored the changes in expression 
at the mRNA level. The mRNA expression level in the cell may not always 
correspond to the level of protein expression. Therefore, it is still possible that the 
protein expression was altered while the mRNA expression remains at similar level, 
and hence the change in protein expression, which ultimately affects function, was not 
picked up in the functional assay used in this experiment. 
 
Since the first microarray that has been employed (Schena, Shalon et al. 1995), a lot of 
experiments started to utilise this technique for investigating the disregulations of 
genes in a genome wide level. This technique was also employed in this chapter in 
hope to better understand the downstream signalling event of TLQP-21 in the primary 
macrophages. The primary macrophages cultures were treated with wild type 
TLQP-21/Scrambled TLQP-21 for 0 minutes, 30 minutes, 3 hours or 24 hours and the 
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differential gene expression was assessed by Affymetrix RG230.2 arrays. Small 
changes in the microarray experiments could easily be interpreted as expression 
changes. Due to the sensitivity of the microarray technique and eliminating the 
chance for negative-positive findings, the biological replicates are essential for 
reliable and reproducible result to be obtained. Each treatment at all time points 
were hence repeated three times in order to enable a more reliable and conclusive 
result to be drawn. The differential expressions of genes were first analysed using 
Limma’s empirical Bayes moderated t-test with an FDR corrected cutoff <0.05 
(performed by Neusentis). It was shown the down-regulation of E2f8 after 24 hours 
of TLQP-21 treatment when compared to time 0 control was the only significant 
result. The reason why the batch correlated analysis showed such low number of 
gene was differentially expressed could be due to that the macrophages were 
differentiated from the bone marrow stem cells. M-CSF that used to drive 
macrophage differentiation could differ from batch to batch when purchased. 
Therefore, the differentiated macrophages in different experimental replicates were 
not identical, and hence the endogenous expression of genes could differ from batch 
to batch. This varying in the background expression before stimulation makes the 
induced gene expressional changes inconsistent and the result interpretation 
difficult. Nevertheless, the result derived using a relaxed stringency with an 
uncorrected p-value cutoff of <0.01 showed that there were 46 and 52 genes 
up-regulated and down-regulated in gene expression (all time points combined), 
respectively, after TLQP-21 treatment when compared to scrambled peptide 
treatment group.  
 
A significant morphological change was noticed after long incubation with TLQP-21 
compared to that treated with scrambled peptide and time 0 control. As observed 
 232 
under the inverted microscope, ramified resting morphology with occasional short 
process was the typical feature of the cultured primary macrophages without 
treatment. The short processes were exhibited in the macrophages mainly to allow 
dynamic surveying their microenvironment and allow movements. This morphology 
was retained during the course of scrambled TLQP-21 peptide treatment (up to 24 
hours). After treatment with TLQP-21 (at least at the 12 hours time point observed), 
the macrophages changed morphology to an elongated shape with bipolar processes. 
This result is intriguing, as change in the macrophage morphology has been shown 
to associate with its activation (Vereyken, Heijnen et al. 2011). The classical 
activated macrophages are often associated with a flattened and rounded amoeboid 
shape, which is distinctive from the stretched and elongated rod-shape of alternative 
activated macrophages (Vereyken, Heijnen et al. 2011). The observed macrophage 
morphology after TLQP-21 treatment was related closer to the alternative activated 
macrophage shape, in terms of the cell body was elongated and not amoeboid in 
shape. However, the morphology was not completely identical to the alternative 
activated macrophage because of the almost neurite-like long, thin bipolar processes. 
Though thin processes were frequently observed in the alternative macrophages, 
they are often not bipolar (i.e. multiple processes could often be observed in a single 
cell). The distinctive neurite-like, long thin bipolar processes in the macrophage 
treated with TLQP-21 could be closely related to its functional outcome, just as the 
amoeboid shape of classical activated macrophage has been associated to the 
increase in phagocytosis activity and the elongated shape of alternative activated 
macrophage to an increase in chemotactic activity (Vereyken, Heijnen et al. 2011). 
The morphology observed after TLQP-21 treatment seems to resemble the 
morphology of the macrophage lacking GTPase-activating proteins, Abr and Bcr 
(Cho, Cunnick et al. 2007). It was demonstrated by Cho et al. that macrophages 
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lacking both Abr and Bcr exhibited an elongated morphology with distinctive 
neurite-like long ends. This morphology can be reproduced by overexpression of 
Abr and Bcr mutants lacking the GTPase-ativating protein domain and continuously 
activating Rac in the primary macrophages (Cho, Cunnick et al. 2007). Due to the 
large extent in the morphological change similarity, it could be possible that 
TLQP-21 stimulation in primary macrophages leads to a sustained Rac activation, 
which subsequently signal downstream to exert ultimate functions. However, this 
hypothesis still awaits to be tested. 
 
In the next session, I briefly review the functional relevance of a few interesting genes 
that have shown to be significantly differentially expressed following TLQP-21 
treatment in the macrophages from the microarray experiment. Some of these genes 
are highlighted here due to its previous implication in the pain pathway and others are 
examined here to offer novel perspective of TLQP-21 signalling in the macrophage 
and suggestion for their potential roles underlying TLQP-21 signalling mechanism. 
 
4.5.2. Candidate genes for TLQP-21 downstream signalling events 
 
Interleukin-18 (IL-18, upregulated by 2.16 folds at 3 hours time point) 
 
Interleukin-18 (IL-18), was first known as interferon-γ inducing factor, is a small 
cytokine belongs to the Interleukin-1 (IL-1) superfamily, which is closely related to 
IL-1β (Okamura, Tsutsi et al. 1995). The nucleotide sequence of murine IL-18 is 582 
bp in length, encodes for a192 amino acids precursor protein, which is processed to 
form a mature protein of 157 amino acids. Murine and human homologues of the 
IL-18 protein were cloned and revealed to share 65% homology in sequence (Ushio, 
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Namba et al. 1996). The expression of IL-18 has been evident in a number of cell 
types including macrophages (Kim, Talanian et al. 1998), microglia (Prinz and 
Hanisch 1999), dendritic cells (Stoll, Jonuleit et al. 1998), kupffer cells (Matsui, 
Yoshimoto et al. 1997), keratinocytes (Stoll, Muller et al. 1997), osteoblasts 
(Udagawa, Horwood et al. 1997), astrocytes (Conti, Park et al. 1999) and intestinal 
epithelial cells (Pizarro, Michie et al. 1999).  
 
The activity of IL-18 is transduced via an IL-18 receptor (IL-18R) complex, which 
is comprised of a binding chain, IL-18Rα, and a signalling chain, IL-18Rβ. Both the 
binding chain and signalling chain of IL-18R are required for IL-18 signalling (Born, 
Thomassen et al. 1998). Upon binding of IL18 to IL-18Rα on the target cells, 
IL-18Rβ is engaged to form a high-affinity complex, which recruits IL-1 
receptor-related protein-activating kinase (IRAK) and Tumer necrosis factor 
receptor-associated fator-6 (TRAF-6) that subsequently phosphorylate nuclear factor 
kappa B (NFκB)-inducing kinase (NIK), leading to an ultimate activation of NFκB 
(Dinarello 1999).  
 
IL-18 has been demonstrated to function as a pro-inflammatory cytokine and exerts 
physiological roles in a variety of immunomodulatory activities (Biet, Locht et al. 
2002), which include host defences against several of infections. Indeed, IL-18 has 
been evident to play an essential role in fighting viral (Fujioka, Akazawa et al. 1999, 
Choi, Dinarello et al. 2001), bacterial (Bohn, Sing et al. 1998, Mastroeni, Clare et al. 
1999), fungal (Kawakami, Qureshi et al. 1997, Qureshi, Zhang et al. 1999) and 
protozoa (Meyer Zum Buschenfelde, Cramer et al. 1997) infections via induction of 
host-derived interferon-γ, which subsequently activate clearance of foreign antigen 
by involving molecules such as nitric oxide. Apart from its physiological role, IL-18 
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has also been associated to induce several inflammatory disorders and their disease 
progression, which includes the rheumatoid arthritis (Tanaka, Harigai et al. 2001, 
Yamamura, Kawashima et al. 2001), multiple sclerosis (Wildbaum, Youssef et al. 
1998, Balashov, Rottman et al. 1999), and inflammatory bowel disease (Furuya, 
Yagihashi et al. 2002, Ishikura, Kanai et al. 2003) especially the Crohn’s disease 
(Monteleone, Trapasso et al. 1999, Kanai, Uraushihara et al. 2003, te Velde, van 
Kooyk et al. 2003).  
 
A role of IL-18 in the pain pathway has also been suggested. It was demonstrated 
that intraplantar injection of IL-18 results in a dose- and time-dependent peripheral 
mechanical hypersensitivity in naïve mice (Verri, Cunha et al. 2007). In addition, 
intrathecal injection of IL-18 activates microglia and astrocytes in the spinal dorsal 
horn and results in the mechanical allodynia in the naïve rats, via a NFκB dependent 
pathway (Miyoshi, Obata et al. 2008). In the context of neuropathic pain, IL-18 and 
its receptor has been evident to be up-regulated in expression in the spinal dorsal 
horn after L5 spinal nerve ligation (Miyoshi, Obata et al. 2008). The increase 
expression of IL-18 was shown to be in the activated microglia and that of IL-18R in 
the astrocytes, which peaks at 3 days and 7 days post-operation, respectively. 
Moreover, the IL-18 and IL-18R neutralising antibodies, which block the IL-18 
signalling following the nerve injury, results in a reversal in the nerve injury-induced 
mechanical allodynia (Miyoshi, Obata et al. 2008). At the periphery, IL-18 
expression was low in the sciatic nerve of the naïve animal, which is dramatically 
increased after sciatic nerve injury (Menge, Jander et al. 2001). The increase in 
IL-18 expression after the peripheral nerve injury was resulted from the strong 
increased in IL-18 expression level in the infiltrated macrophages at the injured site 
(Menge, Jander et al. 2001). Together, IL-18 expression has been suggested to be 
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up-regulated, both centrally and peripherally, after nerve injury and both central and 
peripheral injection of IL-18 results in nociceptive behaviours in the naïve animals. 
Thus, the proinflammatory cytokine IL-18 may plays pivotal roles, both centrally 
and peripherally, in the initiation and/or maintenance of the neuropathic pain. 
 
CD40 molecule, TNF receptor superfamily member 5 (CD40, upregulated by 1.58 
folds at 30 minutes time point) 
 
CD40 molecule belongs to the tumour necrosis factor receptor superfamily because 
of its homology with the TNF receptor (Smith, Farrah et al. 1994). It is an 
ubiquitously expressed type I transmembrane protein that is shown to be expressed 
on a various of cell types including macrophage, basophils, eosinophils, dendritic 
cells, fibroblasts and B and T lymphocytes (Schonbeck and Libby 2001). CD40 
binds to its trimeric ligand CD40L, also known as GP39 or CD154, and 
subsequently triggers complex downstream signalling cascade involving activation 
of multiple pathways including the NFκB (Pype, Declercq et al. 2000), 
phosphatidylinositol 3-kinase (PI3K) (Deregibus, Buttiglieri et al. 2003) and signal 
transducers and activators of transcription-3 (STAT3)(Ahmed-Choudhury, Williams 
et al. 2006).  
 
The first documented biological function of CD40 upon CD40L binding is the 
immunoglobulin synthesis and DNA recombination by the B cells (Zan, Cerutti et al. 
1998). Since the advance in the understanding of the CD40 functional role, it was 
also evident that CD40/CD40L signalling results in release of proinflammatory 
cytokines in a number of cells type and subsequently contribute to inflammation. 
Indeed, the CD40/CD40L interaction was shown to induce production of various 
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cytokines including IL-8, IL-12, TNF-α and macrophage inflammatory protein 
(MIP)-1α in the dendritic cells (Caux, Massacrier et al. 1994, Cella, Scheidegger et 
al. 1996). In addition, ligation of CD40 on monocytes has been shown to induce 
secretion of IL-1β, IL-6, IL-8, IL10 TNF- α and MIP-1α (Grewal and Flavell 1998). 
Furthermore, CD40 and CD40L interaction signals to activate macrophages 
(Andrade, Portillo et al. 2005) and is essential for the subsequent nitric oxide (NO) 
and IL-12 production by macrophages (Imaizumi, Kawabe et al. 1999, Reichmann, 
Walker et al. 2000).  
 
Aberrant expression of CD40 has been associated in multiple sclerosis, in which the 
majority of CD40 positive and CD154 positive cells found in the brains of MS 
patients were macrophage/microglia/B cells and CD4+ T cells, respectively, and 
interfering the interactions between CD40 and CD40L was suggested to disrupt MS 
disease progression (Gerritse, Laman et al. 1996). CD40 signalling has also been 
reported to play a pivotal role in another autoimmune inflammatory disease, 
rheumatoid arthritis (RA). It was demonstrated that activating CD40 in the synovial 
cells from RA patients resulted in elevated expression of IL-1α, IL-1β and TNF-α, 
which in turn exacerbate the synovial inflammation in RA (Harigai, Hara et al. 
2004) 
 
CD40 has been implicated in the neuropathic pain. CD40-CD40L interaction 
between microglia and CD4+ lymphocytes has been evident to be pivotal for the 
cell-to-cell communication (Grace, Rolan et al. 2011), and the microglial CD40 is 
essential in maintenance of mechanical hypersensitivity in the spinal nerve L5 
transection model of neuropathic pain (Cao, Palmer et al. 2009). It was shown in the 
study that CD40 knock out mice exhibited less mechanical hypersensitivity 
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compared to the wild type mice that underwent the surgery on post-operative day 5 
(Cao, Palmer et al. 2009). It was later demonstrated that CCL2 production and the 
increase in CGRP expression that is often observed after nerve injury was reduced in 
the CD40 knock out animal underwent spinal nerve L5 transection compared to the 
wild type. It was hence suggested the microglial CD40 may contribute to the onset 
and maintenance of neuropathic pain after spinal nerve transection injury through an 
increase in CGRP expression and CCL2 synthesis (Malon, Maddula et al. 2011). 
 
Transforming growth factor β3 (Tfgb3, downregulated by 2.08 folds at 30 minutes 
time point) 
 
Transforming growth factor β3 (TGF-β3) is an anti-inflammatory cytokine belongs 
to the transforming growth factor β superfamily, which is comprised from the 
TGF-βs, bone morphogenetic proteins (BMPs), growth and differentiation factors 
(GDFs), inhibins and activins (Herpin, Lelong et al. 2004). TGF-βs are one of the 
most versatile cytokines, which are involved in a variety of cellular events in the 
development, maintenance of homeostasis and disease ((Kingsley 1994, Unsicker 
and Krieglstein 2002)). There are three mammalian TGF-β isoforms, TGF-β1, 
TGF-β2 and TGF-β3. Although little information is available about TGF-β3, it is 
evident to be expressed in a variety of cells including macrophage, dorsal root 
ganglionic neurons, Satellite cells and Schwann cells (Unsicker, Flanders et al. 1991, 
Bottoms, Howell et al. 2010).  
 
TGF-β3 binds to its receptors, type I/II/III TGF-β receptors, with high affinity to 
exert its physiological functions. Binding of TGF-β3 to the Type I and II TGF-β 
receptors induce receptors assembly into a heteromeric complex, which is comprised 
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of two TGF-β type I and two TGF-β type II receptors. Upon activation, type II 
TGF-β receptors phosphorylate the type I TGF-β receptors, and such 
phosphorylation is essential for subsequent TGF-β signalling (ten Dijke and Hill 
2004). Unlike Type 1 and type II TGF-β receptors are the integral transmembrane 
proteins, type III TGF-β receptor is an extracellular proteins that has been suggested 
to act as a negative regulator of TGF-β signalling (Chu, Li et al. 2011). The TGF-β 
receptors induced downstream signalling pathway can be receptor-regulated Smads 
(R-Smads) dependent (Schmierer and Hill 2007) or non-Smad dependent signalling 
(Aomatsu, Arao et al. 2011).  
 
Functionally, TGF-β3 has been shown to play an important role involved in wound 
healing and cutaneous scarring and has been suggested to be an anti-scarring agent 
(Shah, Foreman et al. 1995). Moreover, it is shown to exhibit anti-inflammatory 
effect and slow the progression of intervertebral disks degeneration in vitro 
(Tramullas, Lantero et al. 2010, Abbott, Purmessur et al. 2013). Furthermore, it has 
also been suggested to act as a negative regulator in the pain pathway. Indeed, it was 
demonstrated that increasing the TGF-β signalling in the transgenic mice by 
depleting TGF-β negative regulator, bone morphogenetic protein and activin 
membrane-bound inhibitors (BAMBI), results in reduction in acute pain to the 
thermal, mechanical, and chemical stimuli (Tramullas, Lantero et al. 2010). In the 
context of neuropathic pain, it was evident that the mechanical allodynia was 
attenuated when TGF-β signalling was enhanced by knocking out its corresponding 
negative regulator (Tramullas, Lantero et al. 2010), and the δ-opioid receptor 
signalling pathway had been suggested to be the attenuation mechanism.  
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Chloride channel, voltage-sensitive 7 (Clcn7, downregulated by 1.98 folds at 24 
hours time point) 
 
Chloride channel, voltage-sensitive 7 (ClC7) is a member of the voltage-gated 
chloride channels family (ClCs). To date, there are 9 members in the ClCs family 
and they can be divided into two groups depending on their subcellular localisations 
and functions: Plasma membrane expression (ClCKa, ClCKb, ClC1 and ClC2 ion 
channels) and intracellular organelle expression (ClC3-7 proton-coupled chloride 
transporters) (Graves, Curran et al. 2008). 
 
Lysosomes are the cellular organelles harbouring hydrolytic enzymes that are 
important for breaking down cellular debris and unwanted materials in the cells. 
Efficient acidification of lysosomes and maintaining low luminal pH are crucial for 
effective function, as the hydrolytic enzymes are activated by the acidic pH (~ pH4.5). 
The acidification of the lysosomes is largely mediated by V-type protein ATPases that 
metabolise ATP and actively transport protons into the lysosome lumens. ClC7 has 
been evident to play a crucial role in balancing the transmembrane voltage generated 
during the process for net pumping to occur (Mindell 2012). CIC7 deficient mice 
was shown to display severe lysosomal diseases, neurodegeneration in the nervous 
system and died within 7 weeks (Kornak, Kasper et al. 2001). In addition, failure to 
acidify the lysosome due to ClC7 disruption has also been associated with human 
disease such as Alzheimer’s (Majumdar, Capetillo-Zarate et al. 2011).  
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Prokineticin receptor 2 (Prokr2, downregulated by 1.93 folds at 30 minutes time 
point) 
 
Prokinetcin receptor 2 is a G-protein coupled receptor which binds to secreted 
proteins, prokineticins (Lin, Bullock et al. 2002). Human mutations in Prokineticin 
receptor 2 and its ligand has been associated with Kallmann syndrome (Dode, 
Teixeira et al. 2006, Sinisi, Asci et al. 2008, Sarfati, Guiochon-Mantel et al. 2010), 
which is characterised by failure to commence or delayed puberty. To date, two 
subtypes of Prokinetcin receptor have been identified, Prokineticin receptor 1 and 
Prokinetcin receptor 2, which share 85% sequence homology with a higher sequence 
conservation at the C terminus (Kaser, Winklmayr et al. 2003). The prokineticin 
receptor 2 is expressed in neurons of the central nervous system, peripheral nervous 
system and the immune cells including macrophages (Martucci, Franchi et al. 2006, 
Negri, Lattanzi et al. 2009). Intriguingly, most of the dorsal root ganglion neurons 
expressing prokineticin receptors also co-express transient receptor potential 
vanilloid receptor-1 (TRPV1) (Hu, Zhang et al. 2006). 
 
Prokinetcin receptors bind to Gq, Gi and Gs and subsequently evoke a number of 
different cellular responses. Indeed, activation of prokineticin receptors has been 
shown to couple to Gq protein and subsequently stimulate an intracellular calcium 
response. The Prokineticin receptor 2 exhibit different affinities for its nature ligands 
(Prokineticin-2 > Prokineticin-1 > Prokineticin 2-ß) and the binding of different 
ligands dictates the potency of its subsequent calcium response (Chen, Kuei et al. 
2005). Moreover, prokineticin receptors activation has also been shown to induce 
downstream phosphorylation of the p44/p42 mitogen-activated protein kinase 
(MAPK) and increase the Akt phosphorylation by coupling to Gi proteins (Chen, 
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Kuei et al. 2005, Keramidas, Faudot et al. 2008) Furthermore, activated Prokineticin 
receptors are suggested to induce cAMP accumulation possibly via Gs 
protein-mediated signalling(Chen, Kuei et al. 2005) .  
 
Prokinetcin receptor 2 exhibits the highest affinity to Prokineticin 2 (PROK2) among 
all of its nature ligands. PROK2 has been heavily implicated in the pain pathway and 
is suggested to be an inflammatory cytokine-like molecule. Indeed, mice injected with 
PROK2 at the intraplantar surface showed hyperalgesia to thermal nociceptive stimuli. 
In addition, PROK2 knock out mice exhibits impaired pain sensation to the thermal 
and chemical noxious stimuli without affecting the inflammatory response to 
capsaicin (Watson, Lilley et al. 2012). Since many sensory neurons that express 
Prokineticin receptors also express TRPV1, it was thus suggested that TRPV1 may 
plays a role in the PROK2 signalling downstream to Prokineticin receptors, leading to 
the nociceptor sensitisation without affecting the inflammatory response (Watson, 
Lilley et al. 2012). 
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CHAPTER 5: 
GENERAL DISCUSSION AND CONCLUSION 
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5.1. Discussion 
 
Neuropathic pain remains a major clinical challenge, severely afflicting up to 8% of 
the adult population in the UK (England, Wagner et al. 2011). Unlike acute pain that is 
often relieved after the primary cause has been resolved, neuropathic pain usually 
remains as a life-long condition and can greatly affect patients’ quality of life. In 
addition, the lack of effective therapeutic treatment for neuropathic pain, largely due 
to the fact that the underlying mechanism is incompletely understood, hinders the 
effective management of persistent neuropathic pain. 
 
In the hope to identify the targets for better neuropathic pain analgesic development, 
there is a growing interest in the field of pain research in the recent years attempting to 
identify the ‘common’ gene that is dis-regulated in the sensory neurons in different 
animal models of neuropathic pain. As a result of this, vgf was found to be one of the 
common genes that were up-regulated among different models by different research 
groups independently. It was found to be upregulated in a number of experimental 
nerve injury models of neuropathic pain (Costigan, Befort et al. 2002, Wang, Sun et al. 
2002, Valder, Liu et al. 2003, Maratou, Wallace et al. 2009, Riedl, Braun et al. 2009) 
and also the disease-induced neuropathy models of neuropathic pain (Maratou, 
Wallace et al. 2009). vgf was shown to be commonly up-regulated in at least 6 
different animal models of neuropathic pain, it is hence hypothesised that VGF may 
play an important role in initiating and/or maintenance of neuropathic pain, rather 
than involved in the pathophysiological responses to a nerve lesion. Indeed, there is 
growing evidence in the literature which implicates the VGF-derived peptides in roles 
in the pain pathways, particularly the LQEQ-19 (Riedl, Braun et al. 2009), 
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TLQP-21(Rizzi, Bartolomucci et al. 2008) and TLQP-62 (Moss, Ingram et al. 2008) 
peptides.  
 
However, the cellular and molecular mechanism of VGF-derived peptide signalling in 
neuropathic pain had not been well established and the precise roles of VGF-derived 
peptides in the development and/or maintenance of neuropathic pain remain unclear 
to date. The works presented in this PhD project attempted to examine the 
mechanisms of action of the VGF-derived peptides, followed by more focussed 
research on elucidating the role of TLQP-21 and its receptor in the pain pathway. The 
project provides an inside into the potential molecular mechanisms of TLQP-21 
signalling pathways and the major findings will be summarised and discussed in the 
following sections.  
 
5.1.1. Summary of data  
 
Depolarisation of the sensory neurons resulting from direct nerve injury or 
disease-associated neuropathy leads to the release of the VGF-derived peptides from 
the dense vesicles of the sensory neurons. Through a pathway that is not yet fully 
characterised, the signal is conveyed to result in an increase in nociception. In order 
to dissect the pathway underlying VGF-derived peptides signalling in the pain 
pathways, it was essential to distinguish the target cells of the VGF-derived peptides. 
Do all the VGF-derived peptides target the same cell type? Or do they function 
through different cell types by associated with different receptors/binding partners? 
The specific cells that the VGF-derived peptides target and exert their functional 
effects remained unknown, and hence were investigated in Chapter 2. The 
peripheral sensory neurons are pivotal for nociception detection. Since VGF is 
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released from the terminus of the sensory neurons, it was speculated that the 
VGF-derived peptide could act on the primary sensory neurons and hence transduce 
the nociceptive signals. I have hence tested the effect of VGF-derived peptides 
(LQEQ-19 and TLQP-21) on the primary DRG neurons by calcium imaging in 
figure 2.2. Though the possibility that the peptides activate the sensory neurons in a 
calcium-independent pathway cannot be rule out, the data suggested that LQEQ-19 
and TLQP-21 do not act on the sensory neuron, at least, via the calcium-dependent 
manner. It is established now that neurons are not the only cells involved in the pain 
pathway. Indeed, neuronal cells, glial cells and immune cells are suggested to all play 
part in the development of neuropathic pain (Scholz and Woolf 2007). In addition, 
macrophages are shown to infiltrate to the injured nerve, DRG and spinal cord after 
peripheral damage and depletion of macrophage has been shown to attenuate 
neuropathic pain development. I next tested the effects of the VGF derived peptides 
on the bone-marrow derived primary macrophage. It was found that one of the 
VGF-derived peptides, TLQP-21 specifically acted on primary macrophage in a 
calcium dependent manner as evident in figure 2.3. 100nM TLQP-21 elicited an 
immediate and transient increase in the intracellular calcium, but not the scrambled 
control. Furthermore, TLQP-21-induced calcium increase in the primary macrophage 
was dose-dependent. As established in figure 2.5, primary macrophages responded to 
TLQP-21 at concentration as low as 10nM and the number of cells responded to 
TLQP-21 plateaued at 100nM concentration. Interestingly, TLQP-21 desensitised the 
macrophage to further TLQP-21 stimulation, as it was shown in figure 2.6, where the 
first application of TLQP-21 elicited an increase in the intracellular calcium, but not 
with the second stimulation. The desensitisation was observed even after a one-hour 
time interval was allowed between the two TLQP-21 applications. Whilst TLQP-21 
induced profound desensitisation upon the second treatment, it was shown in figure 
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2.7 that pre-treatment with another VGF-derived peptide, TLQP-62, which harbours 
TLQP-21 at its N-terminus, did not desensitise the cells to the subsequent TLQP-21 
stimulation.  
 
Having demonstrated that TLQP-21 acted on primary macrophage in a 
calcium-dependent manner, some intriguing questions were raised. Was the calcium 
response a result of influx of extracellular calcium or a release of intracellular calcium 
stores? Do polarised macrophages respond to the TLQP-21 peptide differently? I have 
demonstrated in figure 2.8 that the TLQP-21-induced calcium response was still 
observed when the extracellular calcium was omitted in the extracellular solution. 
This implied that the source of calcium of the calcium response is likely to be a release 
of calcium from the intracellular stores such as ER or mitochondria. Moreover, I have 
demonstrated in figure 2.9 that different subsets of macrophages responded to 
TLQP-21, in terms of calcium response, with a similar percentage of cells responding 
to the peptide. Indeed, the percentages of responding cells to TLQP-21 for different 
macrophage subsets were not significantly different. This is, to our knowledge, the 
first evidence of a VGF- derived peptide acting on macrophages. Interestingly, other 
VGF-derived peptides, LQEQ-19 and TLQP-62, did not induce an increase in 
intracellular calcium levels in cultured macrophages, suggesting a specific action of 
TLQP-21 on macrophages. I next investigated further the effect of 
TLQP-21-stimulated macrophages in the pain pathway in an in vivo study and 
demonstrated in figure 2.13 that TLQP-21-stimulated macrophage intraplantar 
injection induced a mechanical hypersensitivity in vivo up to POD3 on the ipsilatereal 
paw but not the contralateral paw, suggesting TLQP-21-activated macrophage elicited 
the pain-like behaviours in the animals. 
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As demonstrated in chapter 2, where repetitive TLQP-21 treatments desensitised 
the primary macrophages to the subsequent TLQP-21 stimulation, I hence 
speculated that this is a receptor-mediated desensitisation event. Fortuitously, Dr. 
Mahmood Ayub identified a potential receptor, GC1qR, for TLQP-21 in our 
laboratory. Therefore, in chapter 3, I have focused on verifying if GC1qR is the 
receptor for TLQP-21 on the primary macrophages. I investigated this in figure 3.5, 
using two GC1qR neutralising antibodies in calcium imaging, and demonstrated that 
blockade of GC1qR by pre-treatment with anti-GC1qR antibodies significantly 
decreased the number of cells responding to TLQP-21. This is confirmed by the in 
vitro siRNA knock down of GC1qR, where that the percentage of cells responding to 
TLQP-21 was reduced in the primary macrophages in figure 3.13. However, 
heterologously expression of GC1qR in HEK293 cells failed to elicit an increase in 
intracellular calcium upon TLQP-21 stimulation in figure 3.17 and figure 3.18. 
Nevertheless, the possibility that the HEK293 cells do not express certain effector 
molecules required for TLQP-21-induced-GC1qR-dependent calcium response 
cannot be ruled out. In this chapter, I have also demonstrated in vivo that application 
of GC1qR neutralising antibody significantly reduced the mechanical 
hypersensitivity in the PSNL animal model of neuropathic pain in figure 3.21. 
Despite the fact that the effect was transient and lasted for only 24 hours, the study 
provides us with preliminary evidence of the involvement of GC1qR in the 
development of neuropathic pain. Nonetheless, the experiment will benefit from 
further optimisation of antibody delivering methodologies and antibody 
concentrations to draw a more conclusive result. In addition, I have also confirmed 
that vgf expression was indeed upregulated in the animal model chosen in the in vivo 
study in figure 3.19. 
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The precise mechanism of transmitting the activation signal upon binding of 
TLQP-21 to GC1qR in the macrophages and how the downstream signalling 
contribute to the development/maintenance of neuropathic pain requires further 
investigation. Nevertheless, the preliminary data of macrophage-conditioned media 
eliciting an increase in calcium response in the primary DRG neurons in figure 2.10 
raises some important questions: 
 
1. Was there an aberrant release of cytokines from the macrophages upon 
TLQP-21 stimulation which in turn stimulated the sensory neurons?  
2. Did TLQP-21 stimulation induce changes in the gene expression in the 
primary macrophages and what were the subsequent consequences of the 
expression alternation? 
 
In order to answer these questions, I decided in chapter 4, to investigate the 
downstream signalling pathway of TLQP-21 in the macrophage using PCR based 
technologies such as qRT-PCR and PCR array. I have also employed a microarray 
study to allow genomic-wide searches in the changes in gene expression in the 
macrophages upon TLQP-21 stimulation. I demonstrated in figure 4.7 that incubating 
primary macrophages with TLQP-21 for long hours induced a morphological change 
to an elongated bipolar shape. In addition, I also showed that 30 minutes treatment of 
TLQP-21 on macrophages induced 22 genes upregulation and12 genes 
downregulated in expression. 3 hours treatment time caused higher expression in 5 
genes and 15 genes reduced in expression. Lastly, 24 hours of TLQP-21 treatment on 
the primary macrophage changed the expression of a total 44 genes, in which 19 were 
upregulated and 25 were downregulated. 
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5.1.2. Possible mechanism of VGF-derived peptides in the pain pathway 
 
While there is growing interest in the literature, beginning to elucidate and implicate 
the roles of VGF-derived peptides in the pain pathway and the underlying 
mechanisms, large gaps still remain. The works presented in this thesis have 
investigated the involvement of TLQP-21 and its receptor GC1qR on the primary 
macrophages in the pain pathway. 
 
Summing all the results presented in this study, the following scenario seems to 
emerge for the mechanism of action of TLQP-21 in the pain pathway (see figure 5.1 
for schematic diagram). In the physiological condition, TLQP-21 is part of the soup 
of molecules that is produced by the sensory neurons. The VGF pro-protein is 
proteolytically cleaved by prohormone convertase upon synthesis and stored in the 
large dense secretory vesicles of the nociceptor terminals. Upon nerve injury, by 
direct nerve damage or disease associated neuropathy, the noxious signals are 
transduced into depolarizing currents by the specialized receptors and channels that 
gathered on the nociceptor terminals. The depolarisation of the sensory neurons 
subsequently leads to the release of stored VGF-derived peptides from the primary 
afferent via the regulated secretory pathway into the extracellular space. Thus, the 
VGF derived peptides, including TLQP-21 (as well as LQEQ-19 and TLQP-62 and 
other functional peptides) are released at the periphery and centrally. The 
VGF-derived peptide TLQP-21 subsequently relays the signal by acting on the 
infiltrated macrophages at the periphery, at least partly, via GC1qR. Other 
VGF-derived peptides may possibly activate other cells types or acts on sensory 
neurons in an autocrine manner. However, the functions of other VGF-derived 
peptides still awaiting further study.  
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Nevertheless, the released TLQP-21 at the periphery activates the macrophages by 
binding to its cell surface receptor and induces an increase in intracellular calcium 
by releasing calcium from the internal stores such as ER (which could possibly be 
IP3 mediated) or mitochondria. Although GC1qR has been shown in this study to be 
the receptor for TLQP-21, it is possible that the calcium elicited was not directly 
downstream to GC1qR, as GC1qR has been shown to associate with multiple 
binding partners. Therefore, the release of calcium from intracellular stores may be 
elicited by the unknown GC1qR associated proteins/channels. Future experiments 
could be carried out to immunoprecipitate the associated proteins of GC1qR using 
purified macrophage membrane proteins. This will provide us further evidence of 
whether GC1qR is associated with any other membrane proteins in macrophages 
and subsequent functional testing will reveal if these associated proteins/channels 
are involved in the TLQP-21-induced calcium response in macrophages. Moreover, 
the release of intracellular calcium from the internal store could be further refined to 
reveal the origins of the calcium sources. Specific inhibitors could be employed in 
conjunction with the calcium imaging, to show which intracellular organelles 
released the calcium store upon TLQP-21 stimulation. Nonetheless, the increase in 
intracellular calcium consequently leads to changes in gene expressions in the 
macrophages, which include upregulation of some poinflammatory cytokines (e.g. 
IL-18) and cytokine receptor (e.g. prokinectin receptor 2). At the same time, the 
expression of some anti-inflammatory mediator such as TGF- β3 is reduced in 
expression. The changes in gene expressions of these genes may consequently lead 
to a change in the amount of pro-inflammatory/anti-inflammatory cytokines, 
chemokines and mediators to be produced/released, which may transduce the signals 
by acting on adjacent cells, such as the damaged Schwann cells or sensory neurons.  
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The functional outcomes downstream of TLQP-21 signalling after the calcium 
response still remain to be further elucidated. Do the stimulated-macrophages exert a 
neuroprotective effect? Or do they contribute to the Wallerian degeneration and thus 
exacerbate the nerve damage? Could it also be possible that they modulate the 
neuron excitability by releasing certain factors that in turn bind to the sensory 
neuron and subsequently change its surface receptors expressions as seen in the 
microglia-mediated excitation of GABAnergic neurons? These intriguing questions 
still need to be investigated to gain a full picture of how TLQP-21 signals via its 
receptor, GC1qR, on macrophages at the periphery upon nerve injuries. Nonetheless, 
the TLQP-21-stimulated macrophages undergo morphological changes, which could 
possibly increase their mobility as it has been demonstrated that elongated shape of 
macrophage are associated with increase in chemotaxis. Could these macrophages 
migrate from the periphery to the central nervous system upon TLQP-21 stimulation, 
since the blood-nerve barrier is disrupted upon nerve damage (as indicated by Isami 
K et al., peripheral macrophages could infiltrate to the spinal cord in a 
TRPM2-dependent mechanism (Isami, Haraguchi et al. 2013))? 
 
This also implies that the macrophages at the periphery and migrated microphage at 
the central nervous system could have dual effects both peripherally and centrally. 
Indeed, two opposite effects of TLQP-21 seem to take place in the animal models: 
on one hand the peripheral hyperalgesic effect of TLQP-21 facilitates the 
nociception at the periphery, on the other hand TLQP-21 administration centrally 
inhibits pain at specific concentration. Does TLQP-21 potentiate the central circuits 
centrally via infiltrating macrophages, thus macrophages bearing the TLQP-21 
receptor could play a dual role at the peripheral and central circuits? Are the 
differential effects of TLQP-21 at the periphery and central loci solely 
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macrophage-mediated, or could it be that other cell types are involved to achieve the 
differential functional outcome? All these interesting questions now remain as 
intriguing pieces of puzzles to be completed by future experiments. 
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Figure 5. 1 Schematic diagram demonstrating the proposed mechanism of action of 
VGF-derived peptide, TLQP-21, in the development of neuropathic pain. 
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5.1.3. Crosstalk of the complement cascade and the pain pathway 
 
The presented work in this thesis highlighted that VGF-derived peptide, TLQP-21, 
acts on the primary macrophage via the complement receptor GC1qR. The TLQP-21 
and GC1qR association subsequently leads to an increase in the intracellular calcium 
levels, which relay to the downstream signalling pathway and ultimately a 
morphological change and possibly functional changes in the primary macrophage. It 
was surprising, and intriguing at the same time, that a complement receptor was 
implicated here to be involved in the signal transduction of the pain pathway. In fact, 
the crosstalk between the complement system and the pain pathway has recently been 
established in the literature and a number of growing evidences had suggested its 
involvement in the initiation and/or maintenances of neuropathic pain. 
 
Complement activation is a pivotal host defence system that is essential for the innate 
immunity to eliminate the pathogens in an organism. However, the lack of 
complement signalling or prolonged/disregulated complement activations are the 
causes of numerous human diseases. Inappropriate activation of the complement 
cascade has been implicated in a diverse neurodegenerative disorders such as 
Multiple sclerosis (Nataf, Carroll et al. 2000, Mead, Singhrao et al. 2002), 
Alzheimer’s (Shen and Meri 2003) and Hungtintion’s disease (Singhrao, Neal et al. 
1999). Complement system has first been implicated in the neuropathic pain by 
Twining et al. in 2004. It was demonstrated blockade of the complement activation 
by complement inhibitor, soluble complement receptor type 1 (sCR1), prevents the 
development of mechanical allodynia in the sciatic inflammatory neuropathy model 
(SIN) of neuropathic pain (Twining, Sloane et al. 2004). Independently, Li et al. also 
demonstrated in the partial sciatic nerve ligation model that inhibiting the 
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complement activation impaired the neuropathic pain development up to 19 days (Li, 
Peake et al. 2007). Interestingly, it was found in several subsequent studies that a 
number of major complement components were disregulated in different animal 
models of neuropathic pain. It was shown that C1qα, C1qβ, C1qγ, C1r, C1s, C2, C3, 
C4, C7 were up-regulated in the Spinal nerve ligation model of neuropathic pain 
(Levin, Jin et al. 2008). In addition, C3 mRNA was shown to be expressed at higher 
level in the ipsilateral DRGs of the spare nerve injury model (Vega-Avelaira, 
Geranton et al. 2009). Moreover, the increased in C3 expression has also been 
confirmed at protein level in the PSNL model, which is shown to be up-regulated 
from 6 hours to 7 days and the time scale of C3 protein up-regulation is correlated to 
the mechanical and thermal hypersensitivity behaviours in the animals (Li, Peake et al. 
2007). 
  
GC1qR has been demonstrated to be a positive regulator in the complement activation 
in the platelet cells. Platelet stimulation by mechanical mean increases the surface 
GC1qR expression, and the activated platelets increase C1q and C4d deposition, 
which is accompanied by a subsequent increase in C4d and C3a generation in the 
plasma fluid. In addition, it is demonstrated that the C4 activation in the platelets is 
signalled via GC1qR in a C1q-dependent manner. Truncated form of GC1qR fails to 
initiate C4 activation and GC1qR neurtralising antibodies also inhibit C4d 
deposition on platelets to some extend (Peerschke, Yin et al. 2006). Although 
GC1qR has been implicated in activating complement in the platelets, its role in 
activating complement pathway in other cell types has not yet been fully 
characteriesd. As mentioned, complement activation has also been reported in the 
DRG and the injured nerves following peripheral nerve injury in the animal models 
of neuropathic pain (Li, Peake et al. 2007, Levin, Jin et al. 2008, Vega-Avelaira, 
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Geranton et al. 2009). Whether this is a GC1qR-dependent activation, possibly via 
VGF-derived peptides, still await to be further elucidated. Nevertheless, macrophage 
seems to play an important role in bridging such crosstalk between the complement 
and pain pathways. As it is demonstrated that inhibiting complement activation in the 
neuropathic pain animal models prevented the neuropathic pain development 
(Twining, Sloane et al. 2004, Li, Peake et al. 2007), and depletion of complement 
prior to nerve damage reduced macrophage infiltration into the injured sciatic nerve 
and the activation of macrophages was reduced as well in the sciatic nerve crush 
injury model (Dailey, Avellino et al. 1998). Furthermore, systemic macrophage 
depletion has been shown to delay progression and reduce hyperalgesia in the animal 
models of neuropathic pain (Liu, van Rooijen et al. 2000, Mert, Gunay et al. 2009). 
These implicate macrophages in the neuropathic pain development, and the 
underlying mechanism involves, at least partly, the activation of complement system 
and infiltration of macrophages to the injured nerve. 
 
Taking all this evidence together, a new hypothetical pathway to the neuropathic pain 
development seems to emerge. Upon peripheral nerve damage (either by direct nerve 
injury or indirect disease-induced damage), complement activation, possibly from 
the damaged Schwann cells or injured nerve itself, induces the infiltration of 
macrophages into the damaged nerve and DRG. The injured nerve releases 
mediators, including VGF-derived peptides, upon depolarisation. VGF-derived 
peptides TLQP-21 signals to the infiltrated macrophage via its surface receptor 
GC1qR, inducing an increase in intracellular calcium and subsequent activation of 
the cells. Macrophages further amplify this damage by releasing harmful substances 
such as proinflammatory cytokines (e.g. IL-18), increasing receptors for 
proinflammtory mediators (e.g. prokinectin receptor 2) and reducing 
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anti-inflammatory molecules to be released (e.g. TGF- β3). The exacerbated damage 
thus leads to an intensified nociception to be detected. In addition, complement 
activation could also disrupts the blood-nerve barrier and hence recruits peripheral 
circulating macrophages into the central nervous system (Isami, Haraguchi et al. 
2013), where the VGF-derived peptide TLQP-21 could exert pro-nociceptive or 
analgesic effect depending on the local concentration of the peptide in the spinal 
cord (Rizzi, Bartolomucci et al. 2008). The summation of the peripheral sensory 
neuron hyperexcitation and the central mechanism of modulation and plasticity thus 
dictate the aberrant nociception in the neuropathic pain. 
 
5.2. Concluding remarks 
 
In conclusion, the present research demonstrated the involvement of the VGF-derived 
peptides TLQP-21 in pain modulation, through a mechanism that, at least partly, 
engages GC1qR receptor on the macrophages. The proposed mechanism of action of 
TLQP-21, through GC1qR, in the macrophages provides a novel insight into the 
comprehension of the neuropathic pain development. Additionally, the understanding 
of the mechanism underlying TLQP-21 signalling in the macrophages during 
neuropathic pain development opens the innovative therapeutic approaches and sheds 
light for novel development of new analgesics. 
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Appendix 
 
TLQP-21 30mins vs. Scrambled TLQP-21 30mins 
Gene Symbol Entrez ID P-Value Fold Change 
Ccna2 114494 0.001421213 3.46518799 
Ptp4a1 29463 0.002452578 2.974659315 
Etv1 362733 0.008545756 2.421056845 
RGD1305110 305579 0.006189354 2.348058575 
Dld 298942 0.003221764 2.3379795 
Scand1 362252 0.008031736 2.2820735 
C1r 312705 0.000814958 2.037630688 
Jrk 315073 0.007172351 1.809726439 
Cenpm 315164 0.001694829 1.785974829 
Cd40 171369 0.004601085 1.584336052 
Gtpbp10 312054 0.003977217 1.569666496 
Orc4 295596 0.009730391 1.442373536 
Neo1 81735 0.009919211 -1.283593412 
Ccdc30 362580 0.007462439 -1.366575499 
Ca2 54231 0.009295187 -1.368431261 
Hs3st1 84406 0.005149167 -1.373733099 
Spata2 114210 0.009825533 -1.406039162 
Itpkb 54260 0.00744075 -1.434963755 
Ereg 59325 0.004623608 -1.481882342 
Parva 57341 0.006779057 -1.55700514 
Col6a2 361821 0.002542384 -1.642900317 
Cog2 690961 0.00974026 -1.684240697 
Fgf9 25444 0.006200487 -1.837384626 
Tyro3 25232 0.006119209 -1.848213632 
Spon1 64456 0.007736186 -1.869626044 
Prokr2 192649 0.001039878 -1.934603385 
Stx11 292483 0.000268294 -1.958065449 
LOC100912606 100912606 0.001083004 -1.98169275 
Tgfb3 25717 0.002865028 -2.084087473 
Tpm1 24851 0.005554108 -2.131683041 
Btg2 29619 0.008323865 -2.179550854 
Mcat 315173 0.007278664 -2.302865345 
Igsf1 302822 0.000667076 -2.511811543 
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Fam168a 361614 0.003894542 -2.641294948 
Table A.1 Table listing genes that are differentially expressed after 30 minutes of 
TLQP-21 treatment when compared to that treated with scrambled TLQP-21. 
The genes that increases the expression by more than 1.5 folds after TLQP-21 treatment are 
highlighted in pink, and those decreases the expression by more than 1.5 folds are highlighted 
in blue. 12 and 22 genes are shown to be significantly upregulated and downregulated, 
respectively, by more than 1.5 folds after 30 minute of TLQP-21 treatment compared to that 
treated with scrambled peptide. A total of 9824 genes are not differentially expressed between 
the two treatment groups. 
 
TLQP-21 3hours vs. Scrambled-TLQP-21 3hours 
Gene Symbol Entrez ID P-Value Fold Change 
Lamp2 24944 0.006249104 3.629120603 
Mrfap1 282585 0.001693708 3.008905743 
Slc24a6 498185 0.002389034 2.872103079 
Mcm6 29685 0.001829167 2.658046214 
Alox5ap 29624 0.005946373 2.651306946 
Slc25a16 361836 0.001133329 2.364588137 
MGC94190 288616 0.009365843 2.354536598 
Map1lc3b 64862 0.008172609 2.343820763 
Mettl7a 315306 0.008439126 2.298627774 
Ino80c 291737 0.006670217 2.277473648 
Il18 29197 0.008592154 2.162657192 
Abhd16a 361796 0.002447063 1.963125362 
Arfgef2 296380 0.008276522 1.924408858 
Htr2b 29581 0.009513113 1.735989671 
Hddc2 361462 0.00445582 1.595229329 
LOC689074 689074 0.008474265 -1.547285884 
RGD1305422 303885 0.008990158 -1.751815559 
Snhg11 362256 0.007973788 -1.966648931 
Pcdh7 360942 0.008175499 -2.083417247 
Srd5a2 64677 0.008929625 -2.540330003 
Table A.2 Table listing genes that are differentially expressed after 3 hours of TLQP-21 
treatment when compared to that treated with scrambled TLQP-21. 
15and 5 genes are shown to be significantly upregulated and downregulated, respectively, by 
more than 1.5 folds after 3 hours of TLQP-21 treatment compared to that treated with 
scrambled peptide. A total of 9839 genes are not differentially expressed between the two 
treatment groups. 
 294 
TLQP-21 24hours vs. Scrambled TLQP-21 24hours 
Gene Symbol Entrez ID P-Value FoldChange 
Fam76a 362618 0.005727266 3.811282024 
Tmem219 308986 0.005625957 3.1552834 
Klc1 171041 0.006013083 3.034474986 
Spats2 300221 0.001701526 2.940853979 
Zc3h13 305955 0.007269521 2.662649774 
Dlgap4 286930 0.005330207 2.630163272 
Apaf1 78963 0.001404337 2.525491004 
Sik1 59329 0.00620099 2.510881287 
Pik3ip1 305472 0.009675336 2.475857758 
Hdlbp 64474 0.001672525 2.460231905 
Serpinb6 291085 0.004530024 2.403154489 
Ube3b 687633 0.006196031 2.378028051 
Pop7 288564 0.007878522 2.189060437 
Prpf38a 298374 0.007309862 2.137690164 
Fgl2 84586 0.009068705 1.954638056 
Fam100a 302941 0.009710433 1.846931593 
Mrpl48 293149 0.003528557 1.84237579 
Clk4 287269 0.007667579 1.791775232 
Carkd 361185 0.008761791 1.791399672 
Trappc2l 292074 0.009061335 1.726548319 
Etnk2 360843 0.006229538 1.694995831 
LOC100912002 100912002 0.007249681 1.688407413 
Dgkq 100361138 0.001893537 1.680135901 
Klf10 81813 0.007633356 1.528017862 
RGD1565411 363000 0.008388717 1.523194546 
LOC690734 690734 0.004795433 -1.312594991 
P2ry1 25265 0.007002704 -1.433480536 
Kcne3 63883 0.008568304 -1.451927492 
LOC100125364 100125364 0.006375943 -1.527931869 
Itpkb 54260 0.004498244 -1.541020717 
Cckbr 25706 0.008168725 -1.645407099 
Fam82a1 313840 0.005471273 -1.655304817 
Hip1r 81917 0.008824254 -1.728609254 
Oprm1 25601 0.007507652 -1.746020971 
Adamts12 294809 0.004293169 -1.859243979 
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Clcn7 29233 0.00327625 -1.984155535 
Als2cl 316017 0.008394751 -2.095622081 
Atat1 361789 0.006259233 -2.117569921 
Fgg 24367 0.009621803 -2.175724782 
Trmt2a 287953 0.001424427 -2.254584811 
Tulp1 309900 0.001186429 -2.267362405 
Lmo7 361084 0.004093187 -2.472343441 
Prkcg 24681 0.004338107 -2.485596452 
Dlgap1 65040 0.007054121 -2.893080413 
Table A.3 Table listing genes that are differentially expressed after 3 hours of TLQP-21 
treatment when compared to that treated with scrambled TLQP-21. 
25 and 19 genes are shown to be significantly upregulated and downregulated, respectively, 
by more than 1.5 folds after 24 hours of TLQP-21 treatment compared to that treated with 
scrambled peptide. A total of 9817 genes are not differentially expressed between the two 
treatment groups. 
 
